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to prevent excessive tissue growth in the cell and subsequent new narrowing, a 
process called restenosis 6. In the past decades, several technical advancements 
were introduced, revolutionizing the field of interventional cardiology. 
As such, progressive techniques to assess intracoronary anatomy and physiology 
(fractional flow reserve (FFR) were introduced 7. FFR is ratio of the distal coronary 
artery pressure (Pd) divided by the aortic pressure (Pa) under stress conditions 
induced by medication (hyperemia) (Figure 1). Intravascular imaging, comprised 
of intravascular ultrasound (IVUS) and optical coherence tomography (OCT) 
are small, tip based cameras, advanced into the coronaries based on either the 
reflection of sound or light respectively. 
The implementation of FFR, IVUS and OCT in addition to quantitative coronary 
angiography, enables the operator to better plan, execute and reevaluate a 
coronary intervention 8. The latter techniques all moved away from the pure 
research setting and have been implemented in daily clinical practice.
Although percutaneous coronary interventions and pharmacologic therapies 
have improved the prognosis for patients with CAD, recurrent major adverse 
cardiovascular events still occur in a substantial proportion of cases. Physiological 
assessment and intravascular imaging to assist during a PCI have emerged as 
excellent tools to evaluate the status of a coronary artery. Nevertheless both 
technologies still have a relatively low uptake in daily clinical practice, specifically 
in a post PCI setting. This thesis aimed to provide the rationale for post PCI FFR 
and intravascular imaging and how the use of these conventional methods can be 
used in a post procedural setting to improve patient outcome. 
Simultaneously new modalities have arisen to provide the operator with a more 
simplistic and faster method to assess the hemodynamic significance of a coronary 
lesion. In the current thesis we aimed to strengthen the body of evidence of 
the quantitative coronary angiography based vFFR and our own version of 
instantaneous free wave ratio (iFR): dPR. 
Finally, we aimed to gain more insight in in-vivo plaque and thrombus vulnerability 
with the use of quantitative polarization properties, measured through standard 
intravascular OFDI catheters. The polarization features offer refined insight into 
intravascular tissue composition, consistent with our current understanding of the 
mechanisms involved in plaque and thrombus progression and destabilization. 
A better understanding of intravascular physiology and imaging, combined with 
the knowledge on when to use it and how to interpret it, might be the key to 
improve patient outcome. 
A brief overview
Cardiovascular diseases and more specifically coronary artery disease (CAD) is a 
major cause of mortality and morbidity worldwide 1. 
CAD is the main cause for heart attacks, which occur when the arteries of the heart 
cannot deliver enough oxygen-rich blood to the heart. CAD or atherosclerosis is 
caused by the buildup of plaque, a waxy substance, inside the coronary arteries 
2, 3. This buildup narrows the blood vessels of the heart which can intermittently 
prevent the heart muscle from receiving optimal blood supply. Atherosclerotic 
lesions typically form over the course of years to decades, making it one of the 
longest incubation periods among human diseases and are mainly comprised of 
fibrous tissue, lipids, calcium and inflammatory cells 2.
Significant coronary artery disease typically presents as symptoms of chest pain, 
shortness of breath and fatigue. Stable CAD is categorized by complaints related 
to physical activity which may reduce in rest and is caused by the gradual increase 
in plaque burden in the coronary arteries. Acute coronary syndrome (ACS) on 
the other hand is associated with the sudden luminal narrowing of the coronary 
arteries, mostly due to the rupture of a plaque, resulting in a blood clot that 
may partially or completely occlude the artery. Complete coronary occlusion may 
cause cardiac muscle cells to go into apoptosis and result in a so called myocardial 
infarction. 
The first line of treatment consists of drugs that stabilize the disease (lipid 
lowering therapies), reduce the myocardial oxygen demand (blood pressure 
lowering agents and vasodilators) and reduce the likelihood of the development 
of blood clots due to plaque rupture (antiplatelet agents) 5. In case of refractory 
symptoms of chest pain, a so called percutaneous coronary intervention (PCI) 
might be indicated 4. A PCI is performed by inserting a catheter (thin flexible 
tube) into the blood vessels through either the groin or the arm. Using a special 
type of X-ray called fluoroscopy, the catheter is advanced up until the ostium of 
the coronary artery 5. In order to fully visualize the coronary anatomy, a contrast 
medium is subsequently injected to visualize the artery, this is called angiography. 
In case of significant narrowing, a wire is used to cross the lesion and can then 
be used as a rail to advance small balloons or stents to treat the narrowing or 
occlusion 5. Once the plaque is compressed and the stent is in place, the balloon 
is deflated and withdrawn. The stent stays in the artery, holding it open. Stents 
primarily consist of metal. In contemporary clinical practice stents are covered by 
drugs to prevent inflammatory reactions by the body to the foreign metal in order 
1
Introduction Chapter 1 - A brief overview
21 || 20
Outlines of the present thesis:
The use of coronary physiology is typically used to assess the hemodynamic 
significance of a coronary artery narrowing, providing valuable information on 
whether or not the individual lesion might warrant stenting. The technology 
however is barely used for post PCI evaluation. In PART I (Chapter 2 through 5) 
we will discuss the contemporary value of post PCI physiology 
In Chapter 2 we begin with a broad overview of and history of post PCI physiology 
and intravascular imaging modalities in a state-of-the-art review format. Recent 
studies demonstrated that with the use of conventional intravascular imaging and 
physiology, clinical outcomes can be improved, while also newer modalities like 
angiography based fractional flow reserve (FFR) and hybrid imaging catheters 
are entering the stage. With the use of these modalities, several vessel and stent 
related predictors of major adverse cardiac events (MACE) can be found and we 
will discuss their impact on outcome and when additional treatment is required. 
FFR is the current gold standard to determine the hemodynamic severity of an 
angiographically intermediate coronary stenosis. Post procedural evaluation is 
typically performed by angiographic guidance alone and much less is known about 
the prognostic effects FFR measured directly after a PCI. Therefore the Chapter 
3 to 5 will focus on the use FFR directly measured after coronary stenting. These 
chapters are based on the FFR SEARCH registry, the largest prospective post 
PCI FFR registry to date including up to 1000 patients. In Chapter 3 the initial 
demographic and descriptive findings of the FFR SEARCH trial will be discussed, 
including the 30 day outcome figures. 
In the next chapter, Chapter 4, we will provide the readers with a dedicated 
analysis, answering the question, what are the predictors of post procedural FFR 
values. The study describes several patient and vessel characteristics which will 
substantially contribute to the post procedural value measured.
In Chapter 5, the primary endpoint of the FFR SEARCH registry, the two year 
clinical outcomes will be evaluated. The study uses a cut-off value for the definition 
of sub-optimal FFR (FFR <0.90) already hypothesized in the FAME 1 and FAME 2 
trials and supported by large meta-analyses but never evaluated in a prospective 
fashion. 
In PART II (chapter 6 through 9) the utility of (post PCI) intravascular imaging 
will be discussed and we will take a closer look at the specifics and merits of 
intravascular imaging to improve patient outcome. 
Figure 1. Intravascular diagnostic tools to evaluate coronary stenosis 
A: schematic drawing of a significant coronary lesion with a microcatheter in place able to measure the 
pressure, the Pa is measured proximal of the lesion, the Pd is measured distal of the lesion (both under 
hyperemia); B: angiographic image of the location of interest; C: microcatheter which measures the 
pressure; D: schematic drawing of a non-significant calcified lesion with an imaging catheter in place; 
E: angiographic image of the location of interest; F: IVUS still frame with a calcified nodule at 1 o’clock; 
G: matched OCT still frame with a calcified nodule at 12 o’clock. 
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procedural FFR and high definition IVUS with the aim to identify specific patient 
populations and vessel characteristic as assessed with IVUS to improve patient 
outcome. 
First, a sub-study of the FFR SEARCH trial is discussed in Chapter 10. A dedicated 
high definition intravascular ultrasound (HD-IVUS) analysis was performed in a 
subgroup of 95 patients 100 vessels with a post PCI FFR ≤0.85 and 20 patients with 
an FFR >0.85. The study provides a quantitative in-depth IVUS and quantitative 
coronary angiography (QCA) analysis of vessels with a suboptimal post procedural 
FFR in order to find a rationale for the low FFR values.
Second, the subsequent sub-study of FFR SEARCH, Chapter 11, focusses on the 
two year outcome figures in the latter IVUS cohort. We discuss the event rates 
between groups of patients with and without luminal abnormalities as seen on 
IVUS. 
While post procedural FFR proved to predict long-term adverse events, little is 
known on whether additional post procedural optimization based on a low post 
PCI FFR improves outcome. 
The latter question resulted in the design of the FFR REACT trial, of which the 
design is described in Chapter 12. In this chapter the specifics of the single center 
randomized control trial are evaluated and substantiated while going into depth 
to discuss the detailed procedural methods of an IVUS guided optimization after a 
suboptimal post procedural FFR (<0.90).
PART IV (chapter 13 through 17) evolves around novel physiology indices and recent 
innovations in this field. The introduction of FFR enabled the physician for the first 
time to evaluate the coronary arteries in vivo 7, 23. FFR and the instantaneous free 
wave ratio (iFR) both moved away from the pure research setting and have been 
implemented in daily clinical practice, however implementation in daily clinical 
practice has been low 24. At the moment, there is a need for faster and easier 
physiologic assessments. First, in Chapter 13, we will discuss the validation of a 
novel 3D-QCA based software tool to calculate FFR without the use of a pressure 
wire or microcatheter: vFFR. Through a pre-clinical technical validation model, we 
aimed to correlate vFFR with computational fluid dynamics and invasively measured 
flow parameters. Additionally, we investigated the agreement and diagnostic value 
of vFFR as compared to invasively measured FFR using a dedicated pressure wire 
under maximum hyperemia. Finally, we assessed the inter-observer variability of 
the vFFR computation. 
Chapter 14 describes an observational cohort study including patients who 
First, stent implantation for the treatment of coronary artery disease can cause 
unintended tearing at the site of vessel wall adjacent to the stent struts resulting 
in a stent edge dissection (SED). Prior research indicated that SEDs increase 
the risk of stent thrombosis and MACE in the short- to mid-term follow-up 9-13. 
SEDs can be assessed with the use of angiography, however the likelihood to spot 
one can be increased with use of IVUS and even more with optical coherence 
tomography (OCT) 14-20. Although SEDs increase the risk of adverse events, not 
all SEDs visualized by OCT warrant additional treatment. Therefore, the aim in 
Chapter 6 was to provide a detailed morphometric characterization of SEDs and 
define predictors for outcome in patients with untreated SEDs. Additionally, we 
assessed the healing patterns of SEDs by serial OCT.
In Chapter 7, we aimed to investigate the luminal integrity 6 to 9 months after 
implantation of the Fantom bioresorbable scaffold (BRS) with the use of IVUS. 
The sirolimus-eluting Fantom BRS is a novel technology that is characterized 
by its thin struts, rapid and broad expansion capability, and most uniquely, its 
high radiopacity 21, 22. The angiographic and clinical results from the first cohort, 
demonstrated that the Fantom scaffold is capable of treating non-complex de novo 
native coronary artery lesions with low late lumen loss and MACE at 6 months 22. 
With a backbone that is designed to be absorbed within 4 to 5 years, minimal loss 
of radial strength is essential to prevent high obstruction volumes 21. The 6 and 9 
months IVUS derived dimensions will therefore provide additional more detailed 
information on the performance and safety of this novel device. 
In Chapter 8, as part of a single center experience, we aimed to assess the 
performance of another bioresorbable scaffold, the commercially available 
Magmaris sirolimus-eluting BRS, at different time points with the use of OCT.
Finally, a high risk patient subset that might benefit in particular from the use of 
intracoronary imaging to guide stent implantation is the cohort of patients with 
left-main stem disease. Although stenting of the left main artery has become a 
valid alternative to coronary artery bypass grafting, patients presenting with left 
main coronary artery stenosis are known to be at significantly increased risk for 
future major adverse cardiac events. The 2018 ESC guidelines provide a class IIa 
recommendation for IVUS-guided assessment of unprotected left main disease. 
In Chapter 9, the normal dimension of left main coronaries will be discussed as 
measured with IVUS. While clear guidelines exist on what threshold of minimal 
lumen area should be treated, no data was yet available on the dimensions that 
should be aimed for. 
PART III (chapter 10 through 12) focusses on the integration of both post 
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and complements birefringence for the polarimetric characterization of tissue 30. 
The study in chapter 18 discusses the results from the OPTICS study performed in 
Rotterdam, Erasmus MC. In this study, a total of 30 patients presenting with stable 
angina underwent a PS-OFDI pullback before or after a coronary intervention. We 
will describe the birefringence and depolarization properties in different plaque 
types as well a dedicated cap analysis on thick and thin cap lipid rich plaques. 
In 2018 we started the POLARIS-I study, a single center study to assess the merits 
of PS-OFDI, focusing on patients presenting with an acute coronary syndrome. 
One case from the POLARIS-I registry was specifically interesting since the 
right coronary artery of a patient presenting with a non-ST elevation myocardial 
infarction displayed a not so often seen honeycomb-like structure on the PS-OFDI. 
In Chapter 19, we will discuss this particular case and include a potential rationale 
for the observed polarimetric distribution.
Finally in Chapter 20, we will dive deeper into the POLARIS-I study and investigate 
the polarimetric properties of thrombus containing lesions in patients presenting 
with an acute coronary syndrome. 
underwent a successful PCI and who received a post PCI FFR measurement with 
the Navvus microcatheter. The aim of the study was to assess the feasibility of the 
vFFR software in a post PCI setting and measure the correlation and agreement 
between vFFR and invasively measured FFR. In addition, we assessed the ability of 
vFFR to identify post PCI FFR values <0.90, since this might be a clinical relevant 
cut-off to predict further MACE 25. 
In Chapter 15, we will show how vFFR might play a future role in lesion assessment 
in patients with a potential impaired microvascular dysfunction. We illustrate this 
using a clinical case from the Erasmus University Medical Center (Erasmus MC).
In contrast to FFR, and recently validated in large randomized trials, iFR provides 
the operator with a resting index in a coronary vessel without the need for a 
hypereamic agent 26, 27. However, the conventional iFR wire and algorithm are 
owned by a single vendor (Phillips, Volcano Corporation), therefore the aim of 
Chapter 16 was to develop and assess the feasibility of a generic non-hyperemic 
ratio: dPR. In this section we discuss the substitutable value of dPR towards IFR, 
Pd/Pa and pressure wire derived FFR. In Chapter 17 we assessed the feasibility 
of this novel index in a post PCI setting. We investigated the correlation of post 
PCI dPR and FFR in order to identify vessels and patients at risk for future events 
without the need for hyperemic agents. 
The final part of this dissertation, PART V (chapter 18-20), will focus on innovations 
in intravascular polarimetry assessment and its potential applicability in daily 
clinical practice. 
Intravascular OCT and optical frequency domain imaging (OFDI) currently 
offer the highest spatial resolution for invasive coronary imaging 28. The 
latter modalities construct a series of cross-sectional images by using a near-
infrared spectrum light to measure the echo time delay and the intensity of the 
backscattered light 29. Despite the merits of contemporary intravascular imaging 
such as OFDI and OCT, there remains a demand to improve plaque morphology 
characterization. In Chapter 18 we will describe the first-in-man cohort study to 
use the novel imaging modality, developed at the Massachusetts General Hospital 
in Boston. The polarization sensitive (PS) OFDI allows automatic co-registration 
of polarimetric measurements along with the standard intensity data, using a 
conventional OFDI catheter 30. Tissue with fibrillar architecture, such as collagen 
or arterial smooth muscle cells, exhibit birefringence, an optical property that 
results in a differential delay, or retardation, between light polarized parallel to 
the tissue fibrillar components and light having a perpendicular polarization. 
Depolarization corresponds to a randomization of the detected polarization states 
1
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MLA  Minimal Lumen Area
MLD  Minimal Lumen Diameter
MSA  Minimal Stent/Scaffold Area 
NC  Non-Compliant
NHPR  Non-Hyperemic Pressure Ratios
NSD  Normalized Standard Deviation
NSTEMI Non ST Elevated Myocardial Infarction
nTAV  normalized Total Atheroma Volume
OCT  Optical Coherence Tomography 
OFDI  Optical Frequency Domain Imaging
OR  Odds Ratio
PAV  Percent Atheroma Volume
PCI  Percutaneous Coronary Intervention
Pd/Pa  the Pressure in the Distal coronary artery to the Pressure in the 
 
  Aorta ratio
PR  Plaque Rupture
PS-OFDI Polarization-Sensitive Optical Frequency Domain Imaging
QCA  Quantitative Coronary Angiography
QFR  Quantitative Flow Ratio
R2  Squared Pearson Correlation Coefficient
RCA  Right Coronary Artery
ROI  Region Of Interest
RVD  Reference Vessel Diameter
SA  Stent/Scaffold Area
SAP  Stable Angina Pectoris
SD  Standard Deviation
SED  Stent Edge Dissection
SEM  Standard Error of the Mean
SE-MEA Scaffold Expansion according to Manufacturer’s Expected Area
SE-RVA  Scaffold Expansion according to Reference Vessel Area
STEMI  ST segment Elevation Myocardial Infarction
TCFA  Thin Cap Fibroatheroma
ThCFA  Thick Cap Fibroatheroma
TLF  Target Lesion Failure
TVF  Target Vessel Failure
VA  Vessel Area
vFFR  Vessel Fractional Flow Reserve
Abbreviations
ACS  Acute Coronary Syndrome 
BMI  Body Mass Index
BRS  Bioresorabable Scaffold
BVS  Bioresorabable Vascular Scaffold (Absorb) 
CABG  Coronary Artery Bypass Graft
CAD  Coronary Artery Disease
CTO  Chronic Total Occlusion
CV  Variance Coefficient 
CVD  Cardiovascular Disease
DAT  Desaminotyrosine
DES  Drug Eluting Stent
DOCE  Device Orientated Cardiovascular Event
dPR  diastolic Pressure Ratio
DS  Diameter Stenosis
EEM  External Elastic Membrane 
FC  Fibro-Calcified plaque
FCT  Fibrous Cap thickness
FFR  Fractional Flow Reserve
FP  Fibrous Plaque
GEE  Generalized Estimating Equation
GM  Geographical Miss
HD  High Definition
HR  Hazard Ratio
iFR  instananeous Wave Free Ratio 
IQR  Inter Quartile Range
ISA   Incomplete Strut Apposition
IVUS  Intravascular Ultrasound
LA  Lumen Area
LAD  Left Anterior Descending Artery
LCX  Left Circumflex Artery
LLL  Late Lumen Loss
LME-model Linear Mixed Effects Model
MACE  Major Adverse Cardiac Event
MI  Myocardial Infarction
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ABSTRACT
Background: Fractional flow reserve (FFR) is the current gold standard to 
determine hemodynamic severity of angiographically intermediate coronary 
lesions. Much less is known about the prognostic effects of FFR measured directly 
after percutaneous coronary intervention (PCI). The aims of this study were to 
evaluate post-PCI FFR values, identify predictors for a low post-PCI FFR, and 
to investigate whether a relationship between postprocedural FFR and outcome 
during 30-day follow-up exists.
Methods and Results: The FFR-SEARCH (Fractional Flow Reserve—Stent 
Evaluated at Rotterdam Cardiology Hospital) is a prospective registry in which 
FFR measurements were performed after PCI in 1000 consecutive patients. All 
FFR measurements were performed under maximum hyperemia with intravenous 
adenosine with the Navvus RXi system (ACIST Medical Systems, Eden Prairie, 
MN). The clinical end point was defined as a composite of death, target vessel 
revascularization, or nonfatal myocardial infarction at 30-day follow-up. 
Measurement of post-PCI FFR was successful in 959 patients (96%), and a 
total of 1165 lesions were assessed. There were no complications related to the 
microcatheter. A total of 322 ST-segment–elevation myocardial infarction patients 
with 371 measured lesions were excluded leaving 637 patients with 794 measured 
lesions for the final analysis. Overall post-PCI FFR was 0.90±0.07. In 396 lesions 
(50%), post-PCI FFR was >0.90. A total of 357 patients (56%) had ≥1 lesion(s) 
with a post-PCI FFR ≤0.90, and 73 patients (11%) had ≥1 lesion(s) with a post-
PCI FFR ≤0.80 with post-PCI FFR ≤0.80 in 78 lesions (9.8%). Complex lesion 
characteristics, use of multiple stents and smaller reference vessel diameter was 
associated with post-PCI FFR ≤0.90. During follow-up, 11 patients (1.8%) reached 
the clinical end point. There was no significant relationship between post-PCI FFR 
and the clinical end point at 30-day follow-up (P=0.636).
Conclusion: Routine measurement of post-PCI FFR using a monorail microcatheter 
is safe and feasible. Several lesion and patient characteristics were associated with 
a low post-PCI FFR. Post-PCI FFR did not correlate with clinical events at 30 days.
WHAT IS KNOWN
Fractional flow reserve (FFR) is the current gold standard to determine the 
hemodynamic severity of angiographically intermediate coronary lesions.
Previous studies, using mainly pressure wires, suggested a relationship between 
low FFR after coronary stenting and future adverse cardiac events but were either 
small in sample-size or used selected patients.
WHAT THE STUDY ADDS
Routine measurement of FFR after coronary stenting using a dedicated monorail 
microcatheter is safe and feasible.
Both lesion and patient characteristics are associated with a low FFR after coronary 
stenting.
Low FFR after coronary stenting is not associated with clinical events at 30-day 
follow-up.
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INTRODUCTION
Fractional flow reserve (FFR) is the current gold standard to determine 
hemodynamic severity of angiographically intermediate coronary lesions. Large 
randomized studies have established the superiority of FFR and even demonstrated 
beneficial effects on long-term outcome (death, myocardial infarction [MI], and 
repeat revascularization) in patients treated with FFR-guided percutaneous 
coronary intervention (PCI) as compared to angiography-guided PCI alone 1-3. 
As a result, the use of FFR in patients with intermediate coronary lesions and no 
previously documented ischemia has been given a class I recommendation in 
current European Society of Cardiology guidelines 4. Although it has been widely 
established that angiographic evaluation is not consistent with the hemodynamic 
severity of a lesion, coronary physiology is not used to assess PCI results. Several 
previous studies suggested a relationship between low post-PCI FFR and future 
adverse cardiac events (mainly repeat target vessel revascularization), but most 
of them were retrospective by nature, contained only limited numbers of selected 
patients and were inconsistent in reporting an optimal cutoff value for post-PCI 
FFR 5–11. Also, most of these studies used selected cases with stable, intermediate 
coronary lesions in which also pre-PCI FFR was performed. Subsequently, the 
aims of the current study were (1) to prospectively evaluate FFR values after 
angiographically successful PCI in a large cohort of consecutive patients, (2) to 
identify predictors of a low post-PCI FFR, and (3) to investigate whether there is 
a relationship between postprocedural FFR and clinical outcome during 30-day 
follow-up.
METHODS
The data that support the findings of this study are available from the corresponding 
author on reasonable request.
Patient population and study protocol
The FFR-SEARCH (Fractional Flow Reserve—stent Evaluated at Rotterdam 
Cardiology Hospital) is a prospective registry in which FFR measurements were 
performed after angiographically successful PCI in 1000 consecutive patients. 
Post-PCI FFR was measured in all patients, regardless of the clinical presentation 
or whether FFR or intravascular imaging was performed before PCI. However, 
patients presenting with cardiogenic shock, high-risk PCI with mechanical 
circulatory support or an estimated vessel size <2.25 mm were excluded.
PCI was performed according to standard techniques and in accordance with 
the European Society of Cardiology guidelines. Unfractionated heparin (70–100 
U/kg) was used to achieve an activated clotting time >250 seconds. Coronary 
artery lesion characteristics were classified according to the American College 
of Cardiology/American Heart Association lesion classification 12. The decision to 
perform a diagnostic hemodynamic assessment with instantaneous free wave 
ratio or FFR, pre-intravascular or post-intravascular imaging, thrombus aspiration, 
predilatation or postdilatation was left at the discretion of the operator.
All FFR measurements were performed with the Navvus RXi system (ACIST Medical 
Systems, Eden Prairie, MN). This rapid exchange monorail microcatheter uses fiber 
optic-based sensor technology to assess FFR and is compatible with all standard 
0.014 inches guidewires 13,14.The microcatheter technology allows easy access 
over any coronary guidewire which makes it particularly useful for assessment 
of post-PCI FFR. In addition, it permits multiple pullbacks while maintaining wire 
access to the vessel. After angiographically successful PCI, the Navvus RXi was 
inserted over the previously used coronary guidewire to ≈20 mm distal of the most 
distal stent edge, this location was defined as P1, Figure 1. Then, hyperemia was 
achieved with a continuous intravenous infusion of adenosine at a rate of 140 µg/
kg per minute through an antecubital vein. Post-PCI FFR values were measured 
under hyperemia after a minimum of 2 minutes of intravenous adenosine infusion. 
The lowest value of hyperemic Pd/Pa of any single beat was used.
Next, the microcatheter was pulled back to the most distal stent edge, this location 
was defined as P2, Figure 1 and the FFR value at that location was noted. The 
microcatheter was then pulled back to the most proximal stent edge, defined as 
P3 and again the FFR value at that location was noted. Finally, the microcatheter 
was pulled back to the ostium to check for pressure drift, this location was named 
P4, Figure 1. Using the FFR values at these 4 locations, pressure drop gradients 
were calculated from 3 segments; the distal segment (ΔFFR P2–P1), the stented 
segment (ΔFFR P3–P2), and the proximal segment (ΔFFR P4–P3). A significant 
pressure drop was defined as a ΔFFR >0.05.
For all later lesion and patient comparisons, only the FFR values measured 20 mm 
distal of the most distal stent edge (P1) were used.
Irrespective of the final post-PCI FFR value, and as directed by the study protocol, 
no further treatment was performed. The latter was directed in order not to bias the 
predictive value of post-PCI FFR on future adverse cardiac events. All angiograms 
and FFR pullbacks were checked to confirm protocol adherence. Based on previous 
studies, comparisons were made between lesions (and patients with lesions) with 
a low post-PCI FFR ≤0.90 versus a high post-PCI FFR >0.90 11.
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For this specific study, patients who presented with ST-segment–elevation 
myocardial infarction (STEMI) were excluded from further analysis as measuring 
FFR in patients with STEMI can be considered unreliable, mainly caused by 
incomplete hyperemia because of endothelial dysfunction and microvascular injury 
and obstruction in STEMI 15–17. Consequently, patients with STEMI are more likely 
to have a high-FFR value which does not necessarily reflect a better procedural 
result or outcome. Specific analysis on FFR-SEARCH patients with STEMI will be 
presented separately.
The study was performed in accordance with the Declaration of Helsinki. The 
study protocol was approved by the local ethics committee. All patients provided 
written informed consent for the procedure and the use of anonymous data sets 
for research purposes in alignment with the Dutch Medical Research Act.
Figure 1. Example of post-percutaneous coronary intervention (PCI) fractional flow reserve (FFR) 
measurements as performed in FFR-SEARCH (Fractional Flow Reserve—Stent Evaluated at Rotterdam 
Cardiology Hospital), in this case in the right coronary artery in a patient presenting with a non–ST-
segment–elevation myocardial infarction (NSTEMI). 
After successful PCI, the Navvus RXi was inserted over the previously used coronary guidewire ( upper 
right). Then post-PCI FFR measurements were collected 20 mm distal of the most distal stent edge (P1), 
the distal stent edge (P2), the proximal stent edge (P3), and finally at the ostium (P4) to check for signal 
drift ( left). The values for this case are shown in the bar below.  
Quantitative coronary angiography
Two-dimensional quantitative coronary angiography analysis was performed pre-
stent and post-stent implantation in all treated lesions. An angiographic view with 
minimal foreshortening of the lesion and minimal overlap with others vessels 
was selected, and similar angiographic views were used pre-stent and post-stent 
implantation. Measurements included lesion length, reference diameter, minimal 
lumen diameter, and diameter stenosis. In case of preprocedural total occlusion of 
the treated lesion (in patients presenting with STEMI or a chronic total occlusion), 
the minimal lumen diameter value was considered 0% and stenosis 100%. 
Reference diameter and lesion length were calculated from the first angiographic 
view with restored flow.
Follow-up and outcome analysis
Clinical follow-up data were obtained from electronic medical records of the 
hospital, general practitioner, and the municipal civil records databases. In 
addition, all patients were contacted personally by letter or telephone contact. 
The clinical end point was defined as a composite of cardiac death, nonfatal MI, 
or target vessel revascularization at 30 days. Clinical events including all-cause 
mortality, cardiac mortality, MI, target lesion revascularization and target vessel 
revascularization, any revascularization, stent thrombosis, stroke, and bleeding 
were collected. Target lesion revascularization was defined as repeat PCI or 
bypass grafting for restenosis at the lesion treated during the index procedure. 
Target vessel revascularization was defined as repeat PCI or bypass grafting for a 
stenosis outside the stented area of the index procedure.
Statistical analysis
Continuous data are presented as mean±SD. Categorical data are presented 
as numbers and percentages. Comparison of data between lesions and patient 
groups was performed using the independent samples t test for continuous data. 
Fisher exact tests or χ2 tests were used as appropriate to compare categorical 
data. All analyses were performed with SPSS statistics for Windows, version 24.0 
(SPSS, Chicago, IL). All statistical tests were 2-sided. A P<0.05 was considered 
statistically significant.
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RESULTS
Patient characteristics and procedural results
Baseline characteristics of the patient population are presented in Table 1. A total 
of 1000 patients were included in the study. In 28 patients, the microcatheter was 
not able to cross the treated lesion, in 11 patients there was another technical 
issue and in 2 patients a severe response to the intravenous adenosine occurred, 
leaving 959 patients (96%) with at least 1 successfully treated and FFR assessed 
lesion. In these 959 patients, a total of 1348 lesions were treated. In 14 of these 
lesions, the microcatheter was not able to cross and in 1 there was another 
technical issue. Furthermore, in 109 lesions, the distal vessel was considered too 
small for the microcatheter. In 9 lesions, the patient was too unstable to administer 
intravenous adenosine, in 22 cases the operator decided not to perform the FFR 
measurement. Finally, in 28 cases post-PCI FFR measurement was not performed 
for other reasons, leaving 1165 successfully treated and measured lesions (Figure 
2). Out of these 959 patients with 1165 lesions, 322 STEMI patients with 371 
measured lesions were excluded leaving a total of 637 patients with 794 measured 
lesions for the final analysis.
Figure 2. Flowchart showing all included and excluded patients and lesions in FFR-SEARCH (Fractional 
Flow Reserve—Stent Evaluated at Rotterdam Cardiology Hospital).
Measurement of ≥1 post-percutaneous coronary intervention (PCI) FFR was successful in 959 patients 
(96%). 
Table 1. Patient baseline characteristics
 
  
 n=1000 
Age, y 64.6±11.8 
Male sex, n (%) 725 (73) 
Hypertension, n (%) 515 (52) 
Hypercholesterolemia, n (%) 451 (45) 
Diabetes mellitus, n (%) 191 (19) 
Smoking history, n (%) 499 (50) 
Prior stroke, n (%) 77 (8) 
Peripheral artery disease, n (%) 76 (8) 
Prior myocardial infarction, n (%) 203 (20) 
Prior PCI, n (%) 264 (26) 
Prior CABG, n (%) 57 (6) 
Hb level, mmol/L 8.7±1.0 
Creatinine, µmol/L 92±51 
Indication for PCI, n (%)  
 Stable angina 304 (30) 
 Unstable angina/NSTEMI 367 (37) 
 Acute myocardial infarction 329 (33) 
No. of lesions treated 1.40±0.6 
No. of lesions measured 1.21±0.5 
CABG indicates coronary artery bypass graft; Hb, hemoglobin; NSTEMI, non–ST-segment–elevation 
myocardial infarction; and PCI, percutaneous coronary intervention.
FFR results
The mean time to perform post-PCI FFR was 5.0±1.4 minutes per lesion. No 
complications related to the microcatheter occurred. The mean Pd/Pa in resting 
condition was 0.96±0.04, while the mean post-PCI FFR under maximal hyperemia 
was 0.90±0.07 (as measured at P1). The mean post-PCI FFR at P2 was 0.95±0.05 
and mean post-PCI FFR at P3 was 0.98±0.04. Finally, mean drift at P4 was 
0.011±0.014 with 50 lesions (6.3%) having a significant drift >0.03, Figure 3. 
This resulted in an ΔFFR 0.04±0.05 along the distal segment, an ΔFFR 0.03±0.04 
over the stented segment, and finally an ΔFFR 0.02±0.04 along the proximal 
segment. Interestingly, a significant pressure drop (>0.05) was observed in 32% 
of the distal segments, in 18% of the stented segments, and finally in 15% of the 
proximal segments.
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Figure 3. Mean post-percutaneous coronary intervention fractional flow reserve (FFR) values as 
measured at the 4 different locations in the coronary artery. 
Distribution of post-PCI FFR values at P1 is shown in Figure 4. Although a satisfactory 
angiographic result was achieved in all cases, post-PCI FFR remained ≤0.80 in 
78 lesions (9.8%). Conversely, post-PCI FFR was >0.90 in 396 lesions (50%). 
Comparison of post-PCI FFR in 3 predefined subgroups revealed no differences 
in men and women (0.89±0.07 versus 0.90±0.06, P=0.134) or in patients 
presenting with a non-STEMI versus stable angina (0.90±0.06 versus 0.89±0.07, 
P=0.100), but did show a significant difference in patients with diabetes mellitus 
and patients without diabetes mellitus (0.88±0.07 versus 0.90±0.06, P=0.027).
Characteristics of lesions with a post-PCI ≤0.90 versus lesions with a post-PCI 
FFR >0.90 are displayed in Table 2. Lesions with a post-PCI ≤0.90 were more 
complex lesions and more frequently included bifurcation lesions (18% versus 
10%, P=0.002) or calcified lesions (47% versus 35%, P=0.001). Conversely, 
lesions with a post-PCI FFR >0.90 were more frequently thrombotic lesions 
(14% versus 7%, P=0.001), had a higher stenosis grade pre (63±20% versus 
57±19%, P<0.001), higher reference diameter pre (2.7±0.5 versus 2.5±0.5 mm, 
P<0.001), and smaller minimal lumen diameter pre (1.0±0.6 versus 1.1±0.5 mm, 
P=0.044). Furthermore, postdilatation was more frequently performed in lesions 
with a post-PCI FFR ≤0.90 (68% versus 57%, P=0.001). Also, intravascular 
ultrasound was more frequently used in lesions with a post-PCI FFR ≤0.90 (16% 
versus 6%, P<0.001). In lesions with a post-PCI FFR ≤0.90 more stents were 
used (1.5±0.7 versus 1.3±0.6, P=0.022), with a smaller mean diameter (3.1±0.4 
versus 3.2±0.5 mm, P<0.001), and a greater stent length (31±19 versus 28±16 
mm, P=0.015). Finally, lesions with a post-PCI FFR >0.90 had a higher reference 
diameter post (2.7±0.5 versus 2.5±0.5 mm, P<0.001) and larger minimal lumen 
diameter post (2.7±0.5 versus 2.5±0.5 mm, P<0.001). Of note, in lesions with a 
post-PCI FFR ≤0.90, a significant pressure drop (>0.05) was observed in 57% of 
the distal segments, in 33% of the stented segments, and finally in 29% of the 
proximal segments (as compared to 9% of the distal segments, 4% of the stented 
segments, and 3% of the proximal segments in lesions with post-PCI FFR >0.90).
Figure 4. Post-percutaneous coronary intervention (PCI) fractional flow reserve (FFR) results on lesion 
level.
In 398 lesions (50%), a post-PCI FFR ≤0.90 was found (light purple box), while in 78 lesions (9.8%), the 
post-PCI FFR was even ≤0.80 (dark purple box). 
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Table 2. Lesion characteristics with FFR ≤0.90 versus FFR >0.90
 All Lesions (n=794) 
FFR ≤0.90 
(n=398) 
FFR >0.90 
(n=396) p value 
Lesion type, n (%)    0.003 
 A 100 (13) 35 (9) 65 (16)  
 B1 163 (21) 78 (20) 85 (21)  
 B2 232 (29) 132 (33) 100 (25)  
 C 299 (37) 153 (38) 146 (37)  
Bifurcation, n (%) 109 (14) 70 (18) 39 (10) 0.002 
Calcified, n (%) 328 (41) 188 (47) 140 (35) 0.001 
In-stent restenosis, n (%) 30 (4) 19 (5) 11 (3) 0.140 
Thrombus, n (%) 81 (10) 26 (7) 55 (14) 0.001 
Stent thrombosis, n (%) 5 (1) 3 (1) 2 (1) 0.658 
Ostial, n (%) 84 (11) 37 (9) 47 (12) 0.239 
CTO, n (%) 39 (5) 25 (6) 14 (4) 0.073 
Stenosis pre, % 60±20 57±19 63±20 <0.001 
Ref diameter pre, mm 2.6±0.6 2.5±0.5 2.7±0.5 <0.001 
Length pre, mm 21±11 20±11 21±12 0.631 
MLD pre, mm 1.0±0.5 1.1±0.5 1.0±0.6 0.044 
Predilatation, n (%) 553 (70) 289 (73) 264 (67) 0.068 
Postdilatation, n (%) 499 (63) 272 (68) 227 (57) 0.001 
IVUS, n (%) 87 (11) 65 (16) 22 (6) <0.001 
Stenosis post, % 3.5±14 2.8±14 4.2±13 0.153 
Ref diameter post, mm 2.7±0.5 2.5±0.5 2.7±0.5 <0.001 
Length post, mm 24±14 24±14 23±14 0.345 
MLD post, mm 2.6±0.5 2.5±0.5 2.7±0.5 <0.001 
No. of stent, n 1.4±0.7 1.5±0.7 1.3±0.6 0.022 
Stent length, mm 29±18 31±19 28±16 0.015 
Stent diameter, mm 3.1±0.5 3.1±0.4 3.2±0.5 <0.001 
 
  
CTO indicates chronic total occlusion; FFR, fractional flow reserve; IVUS, intravascular ultrasound; and 
MLD, minimum luminal diameter.
Patients With all measured post-PCI FFR >0.90 versus any 
FFR ≤0.90
In a total of 280 patients (44%), all measured lesions had a post-PCI FFR >0.90. 
There were 357 patients (56%) with ≥1 lesion ≤0.90, 182 patients (29%) 
with ≥1 lesion ≤0.85, and 73 patients (11%) with ≥1 lesion ≤0.80 despite an 
angiographically satisfactory result of the procedure. Baseline and procedural 
characteristics of patients with ≥1 lesion ≤0.90 versus patients with all lesions 
>0.90 are shown in Table 3. Patients with ≥1 lesion ≤0.90 were more likely to have 
diabetes mellitus (28% versus 19%, P=0.007) or peripheral arterial disease (11% 
versus 6%, P=0.038) as compared to patients with all lesions >0.90. Conversely, 
patients with all lesions >0.90 more frequently had prior coronary artery bypass 
graft (12% versus 5%, P=0.002). Finally, patients with ≥1 lesion ≤0.90 had more 
lesions treated (1.59±0.7 versus 1.31±0.6, P<0.001) and measured (1.36±0.6 
versus 1.11±0.4, P<0.001) as compared to patients with all lesions >0.90.
Table 3. Patient baseline characteristics with any FFR ≤0.90 versus FFR >0.90
 
 FFR ≤0.90 (n=357) 
FFR >0.90 
(n=280) p value 
Age, y 65.8±10.6 65.6±12.1 0.878 
Male sex, n (%) 261 (73) 185 (66) 0.054 
Hypertension, n (%) 215 (60) 164 (59) 0.684 
Hypercholesterolemia, n (%) 202 (57) 145 (52) 0.476 
Diabetes mellitus, n (%) 99 (28) 52 (19) 0.007 
Smoking history, n (%) 152 (43) 131 (47) 0.303 
Prior stroke, n (%) 35 (10) 17 (6) 0.088 
Peripheral artery disease, n (%) 40 (11) 18 (6) 0.038 
Prior myocardial infarction, n (%) 92 (26) 69 (25) 0.745 
Prior PCI, n (%) 113 (32) 95 (34) 0.543 
Prior CABG, n (%) 18 (5) 33 (12) 0.002 
Hb level, mmol/L 8.6±1.0 8.5±1.1 0.519 
Creatinine, µmol/L 99±75 92±32 0.192 
Indication for PCI, n (%)   0.243 
 Stable angina 167 (47) 118 (42)  
 Unstable angina/NSTEMI 190 (53) 162 (58)  
No. of lesions treated 1.59±0.7 1.31±0.6 <0.001 
No. of lesions measured 1.36±0.6 1.11±0.4 <0.001 
 
 
  CABG indicates coronary artery bypass graft; FFR, fractional flow reserve; Hb, hemoglobin; NSTEMI, 
non–ST-segment–elevation myocardial infarction; and PCI, percutaneous coronary intervention.
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Follow-up
Clinical follow-up at 30 days was available in 618 patients (97%). In total, 11 
patients (1.8%) experienced a clinical end point. All separate end points and 
corresponding incidences are displayed in Table 4. No significant difference was 
found for the occurrence of the combined end point between the groups (2.0% in 
patients with ≥1 lesion ≤0.90 versus 1.5% in the patients with all lesions >0.90, 
P=0.636), or in any of the separate end points. Finally, no differences were found 
in event rates between men and women (2.0% versus 1.1%, P=0.385), patients 
with or without diabetes mellitus (2.7% versus 1.5%, P=0.316) and patients 
presenting with a non-STEMI versus patients with stable angina (2.7% versus 
0.7%, P=0.064).
Table 4. Thirty-day clinical outcome
  
 All Patients (n=618) 
FFR ≤0.90 
(n=350) 
FFR >0.90 
(n=268) p value 
Combined end point, n 
(%) 
11 (1.8) 7 (2.0) 4 (1.5) 0.636 
All-cause mortality, n (%) 5 (0.8) 4 (1.1) 1 (0.4) 0.290 
Cardiac mortality, n (%) 4 (0.6) 3 (0.9) 1 (0.4) 0.457 
Nonfatal MI, n (%) 4 (0.6) 4 (1.1) 0 (0) 0.079 
TLR, n (%) 1 (0.2) 1 (0.3) 0 (0) 0.380 
TVR, n (%) 2 (0.3) 1 (0.3) 1 (0.4) 0.851 
Any revascularization, n 
(%) 
7 (1.1) 4 (1.1) 3 (1.1) 0.978 
Stent thrombosis, n (%) 1 (0.2) 1 (0.3) 0 (0) 0.380 
Stroke, n (%) 0 (0) 0 (0) 0 (0) 1.000 
Bleeding, n (%) 1 (0.2) 1 (0.3) 0 (0) 0.380 
FFR indicates fractional flow reserve; MI, myocardial infarction; TLR, target lesion revascularization; and 
TVR, target vessel revascularization.
DISCUSSION
The main findings of FFR-SEARCH at 30-day follow-up can be summarized as 
follows: (1) Routine measurement of post-PCI FFR is safe and feasible. (2) Mean 
post-PCI FFR was 0.90±0.07, with 73 patients (11%) having ≥1 lesion(s) with 
a post-PCI FFR ≤0.80 despite angiographically successful PCI and 357 patients 
(56%) having a low post-PCI FFR ≤0.90. (3) A significant pressure drop (>0.05) 
was found in 32% of the segments distal of the stent, while only in 18% of the 
stented segments and 15% of the proximal segments. (4) Several factors were 
associated with a low post-PCI FFR, including bifurcations or calcified lesions. 
Furthermore, patients with diabetes mellitus or peripheral arterial disease were 
more likely to have ≥1 lesion with a post-PCI FFR ≤0.90. (5) Finally, no significant 
relationship was found between post-PCI FFR and the combined clinical end point 
at 30-day follow-up.
Since the beginning of coronary angioplasty, interventional cardiologists have been 
on an evercontinuing search to further optimize outcome in patients undergoing 
PCI. In the last decade, intracoronary physiological assessment with FFR has 
become an established diagnostic tool to measure the hemodynamic importance 
of intermediate coronary lesions and guide the need for revascularization 1-3. 
However, FFR is only rarely used to assess the functional result after PCI. The 
angiographic result after PCI does not correlate with FFR post-PCI 5-8,10, 18. Pijls 
et al 19 studied 750 patients with post-PCI FFR measurements and a total of 44 
patients (6%) had an FFR <0.80. In our study, more complex lesion phenotypes 
like bifurcations lesion or extensive calcification were associated with a post-PCI 
FFR ≤0.90. Furthermore, balloon postdilatation and invasive imaging were more 
frequently performed in lesions with a post-PCI FFR ≤0.90.
On a patient level, diabetes mellitus and peripheral arterial disease were more 
prevalent in patients with ≥1 lesion with a post-PCI FFR ≤0.90.
Currently, no substantial data on the exact mechanism of a suboptimal result after 
PCI (as measured with FFR) exist. There are several potential explanations for a 
low FFR value after PCI, including incomplete stent deployment, underexpansion 
or malapposition, protruding struts in bifurcations, small edge dissection or plaque 
shift proximally or distally to the stent and remaining nontreated atherosclerotic 
disease throughout the coronary artery. In the present study, a significant pressure 
drop (>0.05) was found almost twice as often in the segments distal of the stent, 
as compared to the stented segments and the proximal segments (32% versus 
18% and 15%, respectively). In patients with post-PCI FFR ≤0.90, a significant 
pressure drop was found in over 57% of the distal segments as compared to 
only 30% of the stented and proximal segments. This could be indicative that 
diffuse atherosclerotic disease distal to the stent may play an important role in 
low FFR after PCI. Although this is currently hypothetical, invasive imaging may 
complement conventional coronary angiography to help elucidate the etiopathology 
of low FFR post-PCI.
In the DOCTORS trial (Does Optical Coherence Tomography Optimize Results of 
Stenting), which randomized 240 patients to either optical coherence tomography 
(OCT)-guided PCI or angiography-guided PCI 20, post-PCI OCT revealed stent 
under expansion in 42% of patients, stent malapposition in 32%, incomplete 
lesion coverage in 20%, and edge dissection in 37.5%. This resulted in more 
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frequent use of postdilatation in the OCT-guided group versus the angiography-
guided group (43% versus 12.5%, P<0.0001). More importantly, the mean 
post-PCI FFR in the OCT-guided group was significantly higher as compared to 
the angiography-guided group (0.94±0.04 versus 0.92±0.05, P=0.005). These 
findings are consistent with data from the earlier ILUMIEN I study (Observational 
Study of Optical Coherence Tomography in Patients Undergoing Fractional Flow 
Reserve and Percutaneous Coronary Intervention) 21. In this specific study, OCT 
and FFR were performed pre-PCI and post-PCI in 418 patients with stable or 
unstable angina or non-STEMI. Not only did post-PCI OCT uncover 14.5% 
malapposition, 7.6% under expansion, and 2.7% edge dissection, but it resulted 
in further stent optimization in 25% of patients with additional postdilatation in 
81% of the cases and placement of additional stents in 12%. As a result, post-PCI 
FFR values improved from 0.86±0.07 to 0.90±0.10 after optimization.
From this data, it may be concluded that post-PCI FFR could signal a suboptimal 
PCI result, unnoticeable by angiography alone. The most important question 
raised by these findings is: “can post-PCI FFR be used to detect and optimize 
procedural results and consequently improve patient outcome?” Agarwal et al 
22 demonstrated in 574 consecutive patients with stable angina that 143 of the 
664 treated lesions (21%) had an FFR of ≤0.80 despite optimal angiographic PCI 
results (mean post-PCI FFR 0.87±0.08). After optimization of these lesions (42% 
received further postdilation of the implanted stent, 33% additional stenting, and 
18% underwent additional stenting and postdilation), 80 lesions (56%) improved 
to an FFR >0.80, leaving 63 lesions (9.5%) with a persistently ischemic FFR of 
≤0.80. A final post-PCI FFR >0.86 was considered as the optimal cutoff, and 
this was associated with improved outcome (major adverse cardiovascular event) 
during a mean follow-up of for 31±16 months. As the percentage of patients in 
this optimal post-PCI FFR group increased from 60% to 74% after the additional 
optimization, the authors concluded these subsequent interventions not only 
improved the overall functional outcome as measured with FFR but also likely 
reduced major adverse cardiovascular event during follow-up. As this study was 
a retrospective nonrandomized study, it remains unclear whether routine FFR 
assessment, followed by additional optimization in case of low post-PCI FFR may 
actually improve patient outcome. This hypothesis is currently studied in the FFR-
REACT trial (Dutch trial register: NTR6711) that will randomize 290 patients with 
post-PCI FFR <0.90 to intravascular ultrasound-guided PCI optimization or control.
Limitations
Some limitations of the study need to be addressed. First, this is a single-center, 
observational study and, therefore, reflects local practice. Second, pressure 
measurements were performed with the Navvus microcatheter. The microcatheter 
may enhance luminal narrowing and thus affect coronary flow and result in a 
lower FFR as compared to wire-based FFR 23, 24. However, in FFR-SEARCH coronary 
physiology was assessed after successful PCI which makes the obstructive effect 
of the microcatheter less relevant, especially because only vessels >2.25 mm 
were eligible. Nonetheless, in ≈8% of the cases, the distal vessel was considered 
too small for the microcatheter. In addition, in 3.4% of the attempted lesions, the 
microcatheter was not able to cross the stented segment. Finally, this analysis 
was restricted to a 30-day clinical follow-up. The association of post-PCI FFR with 
clinical events may only appear during longer-term follow-up. The primary clinical 
end point of FFR-SEARCH is, therefore, set at 2 years.
CONCLUSION
Routine measurement of post-PCI FFR using a monorail microcatheter is safe and 
feasible. Mean post-PCI FFR was 0.90±0.07, with 73 patients (11%) having ≥1 
lesion(s) with a post-PCI FFR ≤0.80 despite angiographically successful PCI. Post-
PCI FFR did not correlate with clinical events at 30 days.
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ABSTRACT
Introduction and objective: Patients with a low post percutaneous coronary 
intervention (PCI) fractional flow reserve (FFR) are at increased risk for future 
adverse cardiac events. The aim of the current study was to assess specific patient 
and procedural predictors of post PCI FFR.
Methods: The FFR SEARCH study is a prospective single center registry including 
1000 consecutive all-comer patients that underwent FFR evaluation after 
angiographic successful PCI using a dedicated microcatheter. Mixed-effects models 
were used to search for independent predictors of post PCI FFR.
Results: Mean post PCI Pd/Pa (distal pressure divided by the aortic pressure) was 
0.96 ± 0.04 and mean post PCI FFR was 0.91 ± 0.07. Adjusting for independent 
predictors of post PCI FFR, left anterior descending artery as measured vessel 
was the strongest predictor (adjusted β =-0.063; 95%CI [-0.070 to -0.056]; 
P < .0001), followed by post procedural minimal lumen diameter (adjusted 
β = 0.039;, 95%CI [0.015 - 0.065]; P = .002). Additionally, male sex, in-stent 
restenosis, chronic total occlusions and pre- and post-dilatation were negatively 
correlated to the post procedural FFR. Conversely, type A lesions, thrombus 
containing lesions, post procedural percentage stenosis and stent diameter 
positively correlated to the post procedural FFR. The R2 for the complete model 
was 53%.
Conclusion: Multiple independent patient and vessel related predictors for post 
procedural FFR were identified, including gender, LAD as measured vessel and 
post procedural MLD.
Central illustration. Forest plot of most important predictor of the post PCI FFR
Adjusted beta values with 95% confidence intervals. The Figure includes all significant predictors from 
the multivariate generalized mix model which predicts post PCI FFR, excluding categorical variables with 
a beta <0.02. LAD = left anterior descending artery; CTO = chronic total occlusion; MLD = minimal 
lumen diameter. 
What is known about the topic?
Fractional flow reserve (FFR) has proven to be a useful technique to address 
coronary physiology and the haemodynamic significance of coronary segments 
both pre- and post-intervention. Moreover, FFR after stenting has proven to be a 
strong and independent predictor of major adverse cardiac events up to 2 years. 
Unfortunately, at present, there is lack of data on independent predictors of post 
PCI FFR.
What does this study add?
The present study is the largest report to date focusing on predictors of post 
PCI FFR. Based on data derived from the FFR SEARCH registry, we were able 
to identify several patient and procedural predictors of post PCI FFR. The main 
predictors included gender, LAD vessels and post procedural lumen dimensions. 
The latter will help to further interpret post PCI FFR values and rightfully identify 
those vessels prone for future events.
INTRODUCTION
Limitations of accurate estimation of the hemodynamic significance of coronary 
artery lesions by angiographic guidance alone are well known 1. Fractional flow 
reserve (FFR) instead has proven to be a useful technique to address coronary 
physiology and the haemodynamic significance of coronary segments both pre- 
and post-intervention 2-4. Moreover, FFR after stenting has proven to be a strong 
and independent predictor of major adverse cardiac events up to 2 years 3-5.
While FFR primarily takes into account the relative luminal narrowing and the 
amount of viable myocardium perfused by a specific vessel, several factors have 
been shown to impact pre percutaneous coronary intervention (PCI) FFR values. 
As such, longer lesion length, high syntax scores, calcifications and tortuosity are 
associated with significantly lower FFR values while the presence of microvascular 
dysfunction, chronic kidney disease and female gender have been associated with 
higher FFR values 6-11.
At present, there is lack of data on independent predictors of post PCI FFR. 
Therefore, the aim of the present study was to assess both patient and procedural 
characteristics associated with low post PCI FFR in an all-comer patient population.
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METHODS
The FFR SEARCH study is a prospective single center registry in which all 
consecutive patients underwent routine Pd/Pa (distal pressure divided by the 
aortic pressure) and FFR evaluation after angiographic successful PCI with the 
primary aim to study the impact of post PCI FFR on major adverse cardiac event 
rates at 2 years. Accordingly, no further actions were taken to improve post PCI 
FFR. The study was performed in accordance with the Declaration of Helsinki. The 
study protocol was approved by the local ethics committee. All patients provided 
written informed consent for the procedure and the use of anonymous datasets 
for research purposes in alignment with the Dutch Medical Research Act. A total 
of 1512 patients treated between March 2016 and May 2017 at the Erasmus 
Medical Center were available for our study. Among them, 504 patients were 
excluded due to either haemodynamic instability (n = 156), distal outflow being 
too small (n = 129), operator’s decision not to proceed with post PCI hemodynamic 
assessment (n = 148) or other reasons (n = 79). A total of 1000 patients were 
included in the study. The microcatheter was not able to cross the treated lesion 
in 28 patients, technical issues with the catheter prohibited post PCI assessment 
in 11 patients and in 2 patients post PCI FFR assessment had to be aborted 
prematurely due to adenosine intolerance, leaving 959 patients in which post PCI 
FFR was assessed in at least 1 angiographically successfully treated lesion. 
Quantitative coronary angiography
Pre procedural lesion type was defined according to the ACC/AHA guidelines and 
divided in 4 categories: A, B1, B2 and C 12. Comprehensive quantitative coronary 
angiography (QCA) analyses were performed pre and post stent implantation in 
all treated lesions. An angiographic view with minimal foreshortening of the lesion 
and minimal overlap with others vessels was selected. Similar angiographic views 
were used pre and post stent implantation. Measurements included: pre and post 
procedural percent diameter stenosis; reference vessel diameter; lesion length 
and minimal luminal diameter (MLD). In case of a total occlusion (in patients 
presenting with ST elevation myocardial infarction (STEMI) or a chronic total 
occlusion (CTO), the MLD was considered zero and percent diameter stenosis 
100%. Reference vessel diameter and lesion length were calculated from the 
first angiographic view with restored flow. All measurements were performed 
using CAAS for Windows, version 2.11.2 (Pie Medical Imaging, Maastricht, The 
Netherlands). 
FFR measurements
All FFR measurements were performed using the Navvus RXi system (ACIST 
Medical Systems, Eden Prairie, MN, USA), a dedicated FFR microcatheter with 
optical pressure sensor technology 13, 14. Measurements were performed after an 
intracoronary bolus of nitrates (200 µg). The catheter was advanced over the 
previously used coronary guidewire approximately 20 mm distal to the most distal 
stent edge. FFR was defined as mean distal coronary artery pressure divided 
by mean aortic pressure during maximum hyperaemia achieved by continuous 
intravenous infusion of adenosine at a rate of 140 μg/kg/min through an antecubital 
vein. No vessels in this study were evaluated using admission of intracoronary 
adenosine. 
Statistical analysis 
Baseline, categorical variables are reported as counts (percentage) and continuous 
variables are reported as mean ± standard. In order to evaluate independent 
predictors for post PCI FFR, all patient and vessel characteristics were primarily 
univariately tested using a mixed-effects model (LME-model) with a random effect 
for patients and a fixed effect for post PCI FFR. All variables were subsequently 
inserted in a multivariate LME-model using the enter method, resulting in all 
significant independent predictors for post PCI FFR values. A forest plot was 
developed to depict all variables with the corresponding 95% confidence intervals. 
Beta (β) values indicate the average in-or decrease in FFR in case of a dichotomous 
variable or the increment per unit increase in case of continuous variables. 
Statistical analyses were performed by using R (version 3.5.1, packages: Hmisc, 
lme4 and nlme, RStudio Team (2020), Boston, MA). 
RESULTS
Demographic characteristics
Mean age was 64.6 ± 11.8 years and 72.5% were males. In 959 patients at least 
one lesion was measured with a total of 1165 successfully treated and measured 
lesions. Patient demographics and baseline characteristics are depicted in Table 1. 
Up to 70% of patients presented with an acute coronary syndrome (ACS), while 
18% had confirmed thrombus on angiography. Intravascular imaging was used in 
9.6% to guide the procedure. Overall, 1.4 ± 0.6 lesions were treated per patient 
and in 1.2 ± 0.5 lesions per patient post PCI FFR was successfully assessed. The 
average total stented length per vessel was 29 ± 17 mm with an average diameter 
stent of 3.2 ± 0.5 mm. 
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Mean post PCI FFR was 0.91 ± 0.07 and 7.7% of vessels had a post PCI FFR ≤ 0.80. 
In the LME-model, adjusting for independent predictors of post PCI FFR, LAD as 
measured vessel was the strongest predictor (adjusted β = -0.063, 95%CI,-0.070 
to -0.056;, P < .0001), followed by the post procedural MLD (adjusted β = 0.039, 
95%CI, 0.015- 0.065]; P = .002). Additionally, male gender, in-stent restenosis, 
chronic total occlusions (CTO) and pre- and post-dilatation were negatively 
correlated to the post procedural FFR. Conversely, type A lesions, thrombus 
containing lesions, post procedural percentage diameter stenosis and stent 
diameter positively correlated to the post procedural FFR. The R2 for the complete 
model was 53%. Figure 1 illustrates all significant and non-significant adjusted 
predictors that were put in the LME-model and Table 2 depicts all adjusted and 
unadjusted predictors with corresponding β values and 95% confidence intervals. 
The central illustrations depicts the most important predictors. 
Table 1. Baseline patient and vessel characteristics
 
Patient characteristics Total FFR SEARCH registry (n = 1000) 
Age 64.6±11.8 
Gender, male 725 (73) 
Hypertension  515 (52) 
Hypercholesterolemia  451 (45) 
Diabetes  191 (19) 
Smoking history  499 (50) 
Prior Stroke  77 (8) 
Peripheral arterial disease  76 (8) 
Prior myocardial infarction 203 (20) 
Prior PCI  264 (26) 
Prior CABG  57 (6) 
Indication for PCI   
   Stable angina 304 (30) 
   NSTEMI 367 (37) 
   STEMI 329 (33) 
Vessel characteristics (n = 1165) 
Lesion type   
 A 125 (11) 
 B1 233 (20) 
 B2 379 (33) 
 C 428 (37) 
LAD 593 (51) 
Bifurcation  138 (12) 
Calcified  402 (35) 
In-stent restenosis 39 (3) 
Thrombus  214 (18) 
Stent thrombosis  14 (1) 
Ostial  97 (8) 
CTO  42 (4) 
Stenosis Pre  69±22 
Ref diameter Pre (mm) 2.6±0.6 
Length Pre (cm) 21±11 
MLD Pre (mm) 0.9±0.6 
Predilatation 769 (66) 
Post dilatation 691 (59) 
Stenosis Post (per 10%) 4.4±13 
Ref diameter Post (mm) 2.7±0.5 
Length Post (cm) 24±13 
MLD Post (mm) 2.6±0.5 
No. Stent  1.4±0.6 
Stent length (cm) 29±17 
Stent diameter (mm) 3.2±0.5 
Mean post PCI Pd/Pa 0.96 ± 0.04 
Mean post PCI FFR 0.91 ± 0.07 
 
 
 
Values are mean ± SD or n (%). PCI = percutaneous coronary intervention; CABG = coronary artery 
bypass graft; NSTEMI = non elevated ST segment myocardial infarction; STEMI = ST elevated 
myocardial infarction; Pd/Pa = Pressure in the Distal coronary artery to the Pressure in the Aorta ratio; 
FFR = Fractional Flow Reserve. 
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Figure 1. Forest plot of independent predictors for post PCI FFR
Adjusted beta values with 95% confidence intervals. Triangles indicate non-significant predictors, while 
circles indicate significant predictors in the multivariate generalized mix model to predict post PCI 
FFR. ACS, acute coronary syndrome; PCI, percutaneous coronary intervention; STEMI, ST-elevation 
myocardial infarction; LAD, left anterior descending artery; CTO, chronic total occlusion; MLD, minimal 
lumen diameter.
DISCUSSION
The present study is the largest report to date focusing on predictors of post PCI 
FFR. Based on data derived from the FFR SEARCH registry, we were able to identify 
several patient and procedural predictors of post PCI FFR. These predictors will 
help to further interpret post PCI FFR values and rightfully identify those vessels 
prone for future events. At first, male gender appeared to be negatively correlated 
to post procedural FFR. The latter finding extends the findings previous studies 
focusing on the impact of gender on pre PCI FFR measurement 6, 11, 15, 16. Males 
are known to have a lower prevalence of microvascular dysfunction as compared 
to females 8, 17. The concept of FFR is based on drug induced maximal hyperemia 
in order to minimize microvascular resistance. Microvascular dysfunction may 
hamper this vasodilator response and consequently result in a dampened flow 
response and elevated FFR 15. Subsequently, males have on average a larger 
myocardial mass and thus, larger myocardial perfusion territories as compared 
to females 18, 19. The importance of the latter can be illustrated by the second and 
strongest predictor of post PCI FFR in the present study, measurement of FFR in 
the LAD. FFR values are associated with myocardial mass and outflow territory of 
the measured vessel. As such, the LAD, the vessel with the largest perfusion area, 
has previously been correlated to lower pre and post procedural FFR values 20-22. 
Stent diameters of implanted stents in the RCA are, on average larger, even 
though the outflow territory of the LAD is larger 23. The discrepancy between 
luminal dimensions and myocardial mass might explain why optimal improvement 
of the FFR in the LAD is hard to achieve 23. 
Third, larger stent diameters and larger post PCI MLD were associated with 
higher post PCI FFR, however, higher post procedural percentage stenosis was 
also correlated to higher post PCI FFR values. While these findings might seem 
contradictory, also in the DEFINE PCI study post procedural percentage stenosis 
was not correlated to post PCI physiology 24. 
In the intravascular ultrasound sub-study of the FFR SEARCH registry van Zandvoort 
et al. demonstrated that clear signs of residual luminal narrowing, including focal 
lesions, underexpansion and malapposition, were present in a significant amount 
of vessels with a post PCI FFR ≤ 0.85, findings that could not linked not readily 
apparent on QCA 25. Percent diameter stenosis was 20% in both the cohort of 
patients with a post PCI<=0.85 and >0.85 26.
Next to the latter predictors of post PCI FFR, we identified several other predictors. 
A dedicated analysis on 26 CTO’s recently illustrated that post procedural FFR values 
initially are typically low; however appeared to increase at 4 months follow-up. 
The initial low post PCI FFR is hypothesized to be due to microvascular dysfunction 
in the recently opened vessel, a phenomena which improves after several months 
27. In-stent restenosis and pre- and post-dilatation were associated with lower 
post PCI values. The latter is in line with previous studies demonstrating that 
complex lesions in general were associated with lower post PCI FFR values 20, 21, 
26, 28. 
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Of interest was also the impact of the clinical presentation on post PCI FFR in the 
study population in which the majority of patients presented with ACS. In contrast 
to previous studies questioning the validity of invasive hyperemic physiological 
indices in patients presenting with ACS, we were not able to confirm an impact 
of clinical presentation on post PCI FFR. The identification of thrombus however, 
often present after a plaque rupture in ACS patients, was associated with 
significantly higher FFR values. Despite the restoration of epicardial flow by the 
PCI, a relatively large proportion of patients with STEMI have abnormal myocardial 
perfusion at the end of the procedure 29. This phenomenon is thought to be related 
to microvascular obstruction due to distal embolization (reperfusion injury) and 
tissue inflammation duo to myocyte necrosis 30, 31. The latter might explain the 
significantly higher post PCI FFR values in patients presenting with thrombus 
containing lesions as compared to those without. Conversely, our findings also 
illustrate that in patients without thrombus containing lesions post PCI FFR might 
be a valuable diagnostic tool to identify those patients with an elevated risk for 
future adverse cardiac events. 
Limitations
The current study was performed with the Navvus microcatheter, a dedicated rapid-
exchange microcatheter with a mean diameter of 0.022’’ that proved to result in 
a slight but significant underestimation of FFR as compared to the conventional 
0.014’’ pressure wires 32. The latter withholds us from direct extrapolation of the 
current findings towards wire based FFR devices 14. Based on the study protocol, 
no further action was taken in case of a low post PCI FFR. The Target FFR and 
FFR REACT study (NCT03259815 & NTR6711) should provide more information 
concerning post-PCI FFR and the potential of further actions intended to improve 
post PCI FFR and clinical outcomes 33, 34. The latter studies should also focus on the 
trade-off of potential benefits and harm when performing additional interventions 
in order to improve the final FFR values. 
CONCLUSION
In this substudy of the FFR SEARCH registry, the largest real world post PCI FFR 
registry thus far, we identified gender, LAD vessels, post procedural MLD and 
several other independent predictors for post procedural FFR. 
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Impact of post-stenting fractional flow 
reserve on long term clinical outcomes – the 
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ABSTRACT
Background: Fractional flow reserve (FFR) guided treatment has been 
demonstrated to improve percutaneous coronary intervention (PCI) results. 
However, little is known on the long-term impact of low post PCI FFR 
Methods: This is a large prospective all comers study evaluating the impact of 
post-PCI FFR on clinical outcomes. All patients undergoing successful PCI were 
eligible for enrollment. FFR measurements were performed immediately after PCI 
when the operator considered the angiographic result acceptable and final. No 
further action was undertaken based on the post-PCI result. Suboptimal post-PCI 
FFR was defined as FFR<0.90. The primary endpoint was major adverse cardiac 
events (MACE), a composite of cardiac death, any myocardial infarction or any 
revascularization at 2-year follow-up. Secondary end-points were target vessel 
revascularizations (TVR) and stent thrombosis (ST) and the separate components 
of the primary endpoint.
Results: A total of 1000 patients were enrolled. Post PCI FFR was successfully 
measured in 1165 vessels from 959 patients. A post-stenting FFR<0.90 was 
observed in 440 vessels (37.8%). A total of 399 patients had at least 1 vessel 
with FFR<0.90 post-PCI. At 2-year follow-up, a patient level analysis showed 
no association between post PCI FFR and MACE (HR1.08 [95%CI, 0.73-1.60], 
p=0.707), cardiac death (HR1.55 [95%CI, 0.72-3.36], p=0.261), any myocardial 
infarction (HR1.53 [95%CI, 0.78-3.02], p=0.217). A vessel level analysis showed 
a higher rate of TVR (HR1.91 [95%CI, 1.06-3.44], p=0.030) and a tendency 
towards higher rate of ST (HR2.89 [95%CI, 0.88-9.48], p=0.081) with final post-
PCI FFR<0.90.
Conclusion: Suboptimal Post-PCI FFR has only a moderate impact on MACE but 
coronary arteries with a post-PCI FFR<0.90 have a higher rate of TVR.
INTRODUCTION
Fractional flow reserve (FFR) is a reliable index of functional severity for epicardial 
vessel stenosis 1. This diagnostic tool facilitates the correct identification of 
hemodynamically significant coronary artery disease, translating into increased 
intervention appropriateness and improved clinical outcomes 2, 3. Therefore, 
the ESC/EACTS guidelines on myocardial revascularization formulated strong 
recommendations towards FFR guidance for percutaneous coronary interventions 
(PCI) 4. 
Conversely, the significance of FFR immediately after stenting to assess the 
impact of the treatment on coronary flow and the possible residual stenosis has 
been poorly investigated and data on this specific FFR application are sparse 5. In 
particular, a relationship between post-PCI FFR and clinical outcomes has mainly 
been derived from retrospective studies and post-hoc analyses of randomized 
studies, with unclear results in terms of optimal cut-off values for the identification 
and definition of sub-optimal post-stenting FFR 6-8. Given this background, we 
performed the FFR-SEARCH prospective study, to investigate the clinical impact of 
post-PCI FFR values on long terms clinical outcomes using a cut-off value for the 
definition of sub-optimal FFR (FFR <0.90) already hypothesized in the FAME 1 and 
FAME 2 trials 7, 9 and supported by large meta-analyses 10 but never evaluated in 
a prospective fashion.
METHODS
Patient population 
The FFR-SEARCH (Fractional Flow Reserve Stent Evaluated at Rotterdam Cardiology 
Hospital) is a large prospective, open label, all comers study evaluating the impact 
of post stenting FFR on long-term clinical outcomes. 
Consecutive patients undergoing coronary intervention with stent implantation, 
irrespectively of the clinical presentation were considered for the study. Culprit 
lesions in patients presenting with ST- elevation or non ST-elevation acute coronary 
syndromes were included in the analysis. Exclusion criteria comprised age <18 
years, cardiogenic shock, high-risk PCI with mechanical circulatory support, 
vessel size <2.25 mm by visual estimation, uncertain neurological outcome after 
cardiopulmonary resuscitation, planned CABG as a staged procedure (hybrid) 
within 12 months of the index procedure.
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Post stenting FFR measurements and analysis
Functional assessments were performed at the end of the procedure when the 
operator considered the angiographic result acceptable and final. 
The Guide-wire access to the vessel was maintained and was used to advance a 
monorail micro-catheter with an optical pressure FFR sensor technology (Navvus 
RXi, ACIST Medical Systems, Eden Prairie, MN 11.
For post-stenting FFR values the microcatheter sensor was positioned in the mid-
distal segment of the investigated vessel and at least 20 mm distal of the most 
distal stent edge and hyperaemia was induced with a continuous intravenous 
infusion of adenosine at 140 μg/kg/minute for at least 2 minutes. 
As per study protocol and in order not to bias the predictive value of post-PCI FFR 
no additional interventions were performed regardless of the final post-PCI FFR 
value 12.
Based on previous reports, comparisons in terms of long-term clinical outcomes 
were made using a post-PCI FFR cut-off value of 0.90 7, 10. In the patient-level 
analysis, patients were stratified based on the presence at least one post-PCI FFR 
value <0.90. Therefore, for the patient-level analysis the patients were divided 
into two groups: 1) at least one FFR<0.90 and 2) No any FFR<0.90. 
In addition, a vessel level analysis was performed. The study was performed in 
accordance with the Declaration of Helsinki. The study protocol was approved by 
the local ethics committee. All patients provided written informed consent for the 
procedure and the use of anonymous data-sets for research purposes in alignment 
with the Dutch Medical Research Act.
Quantitative Coronary Angiography
Two-dimensional quantitative coronary angiography (2D-QCA) was performed for 
descriptive purposes, pre- and post-stent implantation in all treated lesions, using 
angiographic projections with minimal foreshortening of the lesion and minimal 
overlap with others coronary vessels. Analyses were performed with a dedicated 
quantitative coronary angiography (QCA) analysis software (CAAS Workstation, 
Pie Medical Imaging, Maastricht, the Netherlands). QCA measurements included 
lesion length, reference diameter, minimal lumen diameter, and diameter stenosis. 
In case of totally occluded vessels either acutely or chronically the minimal lumen 
diameter value was considered 0% and diameter stenosis 100% in the pre-
stenting analysis and reference vessel diameter and lesion length were calculated 
from the first angiographic view with restored flow.
Clinical Follow-up and definitions
Clinical follow-up was obtained for each patient from electronic medical records 
of the hospital, general practitioner, and the municipal civil records databases. 
In addition, all patients were contacted personally by letter or telephone. 
Clinical events including all-cause mortality, cardiac mortality, any spontaneous 
myocardial infarction, target vessel revascularization, any revascularization and 
stent thrombosis, were collected. 
The primary endpoint was major adverse cardiac events (MACE), defined as 
a composite of cardiac death, any spontaneous myocardial infarction or any 
revascularization. The secondary end-points were target vessel revascularizations 
(TVR), stent thrombosis (ST) and the separate components of the primary 
endpoint. Cardiac death was defined as any death in which a cardiac cause could 
not be excluded 13. Myocardial infarction was defined according to the fourth 
universal definition of myocardial infarction 14. Target vessel revascularization 
(TVR) was defined as a re-intervention driven by any lesion located in the same 
epicardial vessel. Stent thrombosis was defined according to the ARC 2 definitions 
13. Event adjudication was performed by two independent cardiologists unaware of 
the final physiological assessment.
Statistical analysis
Baseline, categorical variables are reported as counts and percentages and 
compared using the Chi Squared test on patient level and generalized linear mixed 
models (GLMM) with random intercepts on vessel level. Baseline, continuous data 
are presented as mean with standard deviation for normally distributed variables 
and as medians with interquartile range for variable that were not normally 
distributed. Differences between both groups for continuous data were assessed 
using the independent t-test on patient level and GLMM with random intercepts 
on vessel level.
The Kaplan-Meier method was applied to show the cumulative incidence of 
clinical endpoints. The association between post PCI FFR and clinical endpoints 
was analysed by Cox proportional hazard regression analysis. First the analysis 
was performed univariably. Then the analysis was adjusted for potential 
confounders. To identify potential confounders, univariable associations of 
baseline characteristics with the clinical endpoints were examined, and variables 
with a univariable p value <0.1 were entered into the multivariate models. In 
the ‘patient level’ analyses the associations of post PCI FFR with MACE, cardiac 
death, MI and any revascularization were consequently adjusted for gender, 
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hypertension, dyslipidaemia, diabetes, smoking, peripheral arty disease, prior 
PCI, prior infarction, prior CABG, STEMI, NSTEMI and stable angina. 
For the analysis on a vessel level, Cox regression with robust standard errors was 
used to account for the correlation between the vessels in case multiple vessels 
were assessed within one patient. In these analyses, the associations of post 
PCI FFR with TVR and stent thrombosis were adjusted for bifurcation, severe 
calcification, in-stent restenosis, thrombotic culprit lesion in STEMI, CTO and 
stented region located in the left anterior descending artery. Data are presented 
as Hazard-Ratios (HRs) with 95% confidence intervals (CI 95%). 
All tests were two-tailed and a P value <0.05 was considered statistically significant. 
Statistical analyses were performed using SPSS statistics for Windows, version 
24.0 (SPSS, Chicago, IL, USA) and R (version 3.4.1).
RESULTS
A total of 1512 patients were screened and 1000 patients with 1207 treated 
vessels were included. Post-PCI FFR measurement was successfully performed 
in 959 patients and 1165 vessels (Table 1, Table 2, Figure 1). No complications 
related to the use of the FFR microcatheter were observed (Table 3). A post-
PCI FFR <0.90 was reported in 440 vessels (37.8%), and ≤0.80 in 90 (7.7%) 
vessels (Figure 2). Baseline clinical characteristics are reported in Table 1. In brief 
the mean age was 64.6±11.8 years, 19% of patients had diabetes, 70% of the 
coronary lesions were B2 (33%), or C (37%) with a median stent length of 23mm 
(IQR 15-36) and a median post-stenting MLD of 2.6mm (IQR 2.25-2.93). Patients 
with a final post-stenting FFR<0.90 more frequently had hypertension (58% vs 
49%, p=0.005), hypercholesterolemia (52% vs 42%, p=0.001), diabetes, (24% 
vs 16%, p=0.001). Patients with a final post-stenting FFR ≥0.90 presented more 
often with a STEMI (20% vs 41%, p <0.001) (Table 1). Vessels with a final post-
stenting FFR <0.90 were more often calcified (45% vs 28%, p<0.001) and less 
frequently thrombotic (11% vs 23%, p<0.001). 
Vessels with post-stenting FFR ≥0.90 showed a smaller pre-intervention MLD of 
0.9mm (IQR 0.4-1.3) vs 1.0 (IQR 0.7-1.4), p<0.001) by QCA, but a larger post-
procedure MLD (median 2.7 vs 2.5mm, p<0.001).
Complete 2-year follow-up was available in 849 patients (88.5%), 39 had at least 
1-year follow-up, 59 patient had follow up between 1-365 days, 12 patients were 
lost at follow up.
Figure 1. Study flow-chart
At 2-year follow-up at the univariate analysis and after adjustment for confounders, 
in the patient level analysis, no associations were found between post PCI FFR and 
MACE (HR 1.08, [95% CI, 0.73-1.60] p=0.707), cardiovascular death (HR 1.55 
[95% CI, 0.72-3.36] p=0.261) and any myocardial infarction (HR 1.53 [95% CI, 
0.78-3.02] p=0.217) (Table 4, Figure 3).
In the individual vessel level analysis, a higher rate of TVR (HR 1.91, [95%CI, 
1.06-3.44], p=0.030) and a tendency towards higher rate of ST (HR 2.89, [95%CI, 
0.88-9.48], p=0.081) was observed with a final post-stenting FFR <0.90 (Table 
4, Figure 4).
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Table 2. Procedural Characteristics 
 
 
 
  
 
All vessels with 
post-PCI FFR 
(n=1165) 
FFR 
<0.90 
(n=440) 
FFR 
≥0.90 
(n=725) 
p value 
Lesion type, n (%)     
 A 125 (11) 34 (8) 91 (13) 0.012 
 B1 233 (20) 84 (19) 149 (21) 0.557 
 B2 379 (33) 150 (34) 229 (32) 0.380 
 C 428 (37) 172 (39) 256 (35) 0.198 
Bifurcation 138 (12) 78 (18) 60 (8) <0.001 
Calcified 402 (35) 196 (45) 206 (28) <0.001 
In-stent restenosis 39 (3) 24 (6) 15 (2) 0.003 
Thrombus 214 (18) 47 (11) 167 (23) <0.001 
Stent thrombosis 14 (1) 7 (1) 7 (1) 0.351 
Ostial 97 (8) 38 (9) 59 (8) 0.783 
CTO 42 (4) 24 (6) 18 (3) 0.011 
Measured vessel, n (%)     
Right coronary artery 331 (28) 57 (5) 274 (24) <0.001 
Left Main 19 (2) 12 (1) 7 (1) 0.029 
Left anterior descending 
artery 593 (51) 339 (29) 254 (35) <0.001 
Left circumflex artery 211 (18) 32 (3) 179 (15) <0.001 
Coronary Artery Bypass 
Graft 10 (1) 0 (0) 10 (1) * 
2D-QCA measurements; 
median (IQR)     
Stenosis Pre, %  63 (50-78) 56 (44-70) 
67 (53-
86) <0.001 
Stenosis Post, %  4 (-4-13) 4 (-5-13) 5 (-3-13) 0.190 
MLD Pre, mm 0.92 (0.56-1.34) 1.0 (0.7-1.4) 
0.9 (0.4-
1.3) <0.001 
MLD Post, mm 2.60 (2.25-2.93) 2.5 (2.2-2.8) 
2.7 (2.3-
3.0) <0.001 
Stent length, mm 23 (15-36) 26 (15-40) 
22 (15-
35) 0.004 
Stent diameter, mm 3 (3-4) 3 (2.75-3.5) 3 (2-5) <0.001 
No. of Stents, n mean±SD 1.4±0.6 1.4±0.7 1.3±0.6 0.007 
Pre-dilation, n (%) 769 (66) 328 (75) 441 (38) <0.001 
Post-dilation, n (%) 691 (59) 305 (69) 386 (53) <0.001 
FFR, mean±SD 0.91±0.07 0.84±0.05 0.95±0.03 <0.001 
Vessel-based analysis: CTO= chronic total occlusion; IQR= Interquartile range; MLD= minimum luminal 
diameter; *Not tested due to complete separation. Data are reported as mean ± SD or median and IQR
Table 1. Baseline clinic characteristics
 
 
Patient characteristics All patients (n=959) 
FFR <0.90 
(n=399) 
FFR ≥0.90 
(n=560) p value 
Age (years) 64.6±11.8 64.7±11.3 64.2±12.4 0.335 
Male gender (n) 725 (76) 301 (75) 424 (75) 0.090 
Cardiovascular risk factors, 
n (%)     
Hypertension 515 (54) 228 (57) 287 (51) 0.005 
Hypercholesterolemia 451 (447) 206 (52) 245 (44) 0.001 
Diabetes 191 (20) 97 (24) 94 (17) 0.001 
Current smoker 499 (52) 184 (46) 315 (56) 0.056 
Prior stroke 77 (8) 37 (9) 40 (7) 0.128 
Peripheral art. Disease 76 (8) 42 (11) 34 (6) 0.004 
Comorbidity, n (%)     
Prior myocardial infarction 203 (21) 100 (25) 103 (18) 0.002 
Prior PCI 264 (28) 120 (30) 144 (28) 0.032 
Prior CABG 57 (6) 17 (4) 40 (7) 0.110 
Hb level (mmol/L), 
mean±SD 8.7±1.0 8.6±1.0 8.7±1.0 0.568 
Creatinine (µmol/L), 
median (IQR) 84 (72-99) 85 (73-98) 83 (71-99) 0.030 
Presentation, n (%)     
Stable angina 304 (32) 151 (38) 153 (27) <0.001 
Unstable angina / NSTEMI 367 (38) 167 (42) 200 (36) 0.006 
STEMI 329 (34) 81 (20) 248 (44) <0.001 
 
 
 
  
BMI= body mass index; CABG= coronary artery bypass graft; Hb= haemoglobin; IQR= Interquartile 
range; (N)STEMI= (non) ST-elevation myocardial infarction; PCI= percutaneous coronary intervention.
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Figure 3. Kaplan-Meier curves for MACE, cardiovascular mortality, myocardial infarction and any 
revascularization. Patient-based analysis.
 
Figure 4. Kaplan-Meier curves for target vessel revascularization and stent thrombosis. Vessel-level 
analysis.
Table 3. Post-stenting FFR measurements and microcatheter performance
  All vessels (n=1165) 
Successful post-PCI FFR, mean±SD 96.5% (1165) 
Average Pd/Pa 20mm distal of stent, mean±SD 0.96 ± 0.04 
Average FFR value 20mm distal of stent, mean±SD 0.91 ± 0.07 
Average FFR value distal stent edge, mean±SD 0.95 ± 0.06 
Average FFR value proximal stent edge, mean±SD 0.98 ± 0.04 
Average drift value, median (IQR) 0.01 (0.00-0.02) 
Average time per lesion (minutes), mean±SD 5.0 ± 1.4 
FFR microcatheter related complications, n (%) 0 (0) 
 
  
Table 4. Clinical outcomes at 2-year follow-up  
 
 FFR <0.90 vs FFR ≥0.90 
 Univariate 
HR [95% CI] p value 
Multivariate 
HR [95% CI] p value 
Patient-based analysis   
MACE 1.17 [0.81-1.70] p=0.397 1.08 [0.73-1.60] p=0.707 
Cardiovascular Death 1.58 [0.77-3.23] p=0.212 1.55 [0.72-3.36] p=0.261 
Any Myocardial Infarction 1.72 [0.91-3.27] p=0.095 1.53 [0.78-3.02] p=0.217 
Any Revascularization 1.23 [0.81-1.88] p=0.33 1.10 [0.71-1.73] p=0.666 
Vessel-based analysis   
TVR 1.71 [0.98-2.99] p=0.061 1.91 [1.06-3.44] p=0.030 
Stent thrombosis 2.71 [0.99-7.46] p=0.054 2.89 [0.88-9.48] p=0.081 
 
 
 
  
Data are presented as Hazard ratio (HR) [95% Confidence Interval (CI)] p-value. MACE= Composite 
endpoint of cardiac death, myocardial infarction and any revascularization. Extended Cox regression 
with time-dependent covariate modelling was performed. Data are reported as mean ± SD or median 
and IQR
Figure 2. Vessels distribution per 0.01 FFR increment
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DISCUSSION
FFR SEARCH is the largest prospective study to date evaluating the impact of 
post-stenting FFR on long-term clinical outcomes. The main findings of our study 
are: 1) post-stenting FFR is safe, feasible and can be easily performed when using 
a rapid exchange microcatheter maintaining wire access. 2) Impaired coronary 
physiology expressed by FFR < 0.90 was common (37.8% of patients). 3) Post PCI 
FFR < 0.90 was not associated with overall MACE. But on a vessel level analysis 
FFR < 0.90 post PCI resulted into a higher rate of target vessel revascularizations 
and a trend towards higher rate of stent thrombosis during a follow up of 2 years.
A large body of evidence has cemented FFR as the standard for invasive ischemia 
detection in the catheterization laboratory and both American and European 
clinical guidelines have formulated strong recommendations for FFR evaluation 
in intermediate coronary stenosis 4, 15. Conversely, not much is known about the 
relevance of coronary physiology to address PCI results. 
Post-PCI FFR with a rapid exchange microcatheter appeared safe and easy to 
execute over the coronary guidewire that was previously used for PCI mitigating 
the need for additional wire manipulations and concomitant risk of wire passage 
behind stent struts and coronary dissections 11.
The FFR cut-off < 0.90 was derived from a post-hoc analysis of the FAME Trials 9 and 
was supported by a large meta-analysis 10, however, never tested in a prospective 
fashion. Using this threshold more than one third of the final results judged as 
acceptable by angiography were categorized as sub-optimal, highlighting its 
clinical relevance. On the other hand we cannot exclude that lower cut-off values 
might have a similar or even higher association with clinical events.
The comparison of clinical outcomes on a patient-level analysis showed a 
consistent numerical, although non-statistically significant, increase in clinical 
events in subjects with suboptimal post-PCI FFR values. Such results are in line 
with previous retrospective studies or post-hoc analyses suggesting a moderate 
impact of sub-optimal post PCI FFR on hard clinical end-points and a more relevant 
impact on vessel-specific end-points 7, 8. Piroth Z. and collegues, comparing the 
2-year outcome of lower and upper tertiles of post-PCI FFR reported a significant 
increase of the vessel oriented composite end point (VOCE), defined as the 
composite of vessel-related cardiovascular death, vessel-related spontaneous 
(nonperiprocedural) MI, and ischemia-driven target vessel revascularization 
(9.2% vs. 3.8%, p=0.037) 7. Lee J.M. showed in patients with low post-PCI FFR a 
higher risk of 2-year TVF compared with those with high post-PCI FFR (9.1% vs. 
2.6%, p = 0.006) 8. Importantly, lesions with FFR <0.90 post PCI was associated 
with more TVR and a numerical increase of definite stent thrombosis, this analysis 
might be able to better capture the real impact of a single post-stenting FFR 
values on a specific vessel. 
From a mechanistic point of view, post-stenting FFR indicates residual flow 
impairment during maximal hyperaemia 7. Various factors that may not be 
appreciated by conventional angiography might contribute to the flow impairment, 
such as proximal or distal residual focal stenosis, stent underexpansion, or diffuse 
atherosclerotic disease 16-18. Invasive coronary imaging may help elucidate the 
pathophysiologic mechanism of impaired coronary flow and guide corrective 
measures including high-pressure balloon post-dilation, additional stenting or 
drug eluting balloon therapy.
Optimization of a suboptimal post PCI FFR may be challenging and FFR pullbacks 
can help identifying focal drops or more gradual decreases 1, 19. Still, FFR pullbacks 
are not devoid of limitations, such as the absence of a clear threshold 20, the need 
for prolonged adenosine infusion, with possible patients discomfort and unstable 
hyperaemia, the occurrence of pressure recovery affecting pressure gradients and 
often increasing the proportion of focal lesion identification 19, 21 and finally cases 
with no clear FFR drop but a diffuse pressure loss indicating a diffuse disease, 
particularly challenge to treat with local therapies 20. therefore, intravascular 
coronary imaging may complement post PCI FFR. 
In this context, the currently on-going FFR REACT Trial (NTR6711) 22 is 
randomizing patients with a post PCI FFR <0.90 to either standard of care (no 
additional intervention) or intravascular ultrasound (IVUS) directed optimization. 
The primary end point is the composite of cardiac death, target vessel MI and 
clinically driven target vessel revascularisation (target vessel failure) at 1 year.
Limitations 
FFR SEARCH is a single centre study. The sample size is limited and might be not 
sufficient to highlight differences in terms of hard clinical outcomes. Given the 
observational nature of the analysis, the results do not evaluate the clinical benefit 
of additional intervention in vessels with sub-optimal post-PCI FFR. No direct 
comparisons between microcathter based and wire based FFR was performed in 
terms of stented lesion crossability. Further large randomized trials are needed to 
fully investigate the relation between sub-optimal post-PCI FFR and clinical events 
and to elucidate PCI optimization strategies.
5
Chapter 5 - Long term outcome of FFR SEARCHPart I - Value of Post PCI Phsicology
119 || 118
CONCLUSION
FFR< 0.90 occurs in approximately one third of patients post stenting. Suboptimal 
Post-PCI FFR has only a moderate impact on MACE. Post PCI FFR <0.90 is 
associated with a higher rate of target vessel revascularizations.
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Stent implantation for the treatment of coronary artery disease can cause 
unintended tearing at the site of vessel wall adjacent to the stent struts resulting 
in a stent edge dissection (SED). At present, limited data is available on the 
exact optical coherence tomography (OCT) characteristics and extent of SEDs that 
might warrant further treatment. Given this background, we aimed to study the 
morphometric features and impact of untreated SEDs on clinical outcomes and 
assess dissection healing by serial OCT. 
We retrospectively identified 295 untreated SEDs in 261 patients from a dedicated 
local database containing all OCT recordings from January 2009 to August 2017. 
Patients were eligible in case they underwent a percutaneous coronary intervention 
with stent implantation and post procedural OCT evaluation. SEDs were defined as 
tearing of the vessel luminal surface within 5 mm of the proximal or distal stent 
border. Selected pullbacks with untreated SEDs were quantitatively analysed using 
dedicated software (Rubo DICOM viewer 2.0, Rubo Medical Imaging, Aerdenhout, 
The Netherlands). 
The plaque type at the site of the SED was categorized into fibrous, fibroatheroma, 
lipid or necrotic core, superficial calcium or deep calcium. The following 
morphometric characteristics of each dissection were measured: longitudinal 
length, circumferential extension, cavity depth, maximal thickness of the dissection 
flap, minimal lumen area and area stenosis in the SED, dissection area and 
reference lumen area. The severity of each dissection was further characterized 
based on its extend to either subintimal or submedial and the presence of an 
intramural hematoma or thrombus 1. Finally, in the subset of 51 patients (53 SEDs) 
with follow-up OCT imaging, the presence of late persisting SEDs on OCT was 
evaluated stratified per follow-up timeframe, (1-7 days, 7 days-6 months, 6-12 
months and > 1 year). The primary endpoint of the study was a device-oriented 
composite endpoint (DOCE) at one year, defined as a composite of cardiac death, 
target lesion myocardial infarction (MI) or target lesion revascularization. In order 
to evaluate independent predictors for DOCE at follow-up, all patients, vessel and 
SED characteristics were first tested univariately using a Cox proportional hazards 
model which accounted for the multilevel nature of the data. Subsequently, 
variables with a p<0.05 were inserted into the model. For the stratified analysis of 
distal and proximal SEDs, only univariate hazard ratios (HR) were examined since 
not enough events occurred for a multivariate analysis. The data and analytical 
methods used in this study will be made available to other researchers for the 
purposes of replicating the procedure or reproducing the results.
The study population consisted of 71% males, 22% of the patients had diabetes 
and 25% presented with an ST-segment elevation MI. The overall median SED 
length was 2.0 ± (1.4-3.0) mm with an median angle of 54 ± (34-92)º. The 
minimal lumen areas in the proximal and distal SEDs were 6.4 ± (4.5-8.3) mm2 
and 4.3 ± (3.1-5.8) mm2 respectively. Clinical follow-up was available for 89% 
of the patients and at one year the cumulative incidence of the DOCE was 6.7%. 
Only SED length (adjusted HR 1.17; 95% CI 1.02-1.34) was associated with an 
increased risk of DOCE. For distal SEDs, cavity depth in mm was the only predictor 
of 1-year DOCE (HR 1.029; 95% CI 1.012-1.047), whereas reference area in mm2 
(adjusted HR 0.63; 95% CI 0.45-0.87) was the only predictor for 1-year DOCE in 
patients with proximal SEDs (Figure 1). Within the first week post procedure, all 
(8/8) of the SEDs were still visible on OCT. Between 1 week and 6 months, SEDs 
remained visible in up to 15% (2/13) while between 6 and 12 months 16% (3/19) 
were still visible. No remaining SEDs were visible after one year (median follow-up 
22 months) (0/13). 
The incidence of the DOCE in the present study was significantly lower as compared 
to previous studies reporting on the outcome of patients with SEDs 2-4. The latter 
might be due to an overall lower risk of the present study population and follow-
up truncation at 1 year. The CLI-OPCI ACS and CLI-OPCI II used an arbitrary 
cut-off for flap thickness of 0.20 mm and found this to be a significant predictor 
for DOCE2, 3. In contrast, we found dissection length (best cut-off for DOCE at 
3.55mm) to be the only independent predictor of the DOCE at one year. Almost 
85% of the SEDs were no longer visible at 6 months while after 1 year, none of 
them were still visible. The latter is in line with previous research reporting SEDs 
were still visible in 10% of cases at 12 months follow-up 5. 
In conclusion, this is the largest cohort of patients with SEDs to date, demonstrating 
a 6.7% risk of 1-year cardiac events potentially linked to untreated dissections. In 
patients with SEDs, dissection length, cavity depth and proximal reference area 
were identified as predictors of the DOCE.
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Figure 1. Independent morphometric predictors of device-oriented clinical endpoint (DOCE) at 1 year 
in patient with stent edge dissections detected by optical coherence tomography 
Upper figure: Dissection length is an independent predictor for DOCE at 1 year in all stent edge 
dissections (SED), cross-section A and B refer to the corresponding location on the longitudinal view. 
The combination of highest sensitivity and specificity for SED length indicated that the best cut-off 
for DOCE at one year was at 3.55mm (Youden’s index = 0.22, area under the curve = 0.56). D and 
P denote distal and proximal respectively. Middle figure: cavity depth is an independent predictor for 
DOCE at 1 year for distal SEDs, the cross-sections correspondent to the dashed line on the longitudinal 
view. Lower figure: proximal reference lumen area is an independent predictor for DOCE at 1 year 
for proximal SEDs, cross-section A and B refer to the corresponding location on the longitudinal view. 
Cross-section B denotes the proximal reference lumen area in white. The red dash-dot lines denote the 
stented segment.
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Chapter 7
Intravascular ultrasound findings of the 
Fantom sirolimuseluting bioresorbable 
scaffold at six- and nine-month follow-up: the 
FANTOM II study
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ABSTRACT
Aims: FANTOM II is a prospective multicenter trial assessing the safety and 
efficacy of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold (BRS). 
The present substudy focuses on the 6 and 9 months IVUS findings. 
Methods and results: A total of 240 patients with de novo coronary artery 
lesions presenting with stable or unstable disease were included in 2 sequential 
cohorts (cohort A (n=117) and B (n=123) in which angiographic follow-up was 
performed at either 6 or 9 months respectively. Matched IVUS data was available 
for 35 paired cases in cohort A and 26 paired cases in cohort B. 
At 6 months, mean and minimum scaffold area (SA) decreased from 6.09±1.08mm2 
to 5.88±1.07mm2, p=0.009 and 5.27±0.99mm2 to 5.05±0.99mm2, p=0.01 
respectively. At 9 months, no significant change in mean scaffold and minimum 
scaffold area was observed (6.46±1.11mm2 to 6.38±0.96mm2; p=0.35 and 
5.45±1.00mm2 to 5.36±0.86mm2; p=0.32 respectively). Neointimal hyperplasia 
area was low at both 6 (0.11±0.12mm2) and 9 months (0.20±0.21mm2) as was 
in-scaffold obstruction volume (1.94±2.25% at 6 months and 3.40±4.11% at 9 
months). 
Conclusion: The use of the Fantom BRS in stable coronary artery disease was 
associated with low rates of neointimal hyperplasia volume and in-scaffold volume 
obstruction at both 6 and 9 months.
INTRODUCTION
Bioresorabable scaffolds (BRS) were developed to address problems associated 
with the use of permanent drug eluting metallic stents (DES) like vascular 
inflammation, neoatherosclerosis, thrombosis, jailing of side-branches and 
impairment of future surgical revascularization options 1, 2. Up until today, multiple 
types of BRS have been studied for their in vivo performance with varying degrees 
of success 2-6. 
The Fantom BRS (REVA Medical, San Diego, California) is a desaminotyrosine-
derived polycarbonate sirolimus-eluting BRS with improved radiopacity and a strut 
thickness of around 125micron 7. The device is primarily made from iodinated 
polycarbonate copolymer of tyrosine analogs (DAT) and biocompatible hydroxyl-
esters 8-10. Due to the iodine atoms, the scaffold has a similar radio-opacity to 
cobalt chromium DES precluding the need for additional tantalum or platinum 
radiopaque markers 11. The polycarbonate is degraded by hydrolysis in I2DAT, CO2 
and water. This initial degradation phase is followed by a resorption process that 
last 4 to 5 years 12. 
The device was first assessed in the Fantom I pilot study, followed by the Fantom 
II study, in the which the use of the scaffold was associated with a major adverse 
cardiac event rate of 2.6% along with a late lumen loss of 0.25+/-0.40mm in 
117 patients included in cohort A with 6 month follow-up 11, 13. The present report 
contains the intravascular Ultrasound (IVUS) findings of patients enrolled in the 
Fantom II study at baseline and either 6 or 9 months. 
METHODS 
Fantom II is a non-randomized prospective multicenter trial, enrolling patients 
in 35 sites from Australia, Belgium, Brazil, Denmark, France, Germany, The 
Netherlands and Poland, assessing the safety and efficacy of the Fantom BRS 11. 
In brief, the study enrolled patients with stable or unstable angina and single de 
novo coronary artery lesions with an average reference vessel diameter between 
2.5mm and 3.5mm and an estimated lesion length of less than 20 mm. The use of 
intravascular imaging including either IVUS and/or optical coherence tomography 
(OCT) was optional though encouraged at baseline, and mandatory at follow-up 
when performed at baseline. A total of 240 patients were enrolled in 2 cohorts 
(cohort A with 6 and 24 months angiographic follow-up and cohort B with 9 and 
48 months angiographic follow-up). 
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The present study reports the baseline and follow-up (6 and 9 months) IVUS 
findings of patients enrolled in cohort A and B respectively. Only paired analyses 
were assessed resulting in 35 paired cases in cohort A and 26 cases in cohort B 
(Figure 1). 
Figure 1. Fantom II inclusion flowchart
QCA analyses
Procedural and follow-up angiograms were assessed at an independent 
angiographic core laboratory (Yale Cardiovascular Research Group). In-scaffold 
late lumen loss (LLL) at 6 and 9 months follow-up, as assessed by quantitative 
coronary angiography (QCA), was defined as the difference between the post 
procedural minimal lumen diameter (MLD) and the MLD at follow-up. In-scaffold 
acute recoil was defined as (A-B)/A. A was the mean diameter of the stent delivery 
balloon at the highest pressure A or in case of post dilatation was used, the mean 
diameter of the post dilatation balloon at the highest pressure. B was the mean 
luminal diameter post procedural.
IVUS analyses
In 10 from the 35 sites, post procedural IVUS pullbacks were performed. Motorized 
IVUS pullbacks were performed after an intracoronary bolus of 200µg nitroglycerine 
at 40MHz (Boston Scientific, Natick, MA, USA or InfraReDx, Burlington, MA, USA) 
with a pullback speed of 0.5mm/sec. The catheter was positioned distally to 
the stented segment, at least 10mm from the distal stent edge. The automated 
pullback acquired footage from the distal reference segment to at least 10mm 
proximal to the proximal scaffold edge. At follow-up IVUS pullback was repeated 
in the same coronary segment, which was matched with post-procedural IVUS 
pullback using the fiducial anatomical landmarks. In case of a required TLR, pre-
procedural IVUS acquisitions was used for follow-up analyses.
All IVUS pullbacks were analysed by an independent core lab (Cardialysis BV, 
Rotterdam, the Netherlands). The region of interest beginning 5 mm distal to and 
extending 5 mm proximal to the treated segment was examined and analysed 14. 
Three contours were delineated on IVUS: The endoluminal contour (lumen area, 
LA), the leading edge of the struts (scaffold area, SA) and the external elastic 
membrane (EEM) area (vessel area, VA). Accordingly, four areas were quantified 
and assessed: the luminal area, the neointimal area between the lumen and the 
scaffold contours (= SA – LA), the plaque behind the struts area (= VA – SA) 
and the vessel area. The total plaque area was defined as: VA – LA 15. Incomplete 
apposition was defined as one or more scaffold struts separated from the vessel 
wall. An illustrative figure of angiographic and IVUS footage at baseline, 6 and 9 
months follow-up is shown in Figure 2
Underexpansion or expansion rate was measured according to the MUSIC criteria 
and was defined as MSA / mean reference LA * 100 16. The manufactured expected 
expansion rate was defined as MSA / (Manufactured radius2π)*100 17. The acute 
recoil was defined as (maximal balloon diameter on angiography – MSA) / maximal 
balloon diameter on angiography * 100 18.
7
Part II - Utility of POST PCI Intravascular Imaging Chapter 7 - Fantom IVUS follow-up
 
Figure 2. Angiographic and IVUS footage of baseline, 6 and 9 months in two patients 
The struts of the Fantom BRS are still clearly visible at 6 months (patient 1) and 9 months follow-up 
(patient 2). A refers to the proximal stent edge while A’ refers to the distal stent edge. The green line in 
the upper right IVUS still frame indicates the external elastic membrane area. The red line indicates the 
lumen area.
Statistical Analysis
Statistical analyses were performed by using SPSS (version 21.0, SPSS Inc, 
Chicago Ill). Categorical variables are expressed as counts and percentages. 
Differences in categorical variables between allocated cohorts are evaluated 
by applying chi-square tests, or Fisher’s exact tests. Continuous variables are 
described as mean ± one standard deviation. Differences in continuous variables 
between allocated treatment groups are evaluated by applying Student’s t-tests. 
For the main analysis a paired sample t test was used. 
RESULTS
Mean age was 59.7 years, 75.4% were male. Diabetes was present in 19.7%. 
Baseline characteristics did not differ between the cohorts (Table 1). 
As compared to cohort A, patients included in cohort B had a slightly longer 
scaffold length (19.4mm vs. 18.0mm, p=0.002), underwent more frequent post 
dilatation (96.2% vs. 74.3%, p=0.023) and average maximum balloon diameter 
was larger (3.38mm vs. 3.20mm, p=0.034) (Table 1). 
Pre-procedural QCA analyses of the entire cohort were available for 238 patients, 
while angiographic follow-up was available in 100 and 105 patients in cohorts A 
and B respectively. Preprocedural RVD was 2.71±0.37mm, MLD 0.82±0.31 mm, 
percentage diameter stenosis was 69.5±11.0%Sand acute recoil 4.0±8.3%. In 
scaffold mean LLL was 0.25±0.40mmat 6 months in cohort A and 0.33±0.36mm 
at 9 months in cohort B. 
IVUS cohort A (6 months follow-up) 
As compared to baseline, vessel area remained unchanged. At 6 months, mean 
scaffold area (SA) and minimum scaffold area (MSA) slightly decreased as 
compared to baseline (mean SA baseline: 6.09±1.08 mm2 vs. 5.88±1.07 mm2, 
p=0.009; baseline MSA : 5.27±0.99 mm2 vs. 5.05±0.99 mm2, p=0.01). Neointimal 
hyperplasia area was 0.11±0.12mm2 resulting in an in-scaffold obstruction volume 
of 1.94±2.25%. Mean and minimum lumen area decreased from baseline to 6 
months by 0.32mm2 (p= 0.005) and 0.40mm2 (p=0.006) respectively (Table 2). 
IVUS cohort B (9 months follow-up)
At 9 months follow-up, struts were still visually recognizable on IVUS as highly 
echogenic material (Figure 2). Mean scaffold area (SA) and minimum scaffold 
area (MSA) remained unchanged as compared to baseline (mean SA baseline: 
6.46±1.11 mm2 vs. 6.38±0.96 mm2, p=0.35; MSA baseline: 5.45±1.00 mm2 
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vs. 5.36±0.86 mm2, p=0.32). Neointimal hyperplasia area was 0.20±0.21 mm2 
resulting in an in-scaffold obstruction volume of 3.40±4.11%. Mean and minimum 
lumen area decreased from baseline to 9 months by 0.27mm2 and 0.49mm2 
(p<0.01) respectively (Table 3).
Comparative IVUS baseline findings of cohort A and B 
respectively
Expansion rates, manufacturer expected expansion rates and acute recoil did 
not significantly differ between the cohorts and expansion rates did not change 
between baseline and follow-up in both cohorts. However, as compared to cohort 
B, a lower in segment MLA at baseline was found in cohort A, a discrepancy which 
was no longer visible at follow-up (6 and 9 months compared) (supplemental 
Table 1). 
Table 1. Baseline and procedure characteristics of IVUS cohort A and B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Cohort A & 
B (n=61) 
Cohort A 
(n=35) 
Cohort B 
(n=26) 
p value 
Cohort A vs B 
Mean age (years)  59.8±9.4 60.5±7.2 58.8±11.8 0.52 
Male (%)  75.4 77.1 73.1 0.72 
Diabetes (%) 19.7 20.0 19.2 0.94 
Hypertension (%) 78.7 80.0 76.9 0.78 
Dyslipidemia (%) 83.6 85.7 80.8 0.61 
Family history of 
coronary artery disease 
(%) 
44.3 45.7  42.3 0.79 
Renal impairment at 
baseline (%) 0.0 0.0 0.0 - 
Peripheral vascular 
disease (%) 3.3 2.9 3.8 0.83 
Current smoker 19.7 20.0 19.2 0.94 
Prior PCI (%) 39.3 40.0 38.5 0.90 
Prior CABG (%) 4.9 8.6 0.0 0.13 
Prior MI (%) 31.1 31.4 30.8 0.96 
LAD (%) 54.1 48.6 61.5 0.32 
LCX (%) 23.0 25.7 19.2 0.55 
RCA (%) 21.3 22.9 19.2 0.73 
Nominal scaffold 
diameter (mm) 2.94±0.16 2.93±0.18 2.96±0.14 0.43 
Scaffold length (mm)  18.59±1.8 18.0±0.0 19.39±2.58 0.002 
Post dilatation (%) 83.6 74.3 96.2 0.023 
Max balloon diameter 
(mm)  3.29±0.30 3.20±0.33 3.38±0.24 0.034 
Data are shown as mean ± SD or percentage (%). LAD = left anterior descending artery; LCX = left 
circumflex artery; PCI = percutaneous coronary intervention; RCA = right coronary artery. 
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DISCUSSION
The present IVUS substudy of the FANTOM II study confirms the efficacy of the 
Fantom BRS in patients with stable coronary artery disease by successfully inhibiting 
neointimal hyperplasia at 6 and 9 months as assessed by IVUS. With a backbone 
that is designed to be absorbed within 4 to 5 years, our results show obstruction 
volumes of 1.9% and 3.4% at 6 and 9 months respectively, strengthening the 
recently published clinical and angiographic findings with late loss of 0.25 mm 
11. Although the Fantom II study only represents the performance of the scaffold 
in highly selected cases, the obstruction volumes found are comparable to 
contemporary metallic DES like Resolute Onyx with reported obstruction volumes 
of 6.9% at 8 months follow-up 19. 
A slight decrease in mean SA and MSA was observed in cohort A (0.21mm2 
(3.45%) and 0.22mm2 (4.17%) respectively) at 6 months, which was not seen in 
cohort B at 9 months in which mean SA and MSA remained unchanged. Although 
the apparent decrease in mean SA on IVUS in cohort A was merely 3.45% and 
expansion rates did not significantly differ between cohorts, post dilatation was 
more often performed in cohort B (p=0.023) and larger balloon diameters were 
used for post dilatation (p=0.034), resulting in a 0.18mm2 larger MSA and 0.37mm2 
mean SA at baseline in cohort B as compared to cohort A – despite identical mean 
labelled nominal scaffold diameters. The latter supports the use of aggressive post 
dilatation with high pressure balloons 20. 
Irrespective of the minor differences between both cohorts in the present study the 
performance of the Fantom BRS appeared comparable to earlier published findings 
on the Absorb BVS (Abbott Vascular, Santa Clara, California, USA) and superior 
to the data on the Dreams 2G (Biotronik, Bülach, Switzerland) 4, 6. Following BVS 
implantation, both mean SA and minimal SA decreased over a period of 6 months 
after implantation (MSA: -0.27 mm2 (4.9%) and mean SA -0.14 mm2 (2.1%)) 
while following implantation of the Dreams 2G, MSA decreased by 0.79 mm2 
(14.6%) (mean SA remained unchanged 0.03mm2 (0.05%)) 4. Interestingly, in 
the 12-month results of Absorb BVS, both MSA and minimum SA were back at 
baseline levels (-0.04 mm2 (0.08%) and +0.04 mm2 (0.06%) respectively) and at 
3 years, mean SA even increased further with 0.65mm2 (10.1%) as compared to 
baseline, whereas the MSA remained unchanged 15. A similar late increase in mean 
SA was seen 12 months after implantation of the DESolve BRS (Elixir Medical 
Corporation, Sunnyvale, California, USA) in which mean SA increased by 0.93mm2 
(15.7%) 21. Conversely, this late restoration of scaffold dimensions was not seen 12 
months after implantation of the magnesium Dreams 2G BRS in which a persistent 
7
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decrease in minimal SA (-0.93 mm2, 16.1%) and mean SA (-0.34 mm2, 5.2%% 
(p=ns)) as assessed by IVUS was found 5, 22. Unfortunately, in the latter studies, 
no information on the aggressiveness of post dilatation and/or post dilatation 
balloon diameters was provided. Prior in vitro research demonstrated 60-70% 
molecular weight loss after 6-9 months post implantation 23. In the present study, 
on IVUS, scaffold struts were still well visible at both 6 and 9 months follow-up 
without any apparent change in strut echogenicity (Figure 2). Although the latter 
might be due to the typical character of the materials, longer-term follow-up is 
needed to confirm the integrity of the Fantom scaffold at 2 and 4 years. 
Limitations
Several limitations need to be mentioned. First, the results of the present study 
should be considered to be applicable to a highly selected patient population 
with stable or unstable coronary artery disease and non-complex coronary artery 
lesions. The external validity might not be as strong due to the strict in- and 
exclusion criteria of the study as well as the fact that not all participating sites 
included patients for the IVUS analysis. Second, although the use of intravascular 
imaging was encouraged, there was no predefined number of IVUS cases resulting 
in a relatively small number of IVUS cases with matched baseline and follow-up 
imaging. Third, the matching of post PCI and follow-up IVUS frames are prone to 
error and we cannot ascertain for discrepancies that might have arisen. Finally, 
we hypothesized that the non-significant difference in baseline mean scaffold area 
and MSA in the subgroup of patients with baseline and follow-up IVUS was driven 
by more aggressive post dilatation in cohort B. However, in the total Fantom 
cohort no difference in post dilatation strategy was found between both cohorts. 
The latter might suggest a play of chance. In addition, the comparison between 
follow-up dimensions in supplement Table 1 between cohorts should be interpreted 
with caution given the differences in follow-up duration. 
CONCLUSION
The use of the Fantom BRS in stable coronary artery disease was effective with 
low rates of neointimal hyperplasia volume and in-scaffold volume obstruction at 
both 6 and 9 months as assessed by IVUS.
Impact on daily practice
The present findings strengthen and extend the recently published main clinical 
safety and efficacy data of the use of the Fantom Sirolimus-Eluting Bioresorbable 
Coronary Scaffold in patients with stable coronary artery disease at 6 and 9 months 
follow-up. The use of the Fantom BRS was associated with in-scaffold obstruction 
volumes of 3.40% at 9 months, comparable to contemporary metallic DES. These 
results support the safe use of the Fantom BRS with aggressive post dilatation in 
daily practice in appropriate patients. Longer-term clinical and invasive imaging 
data are needed to confirm the current findings. 
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ABSTRACT
Objectives: To assess the performance of the commercially available Magmaris 
sirolimus-eluting bioresorbable scaffold (BRS) with invasive imaging at different 
time points.
Background: Coronary BRS with a magnesium backbone have been recently 
studied as an alternative to polymeric scaffolds, providing enhanced vessel 
support and a faster resorption rate. We aimed to assess the performance of the 
commercially available Magmaris sirolimus-eluting BRS at different time points.
Methods: A prospective, single-center, nonrandomized study was performed 
at the Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands. Six 
patients with stable de novo coronary artery lesions underwent single-vessel 
revascularization with the Magmaris sirolimus-eluting BRS. Invasive follow-up 
including intravascular imaging using optical coherence tomography (OCT) was 
performed at different time points.
Results: At a median of 8 months (range 4–12 months) target lesion failure 
occurred in one patient. Angiography revealed a late lumen loss of 0.59 ± 0.39 mm, 
a percentage diameter stenosis of 39.65 ± 15.81%, and a binary restenosis rate 
of 33.3%. OCT showed a significant reduction in both minimal lumen area (MLA) 
and scaffold area at the site of the MLA by 43.44 ± 28.62 and 38.20 ± 25.74%, 
respectively. A fast and heterogeneous scaffold degradation process was found 
with a significant reduction of patent struts at 4–5 months.
Conclusion: Our findings show that the latest iteration of magnesium BRS suffers 
from premature dismantling, resulting in a higher than expected decrease in MLA.
INTRODUCTION
Bioresorbable scaffolds (BRS) provide short-term vessel scaffolding while avoiding 
long-term consequences of metallic drug-eluting stents (DES). Recent studies 
demonstrated higher rates of clinical events with polymeric BRS as compared to 
contemporary metallic DES 1. In order to improve BRS performance, alternative 
backbone materials such as magnesium are currently under investigation. First 
generations of absorbable magnesium scaffolds (AMS-1 and AMS-2; Biotronik, 
Berlin, Germany) failed to maintain vessel support due to rapid degradation 
process 2. Later iterations of the device (DREAMS and DREAMS 2G; Biotronik 
AG, Bülach, Switzerland) demonstrated safety and efficacy in the BIOSOLVE I 
and BIOSOLVE II trials 3, 4. The Magmaris sirolimus-eluting BRS (Biotronik AG) 
represents the latest generation and is currently being tested in the BIOSOLVE III 
and IV studies.
We present the findings of clinical and intravascular imaging at different time 
points following the commercial use of the Magmaris sirolimus-eluting BRS.
MATERIALS AND METHODS
All commercial cases treated with the Magmaris BRS (six cases) in the Thoraxcenter 
of the Erasmus Medical Center, Rotterdam, The Netherlands, from September 
2016 to April 2017 were included in the analysis. Angiographic follow-up was 
available for all patients at a median of 8 months (range 4–12 months). Quantitative 
coronary analysis (QCA) and optical coherence tomography (OCT) imaging analysis 
were performed offline. In-device measurements are reported and presented as 
mean ± 1 standard deviation (SD) or percentages. Wilcoxon’s signed rank test was 
used to analyze paired comparisons between continuous values. The coefficient of 
correlation of Pearson (r) was used to determine the linear relationship between 
quantitative variables. A value of p < .05 was considered statistically significant. 
Statistical analysis was conducted using SPSS for Windows version 21 (SPSS Inc., 
Chicago, IL) (see Supporting Information, Methods).
RESULTS
All patients presented with stable angina and noncomplex single-vessel coronary 
artery disease. Mean age was 57.2 years and 50% were male. One scaffold per 
patient was implanted; mean BRS diameter and length were 3.08 ± 0.20 and 
20.00 ± 4.47 mm, respectively. High-pressure predilatation and post-dilatation 
was implemented in all cases using noncompliant (NC) balloons. (see Tables S1 
and S2). 
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OCT post-procedure was performed in five cases. Procedural and device success 
was 100%. Patients were discharged on dual antiplatelet therapy (DAPT) for at 
least 12 months along with high-intensity statin treatment.
Offline pre-percutaneous coronary intervention (pre-PCI) QCA revealed a lesion 
length of 16.50 ± 4.61 mm, percentage diameter stenosis (%DS) of 61.95 ± 5.30%, 
and a reference vessel diameter (RVD) of 2.75 ± 0.25. Pre-dilatation balloon 
diameter/RVD ratio was 1.10 ± 0.10. BRS diameter/RVD ratio was 1.13 ± 0.10, 
and post-dilatation balloon diameter/BRS diameter ratio was 1.14 ± 0.10. Residual 
%DS was 22.41 ± 8.13%. Acute recoil was 5.34 ± 3.99%. Offline post-percutaneous 
coronary intervention (post-PCI) OCT showed a minimal lumen area (MLA) of 
5.64 ± 1.47 mm2 and a minimal scaffold area (MSA) of 5.62 ± 1.60 mm2. Scaffold 
expansion (SE) according to reference vessel area (SE-RVA) was 91.04 ± 18.13% 
and scaffold expansion according to manufacturer’s expected area (SE-MEA) was 
73.84 ± 16.33%. Eccentricity index and symmetry index were 0.88 ± 0.01 and 
0.32 ± 0.08, respectively. Incomplete strut apposition was 3.16 ± 4.22% (Table 1). 
No edge dissections were found.
At a median of 8 months (minimum 4 months, maximum 12 months), all patients 
were under DAPT and target lesion failure occurred in one patient (patient #5, see 
Figure S1) based on severe constrictive remodeling. All other patients remained 
asymptomatic.
Offline QCA of the invasive follow-up procedure revealed a late lumen loss (LLL) of 
0.59 ± 0.39 mm, %DS of 39.65 ± 15.81%, and a binary restenosis rate of 33.3%. 
Offline OCT at follow-up demonstrated a decrease in MLA by 43.44 ± 28.62% 
(p = .042), along with a significant decrease in scaffold area (SA) at the site of the 
MLA by 38.20 ± 25.74% (p = .043) (Figure 1 and Table 1). 
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Figure 1. Angiography and OCT imaging at baseline and follow-up
Angiography imaging available for six patients showing target vessel at baseline before intervention 
(pre-PCI), post-intervention (post-PCI) and at invasive control (follow-up). OCT imaging available 
for five patients at post-intervention (post-PCI) and for six patients at invasive control (follow-up). 
Comparison of cross-sectional image at follow-up with the MLA matched with the same cross-sectional 
image at baseline. LA, lumen area; MLA, minimal lumen area; OCT, optical coherence tomography; 
post-PCI, post-percutaneous coronary intervention; pre-PCI, pre-percutaneous coronary intervention; 
SA, scaffold area
Percentage lumen area (%LA) stenosis was 56.64% with a binary restenosis rate 
of 83.3%.
In a per-scaffold subsegment analysis, a strong linear correlation between 
SA at baseline and %LA reduction at follow-up was found (r = −.87, p = .001). 
Furthermore, a similar correlation was present between SE at baseline and %LA 
reduction at follow-up according to both RVA and MEA (r = −.86, p = .001 and 
r = − .85, p = .002, respectively) (see Figure S2a–c). Attenuation and backscattering 
analysis demonstrated a numerical reduction of maximum indices that correspond 
with strut degradation. Yet, both high and low values were within the same 
scaffolded segment at follow-up illustrating a heterogeneous strut degradation 
process (see Figures S3 and S4). No evidence of edge dissection or thrombosis 
was found.
DISCUSSION
Sufficient radial force to overcome elastic recoil and plaque resistance is an 
essential feature of contemporary stents. The mechanical properties of coronary 
stents are influenced by backbone/polymer material, geometry, and strut 
thickness5; recently, with the advent of BRS, the resorption time was also added 
to this equation. Driven by the presentation of case #5 with severe early scaffold 
collapse at 4 months, and the recent data on adverse events related to Absorb 
Bioresorbable vascular scaffold (BVS), our hospital institutional board mandated 
us to call back all previous cases treated with the commercially available Magmaris 
BRS and to perform invasive control in order to assess the performance of this 
device. This resulted in imaging assessment at different follow-up time points.
The Magmaris BRS starts its degradation process as soon as 3 months and 
completes at 12 months.6 Our results revealed a significant decrease in 
patent struts with a heterogeneous resorption pattern as soon as 4–5 months 
postimplantation; the latest was demonstrated by an important reduction of 
attenuation and backscattering indices; this is in line with a serial OCT imaging 
analysis performed in the BIOSOLVE II trial, showing a significant decrease in 
MLA of 28.3% at 6 months, and reduction of attenuation and backscattering 
values with fewer struts remnants visible 3, 7. A rapid bioresorption rate might 
induce nonuniform vessel support and loss of radial strength, which has been 
corroborated with the first generation of Absorb BVS and magnesium BRS 2, 8. 
The present report suggests that the most recent version of magnesium BRS also 
suffers from premature dismantling.
Whether the high LA reduction as found in our study could be attributed to a 
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lower radial strength secondary to rapid bioresorption, an excessive neointimal 
formation, or both, is yet to be proven. Complete SA and neointimal volumes 
throughout the scaffolded segment could not be determined due to the difficulty 
in recognizing patent struts; however, when the SA was analyzable, a significant 
reduction of SA was found compared to the postimplantation result at the same 
location. These findings are in line with seven recently published case reports on 
severe lumen reduction and scaffold collapse after Magmaris BRS implantation 
9-15. Furthermore, acute recoil was only 5.3%, in line with current generation 
metallic DES and BVS 16, 17 Preclinical data have suggested that increased local 
inflammation is responsible for the higher LLL obtained during the Magmaris 
degradation process, and a switch to a progressive positive vessel remodeling 
once the bioresorption is completed might be expected 18 The latest warrants for 
serial invasive evaluation of the vessel response beyond 12 months. Nevertheless, 
vessel constrictive remodeling occurs between 1 and 6 months after PCI; therefore, 
assuring optimal radial support for at least 6 months after device implantation 
seems to be crucial 19
Although careful lesion preparation and systematic high-pressure post-dilatation 
with NC balloons were routinely performed in all cases, a trend toward enhanced 
lumen loss in the distal scaffold edges was noticed. The latter appeared to 
be strongly linked to the post-procedural SA and lower SE at the most distal 
scaffold subsegments, compared to the middle and proximal subsegments. This 
discrepancy could be explained by the presence of smaller vessel diameter in the 
distal subsegments leading to scaffold oversizing, and potentially less aggressive 
post-dilatation due to the challenge in visualizing the tantalum markers. OCT 
assessment of magnesium BRS has shown an increase of lumen volume loss 
when expansion index is >1, 20 and previous data on Absorb BVS have correlated 
implantation in small vessel diameter with a higher rate of in-device restenosis, 21 
eccentricity, and asymmetry 22. Performing pre-procedural intracoronary imaging 
for vessel sizing and lesion characterization might help to further improve lesion/
device selection 23 On the other hand, increasing device visibility under fluoroscopy 
for future BRS generations could boost expansion optimization.
Study limitations
This is a nonrandomized single-center study with small sample size. Patient and 
lesion selection was at the operator’s discretion. Pre-PCI intracoronary imaging 
was not systematically performed. The heterogeneity of the invasive follow-up 
time points might have resulted in high SD caused by extreme values, and the 
clack of serial invasive imaging after 12 months prohibited statements on potential 
long-term lumen enlargement. The difficulty of identifying patent struts at follow-
up did not allow us to perform methodical analysis of the entire scaffold and 
precluded any detailed analyses on neointimal hyperplasia volumes.
CONCLUSION
The latest magnesium BRS iteration suffers from premature dismantling with 
subsequent loss of vessel support; together with incomplete distal device 
expansion, could have contributed to a higher than expected lumen loss. While 
our findings need to be confirmed in a randomized fashion, it seems imperative 
to follow the European working group recommendations on BRS and limiting their 
use to clinical trials or registries with adequate follow-up 24. Finally, our results 
suggest that clinical and angiographic follow-up alone might not be sufficient to 
establish the safety and long-term efficacy of new BRS, and warrants the use of 
serial invasive coronary imaging at baseline and follow-up.
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Supplementary Figure 1. Severe scaffold collapse at 4 months post-implantation of Magmaris BRS
Optical coherence tomography imaging at baseline and follow-up at the same cross-section sites 
illustrating proximal and distal constrictive remodeling and scaffold severe recoil. Lumen Area (LA); 
Minimal Lumen Area (MLA); Minimal Scaffold Area (MSA); Scaffold Area (SA).
Supplementary Figure 2. Per scaffold 10-subsegment serial changes in OCT measurements
Per scaffold subsegment correlation between SA at baseline and LA reduction at follow-up (a). Per 
scaffold subsegment correlation between SE-RVA at baseline and LA reduction at follow-up (b). Per 
scaffold subsegment correlation between SE-MEA at baseline and LA reduction at follow-up. Most 
distal subsegments (light color). Most proximal subsegments (dark color). Scaffold Area (SA); Lumen 
Area (LA); Scaffold Expansion according to Manufacturer Expected Area (SE-MEA); Scaffold Expansion 
according to Reference Vessel Area (SE-RVA).
Supplementary Figure 3. OCT of Magmaris degradation from baseline to 12 months
Upper row shows OCT representation of the degradation process of different scaffolds visualized at 
different follow-up time points. The bottom row shows attenuation values of the scaffolded segment. 
Attenuation values reduce from very high to low with struts bioresorption; higher attenuation values 
correspond to patent struts, middle attenuation values correspond to struts undergoing degradation. 
Lower attenuation values correspond to absence of struts remains. Optical Coherence Tomography 
(OCT).
Supplementary Figure 4. In-scaffold heterogeneous strut degradation
Optical coherence tomography longitudinal view (first row) and cross-section images of one Magmaris 
BRS illustrating different stages of strut degradation at 5-month follow-up in patient #6.
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ABSTRACT
Background: Angiographic assessment of left main coronary artery (LMCA) lesions 
remains challenging and limited data is available on reference diameters and 
length of non-obstructive LMCA dimensions. Our aim was to provide insights in 
the dimensions of non-obstructive LMCA and to find a possible correlation with 
gender and patient habitus.
Methods: This retrospective single centre study was performed in a consecutive 
cohort of patients who underwent Intravascular Ultrasound (IVUS) guided 
percutaneous coronary interventions of the left coronary system including 
complete pullbacks of a non-obstructive LMCA (n=254).
Results: Mean LMCA length as measured with IVUS was 7.37±4.2 mm and mean 
lumen area (LA) was 15.63±4.76 mm2 corresponding to a mean lumen diameter 
(LD) of 4.41±0.67 mm. An IVUS derived mean LD of >4 mm was present in 
71.7%, >4.5 mm in 43% and >5 mm in 19% of patients. LMCA mean LA was 
significantly smaller in women as compared to men (14.1±4.1 mm2 and 16.2±4.8 
mm2, p<0.01). Multivariable analysis identified weight of the patient as the sole 
significant predictor for LMCA length while height of the patient and LMCA length 
were predictors of LMCA mean LA. Correlation coefficients of determination for all 
independent predictors were low (R2<0.1 for all).
Conclusion: The current study demonstrated that the mean LD of a non-obstructive 
LMCA is 4 mm or greater in the majority of patients, with a mean LMCA length of 
7.4 mm. Women have smaller luminal dimension than men. No clinically relevant 
predictors were found for both LMCA length and mean LA. 
INTRODUCTION
Limitations of the angiographic assessment of left main coronary arteries (LMCA) 
lesions have been well-documented 1-3. Instead, intravascular ultrasound (IVUS) 
has proven to be a reliable tool to more precisely determine LMCA luminal 
dimensions 4-10. Multiple studies provide IVUS criteria for revascularization based 
on minimal lumen diameters (MLD) or minimal lumen areas (MLA) for diseased 
LMCAs. An MLD below 2.8 mm and MLAs smaller than 4.5 mm2 to 7.5 mm2 
were significantly correlated to late adverse events 7, 8, 11-17. Although numerous 
studies focussed on diseased LMCAs, no data is available on reference dimensions 
of LMCA as measured using IVUS and their potential relationship with patient 
characteristics. 
METHODS
Study population
This study consists of all consecutive patients undergoing percutaneous coronary 
intervention (PCI) in combination with IVUS for suspected or confirmed coronary 
artery disease in the Thoraxcenter, Erasmus Medical Centre, Rotterdam, The 
Netherlands, between January 2010 and December 2016. Patients were included 
if IVUS images from either the left anterior descending artery (LAD) or the left 
circumflex artery (LCX) were available. Patients were excluded if only IVUS images 
from the right coronary artery (RCA), or a graft vessel were present, or in case 
stenting of the LMCA was scheduled due to obstructive atherosclerotic disease. 
IVUS analysis
Targeted segments were examined with an IVUS system with automatic pullback 
at 0.5 mm/s (OptiCross, Boston Scientific, Natick, MA, USA; Eagle Eye, Volcano 
Corp, Rancho Cordova, CA, USA; TVC Insight, InfraReDx, Burlington, MA, USA) or 
2.5 mm/sec (Kodama, Acist Medical, Eden Prairie, MN, USA). IVUS images were 
digitally stored and analysed offline. Volumetric analysis of the region of interest 
was performed in fixed 0.5 mm intervals between the LMCA ostium and its distal 
bifurcation using dedicated software (QCU-CMS, CMS, Leiden University Medical 
Centre, LKEB, Division of Image Processing, version 4.69). The proximal border 
of the LMCA, the ostium, was defined as the first frame which contained a 360 
degrees luminal border of the LMCA. Whenever the transition from aorta to LMCA 
ostium was not seen because of a too deeply engaged guiding catheter, the patient 
was excluded. The distal border was defined as the last frame that contained a 
complete LMCA before an asymmetric lumen indicating the start of the bifurcation. 
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Furthermore, the external elastic membrane (EEM) had to be completely visible 
within the IVUS image. Morphometric analysis included EEM measurements, lumen 
measurements, and percent intima-and-media measurements (area stenosis; 
calculated as EEM minus lumen divided by EEM). Two volumetric intima-and-media 
indices, normalized total atheroma volume (nTAV) and percent atheroma volume 
(PAV), were also derived from these measurements. These indices have been 
used in coronary atherosclerosis regression studies and are defined as follows:
and: 
where EEMarea is the cross-sectional EEM area and lumenarea is the cross-sectional 
LA 18.
Statistical analysis
Statistical analyses were performed in SPSS (version 21.0, SPSS Inc., Chicago 
IL, USA). Categorical variables are reported percentages. Continuous variables 
are reported as mean ± standard deviation (SD). For the calculation of body 
mass index (BMI) the following formula was used: . Whenever one of the two 
variables of this formula was missing (<10% of the cases), it was imputed using 
the mean of 5 multiple imputations within the multivariable regression analysis. 
The variance coefficient (CV) was calculated with the following formula: 
For the univariate analysis the Pearson correlation coefficient was used when two 
continues variables were compared. The Pearson correlation coefficient R was 
squared in order to demonstrate the proportion of variance in the dependent 
variable that is predictable from the independent variable. In order to investigate 
the difference of continuous variables between binary groups, in this case gender, 
the independent t test was used. The Chi-Square test was used in case of two 
categorical variables. 
Finally, a multivariable regression model with a stepwise exclusion method was 
used in order to estimate the best predictive model. 
RESULTS
A total of 1197 IVUS pullbacks were performed in patients with supposedly non-
obstructive LMCA’s between 2010 and 2016, 946 patients were excluded because 
of incomplete footage of the LMCA (n=543) or other reasons (n=403) (Figure 1). 
The mean length of the LMCA as measured by IVUS was 7.3±4.2 mm. Mean LA was 
15.7±4.7 mm2, MLA was 12.7±4.6 mm2 and IVUS derived mean LD was 4.4±0.7 
mm. A mean LD >4 mm was present in 71.7% of patients, while 43% and 19% of 
the patients had IVUS derived mean LD >4.5 mm and >5 mm respectively. All the 
luminal dimensions as measured by IVUS are depicted in Table 2. The percentage 
CV for all luminal dimension displayed in Table 2 ranged between 12.5% and 
44.9% with the exception of length of the LMCA which demonstrated a percentage 
CV of 57.5%. 
Figure 1. Patient inclusion flowchart
A total of 254 patients were used for the final analysis. The study population consisted of 197 males 
(78%) and 57 females (22%), mean age was 63±11 years and mean BMI was 27.27±4.46 kg/m2. 
Baseline characteristics of the study population are depicted in Table 1. 
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Table 1. Baseline characteristics 
 
 
 
 
 
 
  
 All patients (n=254) 
Age, years (±SD) 64±11 
Male, n (%) 197 (78) 
Length, cm (±SD) 175.0±9.2 
Weight, kg (±SD) 83.8±15.9 
BMI, kg/m2 (±SD) 27.27±4.46 
DM, n (%) 53 (21) 
Hypertension, n (%) 141 (56) 
Hypercholesterolemia, n (%) 115 (45) 
Family history, n (%) 96 (38) 
Current smoking, n (%) 70 (28) 
Table 2. Quantitative IVUS dimensions analysis 
 All patients (n=254) 
Mean lumen area mm2 (±SD) 15.7±4.7 
Mean lumen diameter mm (±SD) 4.4±0.7 
Mean plaque burden mm2 (±SD) 9.4±3.4 
Minimal lumen area mm2 (±SD) 12.7±4.6 
Mean vessel diameter mm (±SD) 4.0±0.7 
Minimal lumen diameter mm (±SD) 3.95±0.7 
Length of the LMCA mm (±SD) 7.3±4.2 
nTAV mm2±SD 62.1±27.9 
PAV % (±SD) 37.7±10.2 
nTAV = normalized total atheroma volume, PAV = percent atheroma volume.
Univariate analysis identified weight and BMI as positive significant predictors 
for LMCA length (β=0.51, CI(0.017:0.085), p=0.003 R2=0.04 and β=0.16, 
CI(0.037:0.028), p=0.011 R2=0.03 respectively). Both height and weight of 
the patient were positive predictors of LMCA mean LA (β=0.09, CI(0.03:0.16), 
p=0.006 R2=0.03 and β=0.04, CI(0.004:0.08), p=0.031 R2=0.02 respectively) 
while length of the LMCA was negatively correlated to LMCA mean LA (β=-0.26, 
CI(0.03:0.16), p=0.006 R2=0.03) (Table 3 and Figure 2). 
Figure 2. Correlation plots of significant predictors for LMCA properties
LMCA mean LA was significantly smaller in women as compared to men (14.1±4.1 mm2 vs. 16.2±4.8 
mm2 respectively (p<0.01)) as were IVUS derived mean LD (4.2±0.6 mm and 4.5±0.7 mm respectively 
(p<0.01)) (Figure 3). 
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LMCA mean LA was significantly smaller in women as compared to men (14.1±4.1 
mm2 vs. 16.2±4.8 mm2 respectively (p<0.01)) as were IVUS derived mean LD 
(4.2±0.6 mm and 4.5±0.7 mm respectively (p<0.01)) (figure 3).  IVUS derived 
LMCA mean LD were >4 mm in 76% of the men, this percentage was significantly 
smaller among women (56%; p=0.003). LMCA mean LD was >5 mm in 23% of 
men and 7% of women (p=0.008). No significant differences were found in LMCA 
length between both sexes. 
Multivariable regression analyses identified weight as the only independent 
predictor of LMCA length (β=0.14, CI(0.017:0.085), p=0.003, R2=0.04) while 
patient height and length of the LMCA were the only independent predictors of 
LMCA mean LA (β=0.20, CI(0.04:0.17), p=0.002 and β=-0.25, CI(-0.41:-0.14), 
p<0.001, R2=0.09 respectively) (Table 3).
Figure 3. IVUS derived average lumen diameters according to gender
Error bars: standard error of the mean (SEM) 
DISCUSSION
By using quantitative IVUS analysis we were able to assess the luminal dimension 
of non-obstructive LMCA in a large real world cohort. We demonstrated for the first 
time how non-diseased LMCA dimensions and length vary within the population 
and how women display smaller luminal dimension compared to men. No clinically 
relevant predictors were found for both LMCA mean LA and length as correlation 
coefficients were low. 
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These findings might guide physicians in deciding on stent- and post dilatation 
balloon sizing, and support the use of intravascular imaging in LMCA stenting 19. 
Given the structural undersizing based on QCA, IVUS helps in correctly identifying 
the exact LMCA length and area and thereby improves outcomes of complex 
LMCA PCI 19-21. More specifically, we demonstrated that 19% of the patients 
presented with IVUS derived mean luminal dimensions of >5 mm, requiring post 
dilatation with balloons up to 5 mm along with the use of stents with sufficient 
post dilatation margins. In real world clinical practice, the multicentre DELTA I 
registry demonstrated that the mean diameter of stents used for LMCA stenting 
was merely 3.51 mm along with a maximal post dilatation balloon diameter of 
3.88±0.58 mm for mid-shaft and ostial treatment and 3.59±0.54 mm for distal 
LMCA treatment 22. Also in the NOBLE trial, comparing PCI and CABG for LMCA 
revascularization, only half of the LMCA stents in the PCI group were post dilated 
with balloons larger than 4 mm 23. The authors of the NOBLE trial even argued 
that underexpansion and malapposition might have contributed to a higher 
revascularisation risk in the PCI group. Our study makes this hypothesis even 
more likely since we demonstrated that IVUS derived LMCA mean LD were 4.4 
mm and 71.7% of LMCAs have a mean LD >4 mm.
Finally, LMCA LA appeared to be significantly smaller in women as compared to 
men (Figure 3). While IVUS derived LMCA mean LD were >4 mm in 76% of 
the men, this percentage was significantly smaller among women (56%). While 
multivariable analysis revealed several other predictors for both LMCA length and 
LMCA mean LA, the overall correlation appeared poor for all predictors suggesting 
a limited clinical applicability of these parameters.
Limitations 
Despite the large sample of IVUS pullbacks eligible for our study (n=1197) a 
significant amount of cases had to be excluded due to either incomplete footage of 
the LMCA or mechanical shortcomings. Although the lack of coverage by the model 
we presented is low, the relatively low percentage CV might not have changed 
substantially by enlarging our sample size. 
Nevertheless we were able to provide a complete quantitative IVUS assessment 
of 254 non-obstructive LMCAs. The latter, therefore, still represents the largest 
sample reported in the literature thus far. Finally, no additional steps were taken 
to reduce structural multicollinearity. 
CONCLUSION
The current study demonstrated that the mean luminal diameter of a non-
obstructive LMCA is 4 mm or greater in the majority of patients, with a mean LMCA 
length of 7.4 mm. Women proved to have smaller luminal dimension compared 
to men. No clinically relevant predictors were found for both LMCA mean LA and 
length.
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ABSTRACT
Background: Fractional flow reserve (FFR) after percutaneous coronary 
intervention (PCI) is a predictor of adverse cardiovascular events during follow-
up. However the rationale for low post procedural FFR values remains often elusive 
based on angiographic findings alone.
Methods and Results: FFR SEARCH is a prospective single center registry in 
which post PCI FFR was assessed in 1.000 consecutive all-comer patients. FFR 
measurements were performed with a microcatheter ±20 mm distal to the most 
distal stent edge. In 100 vessels with a post procedural FFR ≤0.85, and 20 vessels 
>0.85 high definition intravascular ultrasound analysis (IVUS) was performed. 
In 100 vessels with a post PCI FFR ≤0.85, mean post procedural FFR was 0.79±0.05. 
Minimal lumen area was 2.19 (1.81-3.19) mm2, mean lumen area was 5.95 (5.01-
7.03) mm2 and minimal stent area was 4.01 (3.09-5.21) mm2. Significant residual 
focal proximal lesions were found in 29% of the assessed vessels while focal distal 
lesions were found in 30% of the vessels. Stent underexpansion and malapposition 
were found in 74% and 22% of vessels respectively. Clear focal signs of luminal 
narrowing were found in 54% of the vessels analysed. While incidences of focal 
lesions, underexpansion and malapposition were similar between both cohorts, 
minimal stent area was significantly smaller in vessels with a post PCI FFR ≤0.85 
as compared to those with an FFR >0.85. 
Conclusion: In patients with a post procedural FFR ≤0.85, IVUS revealed focal 
signs of luminal narrowing in a significant number of cases. 
Clinical perspective
What’s known? 
 FFR after stenting is a strong and independent predictor of major adverse 
cardiac events.
 Unfortunately, the rationale for low post procedural FFR values often 
remains elusive based on angiographic findings alone.
What the study adds? 
 Residual treatable lesions or lumen compromising hematomas were 
present in 54% in vessels with a post PCI FFR ≤0.85. 
 Underexpansion was present in 75% of the treated vessel
 More data on the use of post-PCI FFR values, their association with 
intravascular findings and potential further treatment in order to improve 
clinical outcome is warranted.
Central illustration. IVUS detected causes of post PCI FFR ≤ 0.85
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INTRODUCTION
In order to overcome the limitations of angiographic lesion assessment, fractional 
flow reserve (FFR) has proven to be a useful tool to identify the hemodynamic impact 
of a coronary artery stenosis 1. Several randomized trials have demonstrated that 
a routine pre-procedural FFR measurement in patients with multivessel coronary 
artery disease undergoing percutaneous coronary intervention (PCI) significantly 
reduces the composite endpoint of death, nonfatal myocardial infarction, and 
repeat revascularization at 1 year as compared to angiographic guidance alone 
2. More recently, FFR after stenting has proved to be a strong and independent 
predictor of major adverse cardiac events (MACE) up to 2 years 3-5. The actual 
scope of the problem of low post PCI FFR was illustrated by recent work from our 
group demonstrating that in up to 43% of the cases, post PCI FFR values ≤0.90 
were found while in 20% of the cases post PCI FFR even dropped below 0.85 6. 
Unfortunately, the rationale for low post procedural FFR values often remains 
elusive based on angiographic findings alone, warranting further assessment using 
an FFR pullback or additional intravascular imaging 7-11. The primary objective of 
the current study was to look for morphological reasons for a post procedural FFR 
≤0.85 in a real world patient cohort with the help of high definition intravascular 
ultrasound (HD-IVUS). 
METHODS
Patient selection 
The FFR SEARCH (Stent Evaluated at Rotterdam Cardiology Hospital) study 
is a prospective, all comer registry, enrolling 1512 consecutive patients who 
underwent successful PCI between March 2016 and May 2017. Among them, 
512 patients were excluded due to several reasons (156 were unstable, in 129 
patients the treated vessel was too small, in 148 cases it was operators decision 
not to perform an FFR and in 79 cases for other reasons). In a total of 1000 
patients after angiographic confirmation of treatment success, FFR was measured. 
In 41 cases, no FFR measurements were performed because of failure of the 
microcatheter to cross the stented segment, equipment failure or the occurrence 
of an adverse reaction to adenosine. Finally, FFR was measured in at least one 
lesion in a total of 959 patients. A total of 1165 post PCI FFR measurements were 
performed. For the present prespecified subgroup analysis, IVUS analysis were 
performed in 100 consecutive vessels with a post procedural FFR ≤ 0.85 as well 
as 20 consecutive vessels with a post procedural FFR >0.85 between August 2016 
and October 2017 in respectively 95 and 20 patients. No complications due to FFR 
measurements were encountered. The study was performed in accordance with 
the Declaration of Helsinki. The study protocol was approved by the local ethics 
committee. All patients provided written informed consent for the procedure and 
the use of anonymous datasets for research purposes in alignment with the Dutch 
Medical Research Act. The data, analytic methods, and study materials will not 
be made available to other researchers for purposes of reproducing the results or 
replicating the procedure.
FFR and IVUS acquisition 
After angiographic confirmation of treatment success, post procedural FFR 
measurements were performed using the Navvus rapid exchange monorail 
microcatheter (ACIST Medical Systems, Inc., Eden Prairie, MN, USA). Measurements 
were performed in all stented segments after an intracoronary bolus of nitrates (200 
µg). Results were based on single FFR measurement performed at approximately 
20 mm distal to the distal stent edge as well as single measurements at the distal 
stent edge, proximal stent edge and ostium. Whenever multiple vessels were 
treated, this method was performed in all treated vessels. Pd/Pa was defined 
as the ratio of mean distal coronary artery pressure to mean aortic pressure 
in the resting state during the whole cardiac cycle. FFR was defined as mean 
distal coronary artery pressure divided by mean aortic pressure during maximum 
hyperemia achieved by continuous intravenous infusion of adenosine at a rate of 
140 μg/kg/min through an antecubital vein. Pullback analyses were performed 
under hyperemic conditions measuring FFR at the distal stent edge, proximal 
stent edge and the ostium to test for drift. 
IVUS imaging was performed with the multi frequency HD-IVUS Kodama catheter 
(ACIST Medical Systems, Inc., Eden Prairie, MN, USA) at 60Mhz with a pullback 
speed of 2.5 mm/sec (24 frames per mm). Imaging assessment was performed 
off-line every 0.5 mm using dedicated software (QCU-CMS, Leiden University 
Medical Centre, LKEB, Division of Image Processing, version 4.69) by three 
dedicated academic intravascular imaging specialists, blinded to the final FFR 
results. Focal lesions were manually detected and defined as treatable lesions 
with an appropriate landing zone either proximal or distal to the stented segment. 
Proximal focal lesions were defined as lesions proximal to the stented segment 
with a minimal lumen area (MLA) <4.0 mm2 or <6.0 mm2 in case of left main (LM) 
lesions. Additionally, the MLA at the residual proximal stenosis had to be smaller 
than the distal reference external elastic membrane (EEM) diameter 12, 13 (Figure 
1). 
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Figure 1. IVUS analysis of a focal lesion
Lumen areas are in mm2 and diameters are in mm. EEM = External Elastic Membrane. MLA = minimum 
luminal area. The EEM, distal of the MLA, is smaller than the MLA, therefor, the luminal narrowing in 
this example can be categorised as a focal lesion. Values in yellow at the bottom of the figure represent 
the FFR measurements, from left to right: 15mm distal, distal stent edge, proximal stent edge and 
ostium respectively. 
Distal focal lesions were assessed based solely on the criteria involving the size of 
the distal reference EEM diameter 12, 13. Underexpansion, according to the MUSIC 
criteria, was defined as an in-stent MLA <90% of the average reference lumen 
area (LA) 14. Reference LAs were measured 5 mm proximal and 5 mm distal to 
the implanted stent. If one of these locations could not be accounted for as a 
reference lumen due to a bifurcation, it was excluded and only one reference 
area was used. Stent malapposition was defined as incomplete strut apposition of 
at least one strut to the lumen wall, without involvement of side branches, thus 
permitting blood to flow between the struts and the underlying wall 15.
An intramural hematoma was defined as a severe lumen narrowing due to a 
intravascular stent edge dissection filled with blood within the medial space, 
displacing the internal elastic membrane inward and the external elastic membrane 
outward 15. Non flow-limiting edge dissections were not assessed in this study.
Coronary vasospasm was defined as severe diffuse intimal thickening and a think 
media, often accompanied by negative remodelling, even in the absence of a 
significant coronary stenosis 16, 17.
Quantitative coronary angiography 
Angiographic success was assessed, offline, with the use of quantitative coronary 
angiography (QCA) (CAAS workstation 8.0, Pie Medical Imaging, Maastricht, The 
Netherlands). The treated vessels were divided into four segments: proximal 
segment (ostium to proximal stent edge); stented segment (in-stent analysis); 
stented segment with (including an additional 5 mm proximal and 5 mm distal 
to stent edges; in-segment analysis); the distal segment (distal stent edge to 
position where FFR was measured, at least 20mm from distal stent edge). If 
multiple stents were implanted with a gap of more than 10 mm in-between, the 
gap segment was considered as a proximal segment. For each segment, length, 
minimal diameter (mm), diameter stenosis (%), reference diameter (mm), 
maximal diameter (mm) and mean diameter (mm) were calculated.  
Statistical analysis
Statistical analyses were performed by using R (version 3.5.1, packages: Hmisc, 
lme4 and nlme). Baseline, categorical variables are reported as either counts or 
percentages and compared using the Chi Squared test on patient level. Normality 
for continuous variables was assessed using the Shapiro-Wilk test. Normally 
distributed continuous variables are reported as mean ± standard deviation 
(SD), Non-Gaussian variables are reported as median (interquartile range (IQR)). 
Normally distributed continuous variable were compared using a generalized 
linear mixed-effects model with a random effect for patients and a fixed effect 
for FFR groups, non-Gaussian variable were log transformed preparatory to the 
generalized linear mixed-effects model. 
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RESULTS 
Patient demographics and baseline characteristics are depicted in Table 1. 
In the cohort of patients with a post PCI FFR ≤0.85, mean age was 65±12 years 
and 85% of the patients were male. Clinical presentation was stable angina in 
42%, unstable angina or non ST elevated myocardial infarction (NSTEMI) in 45% 
and ST segment elevation myocardial infarction (STEMI) in 13% of the patients. 
In the vessels assessed an average of 1.6±0.8 stents were used with a median 
stent diameter of 3 (2.75-3.25) mm. Median total stented length was 28 (15-46) 
mm. 
Comparable baseline characteristics were observed in the >0.85 cohort, with the 
exception of a lower total stented length. Mean post procedural Pd/Pa and FFR were 
0.91±0.04 and 0.79±0.05 in the ≤0.85 cohort and 0.96±0.03 and 0.90±0.03 in 
patients with a post PCI FFR >0.85 respectively. 
IVUS analysis in the post PCI FFR ≤0.85 cohort
IVUS analyses showed a mean LA of 5.95 (5.01-7.03)mm2 with an MLA of 2.19 
(1.81-3.19) mm2 and minimal stent area was 4.01 (3.09-5.21)mm2 (Table 2).
Significant focal lesions proximal or distal to the stented segment were found 
in 29% and 30% of the vessels respectively. With an average of 1.6±0.8 stents 
implanted, a total of 115 nonadjacent stented segments were analysed. According 
to the MUSIC criteria stent underexpansion was present in 88% of these segments 
(74% of the vessels). Mean stent expansion rate in the segments was 78.7%. 
Malapposition was found in 21% of the segments (23% of the vessels). In 54% of 
the vessels clear focal signs of luminal narrowing were found due to residual focal 
lesions or lumen compromising hematoma (3%). Spasm was present in 9% of the 
vessels analysed and in 8% of the vessels diffuse disease was present. 
In 87% of the vessels, either a focal lesion, underexpansion, a lumen compromising 
hematoma or malapposition were present. 
A dedicated sub-analysis on vessels with FFR values ≤0.75 and ≤0.80 can be found 
in Table 3.
 Table 1. Baseline characteristic  
 
 FFR ≤0.85 
(n=95) 
(100 vessels) 
FFR >0.85 
(n=20) 
(20 vessels) 
p value 
 
Age, years 65±12 66±12 0.67 
Gender, male 81 (85) 19 (95) 0.29 
Hypertension 58 (61) 14 (70) 0.40 
Hypercholesterolemia  50 (53) 50 (53) 0.29 
Diabetes  24 (25) 6 (30) 0.57 
Smoking history  39 (41) 6 (30) 0.32 
Prior stroke  11 (12) 0 (0) 0.23 
Peripheral art. disease  6 (6) 1 (5) 0.86 
Prior PCI  29 (31) 7 (35) 0.66 
Prior CABG  3 (3) 1 (5) 0.65 
Indication    
   Stable angina  41 (43) 9 (45) 0.80 
   Unstable angina or NSTEMI  41 (43) 8 (40) 0.68 
   STEMI  13 (14) 3 (15) 0.81 
Target vessel    
   Left anterior descending 
artery (LAD) 81 (81) 12 (60) 0.24 
   Left circumflex artery (LCX) 7 (7) 3 (15) 0.25 
   Left main artery (LM)  3 (3) 1 (5) 0.65 
   Right coronary artery (RCA)  9 (9) 4 (20) 0.16 
Predilatation 74 (74) 10 (50) 0.04 
High pressure post dilatation 
(NC balloon) 74 (74) 13 (65) 0.41 
Mean post PCI Pd/Pa  0.91±0.04 0.96±0.03 <0.001 
Mean post PCI FFR 0.79±0.05 0.90±0.03 <0.001 
No. of vessels with a post PCI 
FFR 0.80 56 (56)   
No. of vessels with a post PCI 
FFR 0.75 22 (22)   
No. of stents   1 (1-2) 1 (1-1) <0.001 
Mean stent diameter, mm 3 (2.75-3.25) 3.25 (3.0-3.5) 0.13 
Total stent length, mm 28 (15-46) 21 (16-25) 0.12 
 
 
 
 
 
  
Values are n (%), mean±SD or median (IQR), PCI = Percutaneous Coronary Artery and CABG = Coronary 
Artery Bypass Grafting, NSTEMI = non ST elevated myocardial infarction, STEMI =ST elevated myocardial 
infarction. NC = non compliant, Pd/Pa = the Pressure in the Distal coronary artery to the Pressure in the 
Aorta ratio, FFR = Fractional Flow Reserve under maximum hyperemia.
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Table 2. IVUS findings in 100 vessels with an FFR ≤0.85 and 20 vessels >0.85
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 FFR ≤0.85 
(n=100) FFR >0.85 (n=20) p value 
Mean lumen area, mm2 5.95 (5.01-7.03) 6.24 (5.12-8.10) 0.15 
Minimal lumen area, mm2 2.19 (1.81-3.19) 2.92 (1.96-4.10) 0.02 
Minimal stent area, mm2 4.01 (3.09-5.21) 5.11 (3.05-7.41) 0.01 
Focal lesion (proximal)  29 (29) 3 (15) 0.78 
MLA at proximal lesion, mm2 2.98 (2.24-3.36) 2.60 (2.30-2.60) 0.98 
Focal lesion (distal)  30 (30) 6 (30) 1.00 
MLA at distal lesion, mm2 2.01 (1.68-2.12) 2.51 (1.88-3.26) 0.02 
Lumen compromising 
hematoma 3 (3) 0 (0) 0.69 
MLA lumen compromising 
hematoma, mm2  1.97 (1.22-1.97) - - 
Underexpansion 74 (74) 15 (75) 0.93 
Malapposition  23 (23) 1 (5) 0.1 
Spasm  9 (9) 0 (0) 0.31 
Diffuse diseased 8 (8) 0 (0) 0.68 
Any focal lesion 51 (51) 9 (45) 0.63 
Any focal lesion or lumen 
compromising hematoma 54 (54) 9 (45) 0.37 
Any focal lesion, 
underexpansion, lumen 
compromising hematoma or 
malapposition  
84 (84) 18 (90) 0.99 
Values are n (%) or median (IQR)
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IVUS analysis in the post FFR PCI > 0.85 cohort
IVUS analysis of the 20 vessels with a post PCI FFR >0.85 showed a median 
LA 6.24 (5.12-8.10) mm2 with an MLA of 2.92 (1.96-4.10) mm2 and minimal 
stent area was 5.11 (3.05-7.41) mm2 (Table 2). Significant focal lesions proximal 
or distal to the stented segment were found in 15% and 30% of the vessels 
respectively. With an average of 1.0±0.0 stent implanted. According to the MUSIC 
criteria stent underexpansion was present in 75% of the vessels with a mean 
stent expansion rate of 79.6%. Malapposition was found in 1 vessel (5%). In 45% 
of the vessels clear focal signs of luminal narrowing were found due to residual 
focal lesions or lumen compromising hematoma (0 instances). Spasm and diffuse 
disease were not present in this cohort. 
Pressure drops per segment in the total cohort
FFR pullback data were available for 107/120 vessels. A significantly higher 
pressure drop over the proximal segment was found in vessels with residual 
proximal focal lesions as compared to segments with no residual proximal 
focal lesions (0.06±0.09 vs 0.03±0.06 respectively, p=0.004). No significant 
differences in FFR drop were found in case of residual distal lesions (0.06±0.05 
in the presence of a distal lesion vs. 0.05±0.06 in the absence of a distal lesion, 
p=0.92) or malapposition (0.06±0.06 with malapposition vs 0.05±0.06 without 
malapposition, p=0.22)(Figure 2). 
Figure 2. FFR drop by presence of residual lesions or malapposition
Values are means with error bars of the standard error of the mean
No significant changes in pressure drops over the stented segment were found 
in case of underexpansion according to either the MUSIC criteria or criteria with 
modified underexpansion limits, however, a trend was observed towards higher 
pressure drops along with more severe underexpansion rates (Figure 3). 
Figure 3. FFR drop by % of underexpansion
Values are means with error bars of the standard error of the mean
QCA analysis 
A total of 103 proximal segments, 123 stented segments and 109 distal segments 
were analysed with QCA (Table 4). 
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In brief, in the proximal segments, QCA did not reveal any significant differences 
in luminal dimensions in the two FFR cohorts, whereas in the distal segments 
diameters were significantly larger in the cohort with a post PCI FFR >0.85. As 
expected, in the presence either proximal- or distal focal lesions on IVUS, 
angiographic luminal dimensions differed significantly as compared to segments 
without residual lesions on IVUS. However, diameter stenosis did not exceed 50% 
in any of the proximal residual lesions detected by IVUS and/or FFR. In 5 cases 
QCA detected a diameter stenosis>50% (range 51 to 61%), corresponding to 3 
cases with an IVUS detected distal focal lesion. Stented length was significantly 
larger in vessels with a post PCI FFR<0.85 as compared to vessels with a post 
PCI>0.85. Finally, QCA was not able to detect a difference in luminal dimensions 
of stented segments with 20% underexpansion or more. 
DISCUSSION 
In this IVUS sub-study of the FFR SEARCH registry we demonstrated, for the 
first time, that clear signs of residual luminal narrowing, including focal lesions, 
underexpansion and malapposition, were present in a significant amount of vessels 
with an impaired post PCI FFR. Findings that were not readily apparent on QCA. 
Several recent studies demonstrated the value of low post PCI FFR in predicting 
late adverse cardiac events 3, 4. Unfortunately, details on the actual rationale 
for these low PCI FFR values often remained elusive since no data on residual 
angiographically apparent disease were reported, nor were details presented on 
intravascular imaging findings. In our study meticulous intravascular ultrasound 
analysis revealed specific morphologic explanations for the suboptimal post PCI 
FFR. 
First, in the low FFR cohort, we found residual focal lesions in 51% of the vessels. 
We found MLAs in focal proximal and distal lesions of 2.88 (2.29-3.37) mm and 
2.03 (1.74-2.21) mm respectively. Several previous studies already indicated the 
strong correlation of IVUS derived low post PCI MLA with both low post PCI FFR 
values (<0.80) and worse outcome 18-22. With QCA conversely, diameter stenosis 
in proximal and distal lesions were 29 (19-34) % and 33.5 (28.25-43.25) % 
respectively. Interestingly, in only 3 of the segments with residual focal lesions on 
IVUS, QCA detected a diameter stenosis >50%.
Secondly, in the low FFR cohort, we found underexpanded stents in 74% of the 
vessels with an FFR ≤0.85, a significantly higher percentage as would be expected 
post stenting in general, with expected underexpansion rates of 20-44% 23. Again, 
these underexpansion figures appreciated with IVUS were not apparent with 
QCA. The latter might illustrate the potential of post PCI FFR to expose more 
severe forms of underexpansion and also fits with previous data showing a clear 
correlation between underexpansion and increased rates of early stent thrombosis 
and restenosis 24-27. 
Thirdly, in the low FFR cohort, malapposition was identified in 23% of the cases. 
Since we could not demonstrate a direct correlation between malapposition 
and a drop in FFR, in most cases malapposition was found in combination with 
underexpansion (87%), residual focal lesions or lumen compromising hematoma 
(52%) and only occurred isolated in one patient. Furthermore, the malapposition 
rate of 23% found in our study fits with previous imaging studies post DES 
implantation, showing rates of malapposition in 7-39% of the cases with no 
significant correlation to either stent thrombosis or restenosis 24, 28-30. Nevertheless, 
stent malapposition is suboptimal and is associated with stent thrombosis in 
intravascular imaging studies and adequate strut apposition might help to avoid 
long-term stent related complications 31. 
Although we only enrolled 20 cases with a post PCI FFR >0.85 as a reference a clear 
trend was seen towards larger minimal stent areas, a lower number of residual 
proximal focal lesions, less stents with malapposition and a lower incidence of 
diffuse disease. Additionally, the incidence of patients presenting with STEMI was 
significantly lower in patients with post PCI FFR<0.85 as compared to those with 
higher post PCI values 32. Nevertheless, also in the STEMI cohort, IVUS revealed 
residual luminal narrowing in a significant proportion of patients.
Despite accumulating outcome data supporting the use of IVUS, its adoption in 
daily clinical practice remains low 33. IVUS has the reputation to be costly and 
time-consuming, and insufficient IVUS knowledge might hamper ad-hoc image 
interpretation. Conversely, FFR allows a faster and more easily interpretable 
assessment of the hemodynamic importance of coronary artery disease. 
In the present study we attempted to link a lower than expected FFR to morphological 
findings by IVUS and QCA. FFR pressure drops were more pronounced in vessels 
with residual proximal focal lesions but not with distal lesions. Previous work 
already alluded to the lack of correlation between anatomic and functional severity 
of stenosis in small vessels, probably due to the small myocardial territory at risk 
34. On the other hand, FFR guided PCI resulted in significantly superior outcomes 
as compared to angiography guided PCI also in studies focussing on small vessels 
35. Finally, we demonstrated that milder forms of underexpansion might remain 
unnoticed on FFR pullbacks while larger, and perhaps more clinically relevant rates 
10
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of underexpansion might be associated with significant pressure gradients. 
While the results of the FFR-REACT trial (Dutch trial register: NTR6711), assessing 
whether FFR directed IVUS guided PCI optimization improves patient outcomes as 
compared to standard clinical practice, are eagerly awaited, there is a clear need 
for larger prospective randomized controlled trials designed to better understand 
the potential benefit of FFR-guided PCI optimization with or without the focused 
use of IVUS. 
Limitations
Several limitations need to be mentioned. First, we only enrolled 20 patients 
with a post PCI FFR >0.85. The absence of clear significant differences in IVUS 
findings between both cohorts might have been due to a lack of power. Second, 
the criteria for underexpansion in this study are based upon the MUSIC criteria 
14. Unlike in the MUSIC study in which only stents with a length of 15 mm were 
used, the average stented length in the present cohort was 34 mm resulting 
in significant differences between proximal and distal reference segments which 
might have impacted the calculation of the percentage underexpansion. This could 
have resulted in a lower mean reference LA and therefore an overestimation of 
the degree of expansion. Third, pressure measurements were performed with the 
Navvus microcatheter, which might underestimate the FFR value as compared to 
the wire based FFR 36-38. The latter might mean that the IVUS finding from this 
study can also be applicable to higher post PCI values, measure with a wired base 
device. Fourth, maximum hyperemic conditions during continuous intravenous 
infusion of adenosine might fluctuate and therefore influence pullback assessment 
in up to 40% of the cases 39. Fifth, for the present study we used an FFR cut-
off of 0.85. While several previous studies demonstrated a clear trend towards 
increased MACE rates with decreasing post PCI FFR values an exact cut-off for an 
optimal post PCI FFR, at present, is elusive. Finally, since the FFR SEARCH registry 
was developed to assess the impact of post PCI FFR measured in routine clinical 
practice, per protocol, no additional interventions were performed based on either 
FFR or IVUS findings. Whether additional treatment will optimize the longer-term 
results of these patients is currently being investigated in the FFR REACT trial.
CONCLUSION
In patients with a post procedural FFR ≤0.85, IVUS revealed focal signs of luminal 
narrowing in the majority of the cases. Only proximal focal lesions resulted in 
significant FFR pressure drops during pullback. 
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ABSTRACT
Background: Patients with a low post PCI fractional flow reserve (FFR) are at 
increased risk for future adverse cardiac events. The aims of the present study 
was to assess the impact of specific intravascular ultrasound (IVUS) findings in 
patients with a low post percutaneous coronary intervention (PCI) FFR on long-
term clinical outcome. 
Methods: In a subgroup analysis, 100 vessels with an FFR value ≤0.85 underwent 
post PCI IVUS to further assess the potential determinants for low post PCI FFR. 
No further action was taken to improve post PCI FFR. The primary endpoint of this 
study was the event free survival of target vessel failure (TVF) at two years in 
patients with a post PCI FFR ≤0.85, which was defined as a composite of cardiac 
death, target vessel myocardial infarction or target vessel revascularization. 
Results: In patients with a post PCI FFR ≤0.85, TVF free survival rates were 88.5% 
vs. 95.5% for patients with versus without residual proximal lesions and 88.2% 
vs. 95.5% for patients with versus without residual distal lesions respectively 
(HR=2.53, 95% confidence interval (CI) 0.52-12.25, p=0.25 and HR=2.60, 95% 
CI 0.54-12.59, p=0.24 respectively). TVF free survival was 92.8% vs. 93.5% 
in patients with versus without stent underexpansion >20% (HR=1.01, 95% CI 
0.21-4.88, p=0.99) and 89.3% vs. 97.8% in patients with versus without any 
residual focal lesion including lumen compromising hematoma (HR=4.64, 95% CI 
0.55-39.22, p=0.18). 
Conclusion: Numerically higher TVF rates were observed in patients with a post 
PCI FFR ≤0.85 and clear focal residual disease as assessed with IVUS. 
BACKGROUND
FFR after stenting proved to be a strong and independent predictor for MACE 1. 
Unfortunately, the exact rationale behind this observation remains elusive based 
on angiographic findings alone let alone the impact on clinical follow-up. Fractional 
flow reserve (FFR) has proven to be a useful technique to address coronary 
physiology and the haemodynamic significance of coronary segments both pre- 
and post-intervention 2. 
In the intravascular ultrasound (IVUS) sub-study of the FFR SEARCH registry we 
demonstrated, for the first time, that clear signs of residual luminal narrowing, 
including focal lesions, underexpansion and malapposition, were present in 
a significant amount of vessels with an impaired post percutaneous coronary 
intervention (PCI) FFR despite optimal angiographic results 3. 
Patients with a low post PCI fractional flow reserve (FFR) are at increased risk for 
future adverse cardiac events. The aims of the present study was to assess the 
impact of specific IVUS findings in patients with a low post PCI FFR on long-term 
clinical outcome (FFR ≤0.85). 
METHODS
Patient selection
The FFR SEARCH (Stent Evaluated at Rotterdam Cardiology Hospital) study is a 
prospective single center registry in which 1000 consecutive patients underwent 
FFR evaluation after angiographic successful PCI with a primary endpoint to study 
the impact of post PCI FFR on major adverse cardiac event rates at 2 years. In a 
subgroup analysis, 95 consecutive patients (100 vessels) with a post PCI FFR value 
≤0.85 and 20 patients (20 vessels) with a post PCI FFR >0.85 underwent post PCI 
IVUS to further assess the potential determinants for the low post PCI FFR. No 
further action was taken to improve the post PCI FFR. The study was performed in 
accordance with the Declaration of Helsinki. The study protocol was approved by 
the local ethics committee. All patients provided written informed consent for the 
procedure and the use of anonymous datasets for research purposes in alignment 
with the Dutch Medical Research Act. 
Specifics on angiographic measurements, FFR assessment and IVUS acquisition are 
discussed in the initial FFR SEARCH registry study and the IVUS sub-study report 
3, 4. In brief, a dedicated FFR Navvus MicroCatheter (ACIST Medical Systems, Inc., 
Eden Prairie, MN, USA) was advanced over the previously used coronary guidewire 
approximately 20 mm distal to the most distal stent edge. IVUS imaging was 
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performed with the multi frequency High Definition IVUS Kodama catheter (ACIST 
Medical Systems, Inc., Eden Prairie, MN, USA).  
The primary endpoint of this study was the event free survival of target vessel 
failure (TVF) at two years, which was defined as a composite of cardiac death, 
target vessel myocardial infarction or target vessel revascularization. 
Myocardial infarction (MI) was defined according to the fourth definition 
recommended by the European Society of Cardiology 5. Cardiac death was 
adjudicated if the cause of death was most probable cardiac cause or could not be 
identified. Clinical follow-up data were collected by hospital visit, chart review or 
telephone contact. 
Categorical variables are reported as either counts or percentages, continuous 
variables are reported as mean ± standard and compared using a generalized linear 
mixed model. Survival analyses were performed using the Kaplan-Meier method. 
In order to evaluate IVUS findings and the impact on TVF at two year follow-up, 
all 100 vessels were tested univariately using a Cox proportional hazards model 
which accounted for the multilevel nature of the data. No multivariable model was 
constructed due to a lack of events. Statistical analyses were performed by using 
SPPS 25 and R (version 3.5.1, packages: lme4, nlme, surv). 
RESULTS
Baseline characteristics and IVUS findings are depicted in Table 1. 
In the dedicated IVUS analyses, in patients with a post PCI FFR ≤0.85, significant 
focal lesions proximal or distal to the treated segment were found in 29% and 
30% of the vessels respectively. Underexpansion >20% was present in 50% of the 
vessels. In 54% of the vessels clear focal signs of luminal narrowing were found 
due to residual focal lesions or lumen compromising hematoma (3%). In 87% of 
the vessels, either a focal lesion, underexpansion (>10%), a lumen compromising 
hematoma or malapposition were present. Baseline characteristics compared in 
different subgroups are depicted in supplementary Table 1. 
Complete two-year follow-up was available for 100% of the patients. At two years, 
the cumulative survival free of TVF was 93.2% in patients with a post PCI FFR 
≤0.85.TVF free survival rates were 88.5% vs. 95.5% (n. events=3 vs. 3) for 
patients with versus without residual proximal lesions and 88.2% vs. 95.5% (n. 
events=3 vs. 3) for patients with versus without residual distal lesions respectively 
(hazard ratio (HR)=2.53, 95% confidence interval (CI) 0.52-12.25, p=0.25 and 
HR=2.60, 95% CI 0.54-12.59, p=0.24 respectively) (Figure 1). 
Table 1. Key characteristic and IVUS findings 
 
 
 
 FFR ≤0.85 
(n=95) 
(100 vessels) 
FFR >0.85 
(n=20) 
(20 vessels) 
p value 
Patient and vessel characteristic    
Age, years 65±12 66±12 0.67 
Gender, male 81 (85) 19 (95) 0.29 
Diabetes  24 (25) 6 (30) 0.57 
Prior PCI  29 (31) 7 (35) 0.66 
Indication    
   Stable angina  41 (43) 9 (45) 0.80 
   ACS  54 (57) 11 (55) 0.80 
Target vessel    
   Left anterior descending artery 
(LAD) 81 (81) 12 (60) 0.24 
   Left circumflex artery (LCX) 7 (7) 3 (15) 0.25 
   Left main artery (LM)  3 (3) 1 (5) 0.65 
   Right coronary artery (RCA)  9 (9) 4 (20) 0.16 
Predilatation 74 (74) 10 (50) 0.04 
High pressure post dilatation (NC 
balloon) 74 (74) 13 (65) 0.41 
Mean post PCI Pd/Pa  0.91±0.04 0.96±0.03 <0.001 
Mean post PCI FFR, maximum 
hyperemia  0.79±0.05 0.90±0.03 <0.001 
No. of stents   1 (1-2) 1 (1-1) <0.001 
Mean stent diameter, mm 3 (2.75-3.25) 3.25 (3.0-3.5) 0.13 
Total stent length, mm 28 (15-46) 21 (16-25) 0.12 
IVUS analysis    
Minimal lumen area, mm2 2.19 (1.81-3.19) 2.92 (1.96-4.10) 0.02 
Mean lumen area, mm2 5.95 (5.01-7.03) 6.24 (5.12-8.10) 0.15 
Minimal stent area, mm2 4.01 (3.09-5.21) 5.11 (3.05-7.41) 0.01 
Focal lesion (proximal)  29 (29) 3 (15) 0.78 
MLA at proximal lesion, mm2 2.98 (2.24-3.36) 2.60 (2.30-2.60) 0.98 
Focal lesion (distal)  30 (30) 6 (30) 1.00 
MLA at distal lesion, mm2 2.01 (1.68-2.12) 2.51 (1.88-3.26) 0.02 
Lumen compromising hematoma 3 (3) 0 (0) 0.69 
MLA lumen compromising 
hematoma, mm2  1.97 (1.22-1.97) - - 
Underexpansion (>10%) 74 (74) 15 (75) 0.93 
Underexpansion (>20%) 50 (50) 8 (40) 0.41 
Malapposition  23 (23) 1 (5) 0.10 
Spasm  9 (9) 0 (0) 0.31 
Diffuse diseased 8 (8) 0 (0) 0.68 
Any focal lesion 51 (51) 9 (45) 0.63 
Any focal lesion or lumen 
compromising hematoma 54 (54) 9 (45) 0.37 
Any focal lesion, underexpansion 
(>10%), lumen compromising 
hematoma or malapposition  
84 (84) 18 (90) 0.99 
Values are n (%) or mean±SD, PCI = Percutaneous Coronary Artery and CABG = Coronary Artery 
Bypass Grafting, NSTEMI = non ST elevated myocardial infarction, STEMI =ST elevated myocardial 
infarction. NC = non-compliant, Pd/Pa = the Pressure in the Distal coronary artery to the Pressure in 
the Aorta ratio, FFR = Fractional Flow Reserve. MLA = minimal lumen area. 
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Figure 1. Kaplan-Meier curves for separated for the presence of proximal focal lesions, distal focal 
lesions, any lesion including lumen compromising hematoma and >20% underexpansion.
Event free survival of target vessel failure (TVF). 
TVF free survival was 93.8% vs. 93.2% (n. events=3 vs. 3) in patients with versus 
without stent underexpansion >20% (HR=1.01, 95% CI 0.21-4.88, p=0.99) 
and 89.3% vs. 97.8% (n. events=5 vs. 1) in patients with versus without any 
residual focal lesion including lumen compromising hematoma (HR=4.64, 95% CI 
0.55-39.22, p=0.16). In contrast to focal residual disease, which clearly tended 
to impact TVF at 2 years, no events were found related to vessels with diffuse 
disease (n=8). TVF free survival in patients with a post PCI FFR >0.85 was 90.0% 
(88.9% and 90.9% in patients with versus without residual lesions or lumen 
compromising hematoma). 
DISCUSSION
Low post PCI FFR proved to be associated with higher rates of TVF 1. However, 
the practical implications of low post PCI FFR remain debated since little is known 
about the exact mechanisms behind the low FFR and potential consequences of 
further intravascular treatment. 
In the FFR SEARCH IVUS study, we found a high proportion of IVUS detected 
anomalies including focal lesions, stent underexpansion and malapposition in 
vessels with a post PCI FFR ≤0.85; findings that were not readily apparent on 
coronary angiography 3. 
The present predefined long-term follow-up analysis demonstrated a clear trend 
towards higher rates of TVF at two years when IVUS derived residual lesions were 
found. 
Patients without clear residual disease on IVUS had a 2.2% risk of TVF at 2 year, 
despite having a post PCI FFR<0.85 (as compared to 10.7% in those with residual 
disease, HR 4.6). 
We therefore believe that IVUS might provide significant benefit in further 
stratifying those at the highest risk for future adverse events (post PCI FFR<0.85) 
and guide further treatment optimization. 
Limitations
The sample size in this sub-study of the FFR SEARCH is registry is limited. 
Although clear clinical trends were observed, the limited number of patients with 
a persistent low post PCI FFR and subsequent IVUS withheld us from providing 
significant hazard ratios. The current study is hypothesis generating and large 
randomized trials are warranted to further investigate the relation between IVUS 
detected anomalies and hard clinical endpoints in patients with persistent low post 
PCI FFR. 
Finally, adverse events were adjudicated by investigators blinded to the final FFR 
values and IVUS findings. No dedicated independent event committee was used
CONCLUSION
At two years, the cumulative survival free of TVF in patients with a post PCI FFR 
≤0.85 was 93.5%. Numerically higher TVF rates were observed in patients with 
clear focal residual disease as assessed with IVUS. 
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Chapter 12
FFR guided PCI optimization directed by 
high-definition IVUS versus standard of care: 
Rationale and study design of the prospective 
randomized FFR-REACT trial
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ABSTRACT
Background: Post percutaneous coronary intervention (PCI) fractional flow 
reserve (FFR) is a significant predictor of major adverse cardiac events (MACE). 
The rationale for low post procedural FFR values often remains elusive based 
on angiographic findings alone, warranting further assessment using an FFR 
pullback or additional intravascular imaging. It is currently unknown if additional 
interventions intended to improve the PCI, decrease MACE rates. 
Study design: The FFR REACT trial is a prospective, single-center randomized 
controlled trial in which 290 patients with a post PCI FFR <0.90 will be randomized 
(1:1) to either standard of care (no additional intervention) or IVUS-directed 
optimization of the FFR (treatment arm). Eligible patients are those treated 
with angiographically successful PCI for (un)stable angina or non-ST elevation 
myocardial infarction (MI). Assuming 45% of patients will have a post PCI FFR 
<0.90, approximately 640 patients undergoing PCI will need to be enrolled. 
Patients with a post PCI FFR≥0.90 will be enrolled in a prospective registry. The 
primary end point is defined as a composite of cardiac death, target vessel MI and 
clinically driven target vessel revascularisation (target vessel failure) at 1 year. 
Secondary end points will consist of individual components of the primary end 
point, procedural success, stent thrombosis and correlations on clinical outcome, 
changes in post PCI Pd/Pa and FFR and IVUS derived dimensions. All patients will 
be followed for 3 years. 
Conclusion: The FFR-REACT trial is designed to explore the potential benefit of 
HD-IVUS-guided PCI optimization in patients with a post PCI FFR <0.90 (Dutch 
trial register: NTR6711). 
Graphical abstract. Study flowchart for the FFR REACT trial
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BACKGROUND
Accurate angiographic assessment of the severity and hemodynamic importance of 
coronary artery stenosis can be challenging and proved to be frequently unreliable 
1, 2. Previous studies demonstrated that routine pre-procedural fractional flow 
reserve (FFR) in patients with multivessel coronary artery disease undergoing 
percutaneous coronary intervention (PCI) with drug-eluting stents significantly 
reduces the rate of the composite end point of death, nonfatal myocardial infarction 
(MI), and repeat revascularization at 1 year as compared to angiographic guided 
PCI 3. More recently, FFR after stenting proved to be a strong and independent 
predictor of major adverse cardiac events (MACE) at 1 year 4. A contemporary 
meta-analysis on the clinical impact of post PCI FFR values showed that an FFR 
<0.90 is associated with an increased risk of target vessel revascularization (TVR)5. 
A number of factors might cause a post-PCI pressure drop over a treated segment 
including residual disease in the proximal or distal segment, a geographically 
misplaced stent, stent underexpansion, malapposition, plaque protrusion, edge 
dissection and plaque shift 6, 7. While these findings are not always readily apparent 
on coronary angiography alone, high definition (HD) intravascular ultrasound 
(IVUS) demonstrated to be a powerful tool to detect potential causes for low FFR 
post stenting. More specifically, these issues proved to be more frequently present 
in patients with low as compared to high post PCI FFR 7. The latter adds to the 
substantial body of evidence on the benefit of IVUS-guided PCI as compared to 
angiography-guided PCI in improving long-term outcomes 8, 9.
While post PCI FFR is at present only rarely performed in routine clinical practice, 
an FFR after stenting <0.90 proved to be present in approximately 45% of 
the patients 10. Additionally, IVUS was able to detect problems of intraluminal 
obstruction in up to 84% of those cases 7. It is currently unknown if additional 
interventions with the intent to optimize post procedure FFR improve patient 
outcome.
The rationale and design of the FFR REACT trial was based on a simple and fast 
way of measuring post PCI FFR using a small microcatheter over the previously 
used coronary guidewire. Although a substantial body of evidence exists towards 
a pressure wire based post PCI FFR of 0.90 to predict MACE, at the moment no 
clear cut-off for post PCI FFR value as measured with a microcatheter to predict 
events has been established 4, 5. The potential findings and clinical implications of 
this study might open the door to a more frequent use of post PCI physiological 
assessment with the intention to further reduce the risk of future MACE with the 
help of IVUS.
Study aims
To assess if FFR guided PCI optimization directed by HD-IVUS in patients with an 
increased risk for MACE (post-PCI FFR below 0.90) will improve clinical outcome 
and reduce target vessel failure, a composite of cardiac death, target-vessel 
myocardial infarction and clinically driven TVR at 1 year.
STUDY DESIGN AND METHODS
The FFR REACT trial is a prospective, investigator initiated single-center 
randomized controlled trial in which 290 patients with a post PCI FFR <0.90 will 
be randomized (1:1) to either standard of care (no additional intervention, control 
arm) or IVUS-directed optimization of the FFR (treatment arm). Eligible patients 
are those treated with angiographically successful PCI for stable or unstable 
angina or a non-ST elevation myocardial infarction (MI). Patients with a post PCI 
FFR ≥0.90 will be enrolled in a prospective registry. All patients will be included in 
the Erasmus Medical Center (MC), the Netherlands, and followed for up to 3 years 
after PCI. The study flowchart is depicted in Figure 1.
Figure 1. Study flow chart including the operator strategy questionnaire
The first two rhombuses contain the operator questions. The third rhombus is not asked but filled 
in according to the additional intervention. Nine possible answers are provided. FFR is fractional 
flow reserve, HD-IVUS is high definition intravascular ultrasound and PCI is percutaneous coronary 
intervention. 
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The study protocol was approved by our local ethical committee on the 26th of 
October 2017 (MEC-2017-489). Financial support is provided by ACIST Medical 
Systems, Inc.. The Erasmus Medical Center is totally independent from ACIST 
Medical Systems, Inc. regarding the conduct of the study and the medical 
treatment of patients and study subjects. The authors are solely responsible 
for the design and conduct of this study, all study analyses, the drafting and 
editing of the paper and its final contents. The study is in accordance with Good 
Clinical Practices (GCP), ISO14155 and with the Declaration of Helsinki (64th WMA 
General Assembly, Fortaleza, Brazil, October 2013). The study is registered at the 
Dutch trial register: NTR6711.
Study population
With the assumption that post PCI FFR will be <0.90 in 45% of the patients, an 
estimated number of 640 patients will be enrolled in order to be able to randomize 
290 patients. Detailed in- and exclusion criteria are depicted in Table 1. 
Table 1. In- and exclusion criteria
 
 
 
 
 
 
 
Inclusion criteria 
 Age ≥18   
 Stable- or unstable angina or Non-ST segment elevation myocardial infarction 
 Target lesion stenosis ≥ 50% by visual estimation or QCA successfully treated 
by PCI and stenting 
 Written informed consent 
 The patient agrees to the follow-up 
Exclusion criteria: 
 Patients with ST-elevation myocardial infarction within the last 72 hours.  
 Target vessel distal reference diameter <2.25mm 
 Cardiogenic shock or severe hemodynamic instability 
 Unsuccessful stenting 
 PCI without stenting 
 Inability to perform post procedure FFR 
 The patient has other medical illnesses (i.e., cancer) that may cause the 
patient to be non-compliant with the protocol, confound the data interpretation 
or are associated with limited life expectancy (i.e., less than one year) 
MI is myocardial infarction, FFR is fractional flow reserve, QCA is quantitative coronary angiography, PCI 
is percutaneous coronary intervention and IVUS is intravascular ultrasound.
Each patient must sign and date the approved informed consent form after the 
study has been thoroughly explained. 
Study endpoints
The primary endpoint will be assessed at 1-year follow-up and is defined as target 
vessel failure, a composite of cardiac death, target vessel Q-wave or non-Q wave 
MI and clinically driven TVR.
Secondary endpoints consist of the individual components of the primary endpoint 
at 6 months, 1, 2 and 3 years, along with other clinical endpoints: all-cause 
death, any coronary revascularization, non-fatal MI, stent thrombosis (according 
the ARC criteria 11), stroke, periprocedural complications and acute kidney injury. 
Procedural characteristics such as contrast medium usage, nr of stents, total 
stent length and procedural time will be compared between groups. Additionally, 
correlations between changes in post procedural FFR and Pd/Pa and luminal 
dimensions on IVUS due to potential optimization will be assessed. Table 2 depicts 
both primary and secondary endpoints. Finally, operator PCI strategy will be 
assessed at multiple time points. 
Table 2. Primary and secondary endpoints of the FFR-REACT trial
  
Primary endpoints  
 Target vessel failure* 
Secondary endpoints 
In hospital 
 Procedural characteristics e.g. contrast medium usage, nr of stents, total stent 
length and procedural time 
 Major access site bleeding  
 Periprocedural MI  
 Acute kidney injury 
 Periprocedural complications 
 Change in post-procedural FFR after optimization therapy 
 Change in post-procedural Pd/Pa and FFR after optimization therapy 
 Correlation of the IVUS parameters and proximal VS stent VS distal FFR drop 
in categories of 0.05.  
 Correlation of FFR segmental drop and minimum luminal area  on IVUS and 3D 
QCA 
 Correlation of Pd/Pa and FFR, both dependent and independent of IVUS 
findings 
 Operators PCI strategy change dependent on the information received from 
either FFR or IVUS 
6 months and longer follow-up 
 The individual components of the primary endpoint (cardiac death, target 
vessel MI, target vessel revascularization)  
 All-cause mortality 
 Cardiovascular mortality 
 Rehospitalisation for heart failure 
 Target lesion revascularization  
 Any coronary revascularization 
 Non-fatal myocardial infarction 
 Stent thrombosis  
 Periprocedural MI  
 Stroke  
 Kidney injury  
 Correlation of Pd/Pa, FFR and the primary endpoints components 
* A composite of cardiac death, target-vessel myocardial infarction and clinically driven TVR at 1 year.
QCA is quantitative coronary angiography, FFR is fractional flow reserve, PCI is percutaneous coronary 
intervention.
12
Chapter 12 - Study design FFR REACT trialPart III - Synergistic use of Intracoronary Imaging and Physiology
227 || 226
Blinding and randomization
Patient randomization will be initiated through a web-based application (ALEA, 
Formvision, Utrecht, The Netherlands). In order to prevent a disturbed allocation 
between treatment arms, a block randomization will be used, varying between 
four and six in size. Subjects will be blinded to the post procedural FFR and 
subsequent treatment allocation. In order to monitor the level of blinding, the 
perceived treatment allocation will be inquired at the 1 year clinical follow-up 
visit. Furthermore, the procedure report will not contain any details about post 
procedural FFR and subsequent treatment arm allocation. More specifically, no 
information will be provided on the measured vessel, post PCI FFR value and 
potential randomization allocation in the procedure report or discharge letter. 
Event adjudication at the set time points of 6 months, 1, 2 and 3 years will be 
performed by an independent critical event committee, not aware of the patients 
specific FFR values and/or randomization allocation. Patients will be unblinded at 
the last follow-up moment (3 years). 
Investigational products
Post PCI FFR will be assessed using the Navvus® monorail microcatheter (ACIST 
Medical Systems, Inc., Eden Prairie, Minnesota) advanced over the previously used 
coronary guidewire. This monorail microcatheter precludes the need to advance 
a separate pressure wire along the treatment segment which will simplify and 
speed-up post PCI FFR measurements 12. 
Additional imaging in the intervention group will be performed using the multi 
frequency (40-60 MHz) Kodama® HD-IVUS catheter (ACIST Medical Systems, 
Inc., Eden Prairie, Minnesota). Both devices are CE marked and are currently used 
in regular clinical practice.
STUDY PROCEDURES
Routine care
Procedures will be performed according to standard clinical practice: angiography 
guided PCI and stenting with the use of periprocedural imaging, (either IVUS 
or OCT) and/or pre-procedural functional assessment (either iFR or FFR) left at 
the discretion of the operator 13. Angiographic success was defined as residual 
stenosis <30% by visual analysis in the presence of TIMI 3 grade flow. Procedural 
success will be identified as angiographic success in the absence of periprocedural 
MI. Dual antiplatelet therapy (including aspirin and a P2Y12 inhibitor) will be 
prescribed for at least 6 months to all patients consisting of clopidogrel in case of 
stable angina, or prasugrel/ticagrelor for at least 12 months in case of an acute 
coronary syndrome 14. 
Study measurements and interventions, if applicable, will only be performed 
after confirmation of angiographic success of the PCI and after administration of 
intracoronary nitrates. 
Post procedural indices: Pd/Pa and FFR
Pd/Pa is defined as a ratio, where Pd is the distal coronary pressure derived from 
the tip of the Navvus® catheter and Pa stands for proximal coronary pressure 
(measured at the tip of the guiding system). The two values are recorded 
simultaneously during resting conditions. FFR is defined as mean distal coronary 
artery pressure divided by mean aortic pressure during maximum hyperemia 
achieved by continuous intravenous infusion of adenosine at a rate of 140 μg/kg/
min through an antecubital vein.
Both indices will be measured approximately 20 mm from the most distal stent 
edge. A pullback will be performed to obtain pressure gradients on the distal 
and proximal stent edges. Drift will be checked at the end of each pullback. 
Measurements with a drift value above 0.02 will be repeated a second time 15. All 
vessels with a drift value above 0.05 during the second attempt will be excluded 
from the study. All pressure tracing will be stored in a dedicated database for off-
line analyses. All tracings will be analyzed for ventricularization, dampening and 
drift by our academic corelab.  
IVUS (Intervention Group)
IVUS-directed FFR optimization will be guided by an automated pullback with 
a 40-60 MHz HD-IVUS catheter at a speed of 2.5 mm/sec (24 frames/mm) 
starting approximately 20 mm distal from the most distal stent edge. Images 
will be analyzed online in order to identify potential reasons for the low post-
procedural FFR. Treatment of potential anomalies will be performed through a 
guidance protocol initiated in order to standardize potential further treatment 
(Table 3) and will be based on the patient’s characteristics, angiographic anatomy, 
distal and interval Pd/Pa and FFR and luminal IVUS dimensions. Final resting Pd/
Pa and FFR will be measured at the end of the procedure if additional treatment 
was performed along with an IVUS pullback assessing the final treatment result. 
All IVUS pullbacks will be analyzed offline using QCU-CMS (Leiden University 
MC, LKEB, Division of Image Processing, version 4.69). Offline analysis will be 
performed by three independent IVUS experts within our academic corelab. All 
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IVUS pullback will be divided in 4 segments, a distal segment, in stent, in segment 
(stent ± 5mm) and a proximal segment. The luminal dimensions for all segments 
will be separately analyzed, including, but not limited to, minimal lumen area, 
minimal lumen diameter, minimal stent area, mean lumen diameter, mean lumen 
diameter and maximum plaque burden. Additionally, malapposition, stent edge 
dissections, underexpansion and residual lesion will be scored according to Table 
3. 
Table 3. Stepwise protocol after high definition intravascular ultrasound (IVUS)
  
Malapposition 
When malapposition is present in more than 1 frame post dilatation with a 
balloon ≥0.25mm larger than the stent balloon is recommended.  
Malapposition due to a non-symmetrical vessel should not be additionally 
dilated.  
 
Edge dissection 
Additional stenting is recommended in case a distal edge dissection of more 
than 90 degrees is encountered. In case of a proximal edge dissection 
additional stenting is left at the discretion of the operator.  
 
Underexpansion 
Underexpansion can be measured with the help of a simple calculating tool, 
based on the MUSIC criteria 16. This will be done ad hoc. When the criteria of 
underexpansion are met, additional dilatation should be performed preferably 
by using a non-compliant balloon with a diameter ≥0.25mm larger than the 
largest balloon used.  
 
Residual lesion 17-21 
 Measure reference vessel diameter (RVD) distally of the potential residual 
lesion. A residual lesion is present in case: 
 RVD is 2.5 – 3.0 mm and lesion MLA is <2.5 mm2 
 RVD is 3.0 - 3.5 mm and lesion MLA is <3.0 mm2 
 RVD is > 3.5 mm and lesion MLA is < 3.5 mm2 
 In case left main lesion: if MLA is <6.0mm2.  
Stent size for additional treatment should be based on lesion length and RVD.  
To ensure a homogenous treatment approach post IVUS imaging of the treated segment the following 
guidelines have been designed.
Conservative treatment (Control Group)
No further treatment or IVUS assessment will be performed. Procedures will be 
concluded based on the confirmation of angiographic success according to routine 
clinical practice. 
Operator strategy
Operator strategy will be assessed at 3 time points during the procedure based 
on the available information at that stage: following angiography, following first 
post-PCI FFR in patients with a FFR <0.90, and following HD-IVUS in subjects 
who are randomized to the IVUS-directed FFR optimization. In the first question, 
the operator will be asked what he/she would do in the hypothetical case the FFR 
would fall below 0.90. Possible answers are: 1) place additional proximal stent 
2) place additional distal stent 3) place additional stent proximal and distal 4) 
post dilatate stent 5) both post dilatate stent and additional proximal stent 6) 
both post dilatate stent and additional distal stent 7) both post dilatate stent 
and additional proximal and distal stent 8) perform intravascular imaging 9) no 
additional treatment. A similar question will be asked directly after the first FFR 
measurement in which the answer may be guided by the information provided by 
the initial post PCI Pd/Pa and FFR (pullback) analyses. The latter two answers will 
be compared to the actual treatment strategy based on the IVUS pullback (Figure 
1). The operator strategy questions were added with the intent to further assess 
how the use of post PCI FFR and IVUS impact treatment strategies intended to 
improve PCI results. 
Follow-up at 6 months, 1, 2 and 3 years follow-up
All patients will be contacted by letter and/or telephone contact at 6, 24 and 
36 months. Before patient contact, survival status will be ascertained by an 
automated civil registry check. A clinical follow-up with ECG will be scheduled at 
12 months. All possible clinical outcomes, including all-cause mortality, cardiac 
mortality, myocardial infarction (MI), target lesion revascularization (TLR) and 
TVR, any revascularization, stent thrombosis, stroke and bleeding. Additional 
information will be retrieved in case of event triggers from local electronic medical 
records, referring physicians and general practitioner.
Data management and monitoring 
Registry of specific endpoints and other details will be managed through 
OpenClinica, an electronic, online, case report form (CRF) application. Follow-up 
contacts will be performed by physicians or study nurses not involved in the index 
procedure and blinded to the final FFR and assigned treatment arm. All data will 
be anonymized and handled confidentially. The key to the de-anonymization will 
be safeguarded by the principal investigator. 
Event adjudication will be performed by an independent Clinical Events Committee 
(CEC) unaware of the post PCI FFR and assigned treatment arm. Specific 
information in the PCI report on the treatment strategy will be masked when 
submitting documents to the CEC.
Monitoring will verify that the rights and well-being of the patients are protected, 
the trial is conducted according to GCP and ISO14155, and that the protocol is 
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followed. The trial specific monitoring program is based on the guidelines for 
on-site monitoring in relationship to the estimated risk of the study (Erasmus 
MC version 15 November 2012). According to these guidelines a negligible risk-
monitoring program was set up for the trial. 
STATISTICAL CONSIDERATIONS
Statistical analysis of endpoints
Categorical variables will be expressed as percentages and counts. Differences 
in categorical variables between randomly allocated treatment groups will 
be evaluated by applying chi-square tests or Fisher’s exact tests. Continuous 
variables will be described as mean ± one standard deviation, or as median and 
interquartile range, accordingly. Shapiro-Wilk tests will be applied to evaluate 
normality of continuous variables. Differences in continuous variables between 
randomly allocated treatment groups will then be evaluated by applying Student’s 
t-tests or Mann-Whitney tests. Parametric correlations will be assessed using the 
Pearson correlation coefficient while the Spearman’s rank correlation coefficient is 
used if the correlation is non-parametric. 
The operator strategy questionnaire will be evaluated using the McNemar’s test. 
Differences between the groups, both randomized and non-randomized, will be 
measured using the log-rank tests to evaluate differences in event-free survival. 
An univariate Cox proportional hazard regression will be used to quantify the 
relation between randomly allocated treatment arms and the incidence of clinical 
outcomes. In order to provide adjusted hazard ratios (HR), a multivariate Cox 
regression will be used, with adjustment for age, sex and (as far as allowed given 
the number of endpoint events) other confounders, possibly including stent size, 
previous coronary artery intervention, previous MI, multivessel disease, a history 
of CABG, dyslipidaemia, hypertension, smoking, diabetes mellitus and renal 
function. Competing risks are taken into account for the analysis. Both primary 
and secondary study parameters are depicted in Table 2. 
All tests will be 2-tailed, and a p-value of <0.05 will be considered statistically 
significant. The secondary outcomes are hypothesis generating and therefore no 
adjustment for multiple testing will be made. We will report estimates of population 
parameters together with their 95% confidence interval.
Sample size calculation 
A recent meta-analysis showed that the incidence of MACE (heterogenous 
definitions used)in patients with post PCI FFR <0.90 was 21.4% versus 5% in 
patients with post PCI FFR ≥ 0.90 4. The average incidence of MACE in the latter 
study was 11%. The average incidence of MACE (comprised of cardiac death, 
any MI and TVR) at 1-year post PCI at the Erasmus MC is 10%. When these data 
are extrapolated, in the Erasmus MC patients with an FFR <0.90 will have an 
estimated MACE incidence of 19%. The MACE incidence of the patients who will 
be randomized to optimal care with IVUS is estimated at 7.5%: the average of the 
incidence at the EMC and the 5% that was found in the meta-analysis. 
In summary, to determine the sample size we made the following assumptions/
choices:
• Incidence of the study endpoint in those randomized to control/standard  
care: 19%
• Incidence of the study endpoint in those randomized to IVUS-directed   
stent placement: 7.5%
• type I error, two-sided: 0.05
• type II error: 0.2 (i.e. power 80%)
• Allocation ratio N2/N1 = 1 
Then a sample size of 272 is required, 136 patients per treatment arm. The sample 
size should be enlarged by an additional 2-5% due to possible technical failures, 
lost to follow-up or unsuitable FFR or IVUS acquisition. Finally 290 patients will be 
randomized.
Based on results of the FFR-SEARCH registry, 45% of the patients will have a post-
procedural FFR <0.90 10. This implies that a total of approximately 640 patients 
need to be enrolled in order find 290 patients with a post PCI FFR <0.90.
Potential issues of concern
The use of FFR and IVUS in daily clinical practice has been shown to be safe with 
a low risk of complications. In the FFR SEARCH study, focusing on the predictive 
value of post-procedural FFR in almost 1000 patients, no complications due to the 
microcatheter were observed, while in only 2 patients a severe response to the 
intravenous adenosine occurred 10. In a study by van der Sijde et al. in which the 
risk of periprocedural complications due to the use of IVUS was assessed in 2476 
procedures, 12 complications (0.5%) occurred 22. All of these were self-limiting 
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after retrieval of the imaging catheter and no major adverse events due to the 
use of IVUS were found. Furthermore, limited evidence is available at the moment 
on the homogeneity of post PCI FFR values in patients presenting with stable 
angina as compared to patients with unstable angina or non-ST elevation MI. 
Additionally, pre PCI FFR assessment using the Navvus microcatheter has proven 
to significantly overestimated the stenosis severity as compared to pressure wire 
based FFR measurements 23, 24. However, this difference was mainly driven by 
a larger delta in vessels with a small minimal luminal area pre procedure. It 
is currently unknown if post PCI FFR assessment with the latter two methods 
will exemplify the same variance and direct extrapolation of the current study to 
pressure wire based post PCI FFR assessment and optimization is therefore not 
possible. 
The sample size calculation presented the current study is based on a meta-analysis 
which included a heterogenous cohort of studies with several outdated registries 
4. The latter might result in a overestimation of the event rates and thus under-
power the study design. Cumulative incidences are expected to diverge between 
the treatment and control group at longer follow-up if the luminal dimension and 
FFR can be increased, ensuring a hypothetical under-powered study at one year 
would be sufficiently powered at two or three years follow-up 4, 5, 25, 26.  
Study status and timeline
The FFR REACT trial is actively enrolling patients since October 31st, 2017 and has 
reached the milestone of enrolling 50% of the target population October 2018. At 
its current pace the study is expected to complete enrolment Q4 2019. 
SUMMARY
The FFR REACT study is an investigator initiated prospective, single-center 
randomized controlled trial conducted at the Erasmus Medical Center designed 
to assess if FFR guided PCI optimization directed by IVUS in patients with an 
increased risk for MACE (post-PCI FFR below 0.90) will decrease target vessel 
failure at 1 year. Inclusion started in October 2017 and enrolment is expected to 
be complete in Q4 2019. 
Public disclosure and publication policy
Findings of the study will be submitted for publication in a peer-reviewed 
international cardiology journal. Publication of the data will remain in the hands 
of the principal investigator and steering committee. The Erasmus MC received an 
unrestricted institutional grant from ACIST Medical Systems, Inc.. 
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Chapter 13
Validation of 3-Dimensional Quantitative 
Coronary Angiography based software to 
calculate vessel-Fractional Flow Reserve: Fast 
Assessment of STenosis severity (FAST)-study
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ABSTRACT
Background: Fractional flow reserve (FFR) assessment requires the use of a 
costly pressure wire combined with the administration of a hyperemic agent, 
which may contribute to its low adoption rate in clinical practice. The aim of the 
study was to validate novel software to calculate vessel FFR (vFFR) based on 
three dimensional quantitative coronary angiography (3D-QCA) and to assess 
inter-observer variability in patients who underwent routine pre procedural FFR 
assessment for intermediate coronary artery stenosis. 
Methods and results: Technical validation of the software (CAAS Workstation 
8.0) was performed in an in vitro experimental model. Clinical validation was 
performed in an observational single-center cohort study. A total of 100 patients 
presenting with stable angina or non-ST segment elevation acute coronary 
syndrome and an indication to perform FFR between Jan 2016 and Oct 2016 were 
included. vFFR was calculated based on the aortic root pressure along with two 
orthogonal angiographic projections and validated against pressure wire-derived 
FFR.
Mean age was 64±11 years and 67% were males. Mean FFR and vFFR were 
0.82±0.08 and 0.84±0.07 respectively. A good linear correlation was found 
between FFR and vFFR (r=0.89; p<0.001). Assessment of vFFR had a low inter-
observer variability (r=0.95; p<0.001). The diagnostic accuracy of vFFR in 
identifying lesions with an FFR≤0.80 was higher as compared with 3D-QCA: 93% 
(95% CI: 88%-97%) vs. 34% (95% CI: 23%-45%) respectively.
Conclusion: The 3D-QCA derived vFFR has a high linear correlation to invasively 
measured FFR, a high diagnostic accuracy to detect FFR ≤ 0.80 and a low inter-
observer variability.
INTRODUCTION
Invasive coronary angiography has served as the cornerstone for the diagnosis of 
patients with known or suspected coronary artery disease (CAD). Unfortunately, the 
technique is limited in its ability to assess the hemodynamic impact of intermediate 
coronary artery stenosis resulting in under- or overestimation of disease severity 
1. In order to overcome this limitation, Fractional Flow Reserve (FFR) has emerged 
as the mainstay of functional hemodynamic assessment of coronary artery lesions 
and is presently regarded as the gold standard for identifying stenoses that cause 
myocardial ischemia 2-5. Despite indisputable evidence supporting the benefit 
of FFR to guide clinical decision making, adoption into daily practice has been 
limited. FFR assessment requires the use of a (costly) dedicated guidewire or 
microcatheter along with the administration of a hyperemic agent associated with 
temporary patient discomfort 6. Although instantaneous wave-free ratio (iFR) has 
emerged as an adenosine-free faster and easier method to achieve physiologic 
assessment, the need for a costly pressure wire remains a fact 7, 8.
Several studies assessed the potential value of FFR derived from three-dimensional 
quantitative coronary angiography (3D-QCA) and blood flow simulation 9-11. The 
recently published FAVOR II China study showed promising results for online 
examination of quantitative flow ratio (QFR) in the diagnostic catheterization 
laboratory 12. The contrast flow mode, which uses a frame count method to derive 
contrast flow velocity from coronary angiography, was used for QFR computation. 
The Fast Assessment of STenosis severity (FAST) study aimed to validate a new 
3D-QCA-based software to calculate vessel-FFR (vFFR) using phantom models. In 
addition we correlated this index with pressure wire derived FFR in a consecutive 
series of patients and studied inter-observer variability.
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METHODS
In vitro experimental model
An in vitro experimental model was developed for technical validation of the 
calculation method performed by the CAAS workstation in phantoms. The 
experimental set-up, as described earlier by Geven et al. consists of a chamber, 
a water-driven systemic and coronary circulation 13. The chamber mimics the 
left ventricle and artificial valves mimic the mitral- and aortic valve of the heart 
(Figure 1). 
Figure 1. Schematic of the in vitro experimental model 
The LV-chamber pumps water through the aorta flow prove (qao) and the artificial valve into the aorta 
and from the aorta into the systemic Windkesssel components (Rao, L, C and Rp). A tube, representing 
the coronary artery, branches off the aorta, passes the phantom, the coronary flow probe (qc) towards 
a venous outlet (V). The pressure sensors are positioned proximal (Pprox.) and distal (Pdist.) to the lesion 
in the phantom, the flow (qc) is measured at the outflow tract of the phantom. The flow through the 
phantom is controlled by the resistance (Rc) in the outflow tract.
The piston is powered by a computer-controlled linear motor (ETB32, Parker) 
creating pulsatile flow at 75 beats per minute. For non-pulsatile flow, a constant 
flow pump (2035, Verder) fills a higher placed reservoir, with overflow function, the 
output of the reservoir connects to the mitral valve. A polyurethane tube models 
the aorta, and input impedance characterizes the systemic circulation behaviour. 
Flow through the aorta was set at approximately 5 l/min and measured using 
an ultrasound flow probe (Transonic 28PAU, with TS 410 flowmeter). The distal 
systemic compliance is modelled using a Windkessel, resulting in physiological 
pressure conditions. 
Coronary circulation
The in vitro coronary circulation comprised a tube (8mm diameter) connected 
to the ostium of the aorta with a phantom attached at the end of this tube. The 
phantom consisted of an 8mm tube with a 75% sinusoidal stenosis (Model: QA-
STV, Simutec). A resistance was placed at the outflow tract of the phantom to 
control the amount of flow through the phantom. The diameter of the tubes in the 
phantom are relatively large compared to human coronary artery dimensions. 14 
To simulate significant pressure drop along the lesion, the average flow through 
the phantom was set higher as compared to physiological coronary flow, and was 
set to an average of 100, 200, 300 and 400 ml/min for both pulsatile flow and 
constant flow15. The proximal and distal pressures to the lesion were measured 
simultaneously with two pressure wires (Certus12006, Radi). The flow rate through 
the phantom was registered by an electromagnetic flow probe. The pressure drop 
over the lesion was obtained by calculating the difference between the measured 
pressures distal and proximal to the lesion. Measurement of pressures was 
averaged over four cycles during pulsatile flow, and the same period was used for 
averaging during constant flow. 
Pressure drop computation methods
The pressure drop over the lesion in the phantom was computed using two 
different approaches: 1) Computational Fluid Dynamic (CFD) being considered a 
reference standard in blood flow simulations 16 and 2) by using CAAS Workstation 
8.0 (Pie Medical Imaging, Maastricht, the Netherlands). 
A 3D surface mesh of the phantom, corresponding to the geometry between the 
locations of the two pressure wires, was used for calculating the pressure drop by 
both approaches. Within both approaches viscosity differences of water against 
blood were taken into consideration.
A single flow value was applied to both computational approaches, to eliminate 
time-variation in flow profile and pressure drop. Assuming that the average 
pulsatile flow has a linear relation with the average pressure drop, the application 
of a single flow value for the computation approaches was justified. The pressure 
drop obtained by both pulsatile and constant flow for the different flow values 
were compared to the computed pressure drop values of both the CFD approach 
and CAAS Workstation vFFR (Figure 2).
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Figure 2. Pressure drop resulting from pressure measurements during pulsatile flow (red line) and 
constant flow (green line) as well as the computed pressure drop by the Computational Fluid Dynamic 
(CFD) (light blue) and CAAS Workstation vFFR (dark blue)
Clinical validation study
Study design and patient population 
The FAST (Fast Assessment of STenosis severity) study is an observational, 
retrospective, single-center cohort study in which offline computation of vFFR 
as compared with conventional invasive FFR measurement using a pressure wire 
based FFR system (St. Jude Aeris, Abbott Vasuclar, St Paul, MA, USA) was studied. 
From January 2016 through October 2016, patients ≥ 18 years of age presenting 
with stable coronary artery disease or non-ST elevation acute coronary syndrome 
who underwent pre-PCI FFR assessment were eligible. Angiographic inclusion 
criteria were: at least one intermediate stenosis in one of the epicardial coronary 
arteries (diameter stenosis of 30-70% by visual assessment). Exclusion criteria 
were FFR measurements with damped pressure curves, patients with ST-elevation 
myocardial infarction (STEMI) or lesions containing thrombus, cardiogenic shock 
or severe hemodynamic instability and adenosine intolerance. 
Procedure protocol
All procedures were performed according to standard local clinical practice. 
Angiographic lesion severity was assessed by two standard monoplane angiographic 
projections (at least 30 degrees apart, preferably orthogonal) after a bolus of 
200mcg nitroglycine. Subsequently, FFR measurement were performed under 
maximum hyperemia achieved by continuous intravenous infusion of adenosine 
at a rate of 140 μg/kg/min through an antecubital vein for at least 2 minutes. 
FFR was defined as mean distal coronary artery pressure divided by mean aortic 
pressure during maximum hyperemic condition. An additional projection was 
recorded with the pressure wire in situ to capture the position of the pressure 
wire. Angiograms and pressure waveforms were stored as DICOM image format 
for offline analyses. Aortic root pressure was constantly recorded. The last blood 
pressure measurement taken before the start of the FFR measurement was used 
as input in the CAAS/vFFR software. 
3D-coronary reconstruction and computation of vFFR
Computation of vFFR was performed offline and assessed blinded by 2 different 
independent observers to assess inter-observer variability (KM, MB). A total 
of 3 two-dimensional images, were exported to the CAAS workstation 8.0 (Pie 
Medical Imaging, Maastricht, the Netherlands): Two views with at least 30 
degrees differences in rotation/angulation to create a 3D reconstruction of the 
coronary arteries and one view to ascertain the position of the FFR pressure wire. 
Temporal alignment of the two orthogonal view phases in the cardiac cycle was 
performed automatically by ECG triggering. Contour detecting was performed 
semi-automatically, delineating the vessel contour from the ostium to the position 
at which the pressure wire sensor was positioned (3cm from the tip). The percent 
diameter stenosis, minimal lumen diameter, reference lumen diameter, minimal 
lumen area and lesion length were measured from the same 3D model as on which 
the vFFR was determined. The lesion segment was defined as proximal, mid, or 
distal. vFFR was calculated automatically incorporating the invasively measured 
aortic root pressure and automatically generated 3D QCA values and vFFR along 
entire vessel instantaneously (Figure 3). 
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Figure 3. Three-dimensional reconstruction of coronary artery and computation of vessel-FFR, using 2 
angiographic projections with at least 30 degrees apart and invasively measured aortic root pressure
Statistical analysis
Continuous variables are presented as mean ±standard deviation. All continuous 
variables were normally distributed. Categorical variables are expressed as counts 
and percentages. All statistical tests are 2-tailed. Pearson’s correlation coefficient 
(r) was used to assess the relationship between FFR and vFFR and to assess 
inter-observer variability. Agreement between the indices and the inter-observer 
reliability were assessed by Bland-Altman plots with corresponding 95% limits of 
agreement. Receiver-operating characteristic (ROC) area under the curve (AUC) 
analysis was used to estimate the diagnostic performance of vFFR as compared to 
the wire-based FFR threshold of ≤0.80. Statistical analysis was carried out using 
the SPSS statistical package version 24 (IBM, Armonk, North Castle, New York, 
USA).
RESULTS
Pre-clinical data
Pressure measurements from the pulsatile flow corresponded well with the pressure 
drops obtained by constant flow (0.36±0.37 mmHg, r>0.99; p=0.002), (Figure 
2). This supports the assumption to apply a single flow value for the computational 
approaches. The CFD pressure drop results showed excellent agreement with 
the experimental pulsatile and constant flow (-0.36±0.28 mmHg and 0.01±0.38 
mmHg respectively, r>0.99; p<0.002), as well as the CAAS Workstation vFFR 
pressure drop results (0.52 ±0.28 mmHg and -0.16±0.11 mmHg respectively, 
r>0.99; p<0.002). The difference between CFD and vFFR was -0.17±0.34 mmHg 
with excellent agreement (r>0.99; p<0.002). 
Clinical data
Patient demographics and procedural data
One hundred patients were included in the study. Baseline and procedural 
characteristics are summarized in Table 1. 
Mean age was 64±11 years and the majority of patients were male (67%). 
Diabetes was present in 26% of the cases. The majority of the FFR measurements 
were performed in the left anterior descending artery (60%). The left circumflex 
artery and the right coronary artery were involved in 13% and 27% of the cases 
respectively. Mean angiographic percent diameter stenosis (DS), lesion length and 
minimum lumen diameter (MLD), measured from 3D-QCA, were 37±13%, 20±13 
mm and 1.7±0.3 mm respectively.
Correlation and agreement between FFR and vFFR
Mean FFR and vFFR were 0.82±0.08 and 0.84±0.07 respectively. A good linear 
correlation was found between FFR and vFFR (r=0.89; p<001) Assessment of 
vFFR had a low inter-observer variability (r=0.95; p<0.001) (Figure 4). vFFR 
had a good accuracy in the identification of patients with significant FFR values 
≤0.80 (AUC of 0.93 [95% CI: 0.88–0.97]) (Figure 5). The diagnostic accuracy of 
3D-QCA, based on percentage diameter stenosis was lower, (AUC of 0.34 [95% 
CI: 0.23–0.45]).
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Table 1. Baseline characteristics
 
 Total, n = 100 
Age, y, mean±SD 64±11 
Male gender, n (%) 67 (67) 
Cardiovascular risk factors, n (%)  
Hypertension 70 (70) 
Hyperlipidemia 59 (59) 
Diabetes Mellitus 26 (26) 
Current smoker 25 (25) 
Peripheral artery disease 10 (10) 
Medical history and co-morbidity, mean±SD  
eGFR, ml/min 88±30 
Hemoglobine, (mmol/L) 8.2±1.4 
BMI  28±5 
Lesions location and characteristics, n (%)  
 Left anterior descending artery 60 (60) 
 Left circumflex artery 13 (13) 
 Right coronary artery  27 (27) 
Tortuous vessels 28 (28) 
Tandem lesions 7 (7) 
Moderate or severe calcification 36 (36) 
Bifurcation lesions 21 (21) 
Coronary angiography indication, n (%)  
Stable coronary artery disease 60 (60) 
Unstable coronary artery disease 14 (14) 
NSTEMI 26 (26) 
3D- Quantitative Coronary Angiography, mean±SD  
Lesion length, mm 20±13 
Minimal lumen diameter, mm 1.7±0.33 
Minimal lumen area, mm2 2.3±0.96 
Diameter stenosis, % 37±13 
Reference vessel diameter, mm 2.8±0.5 
Indices, mean±SD  
FFR 0.82±0.08 
vFFR  0.84±0.07 
 
 
 
  
Values are n, mean±SD of n (%); BMI= Body Mass Index; eGFR= estimated glomerular filtration rate; 
FFR= Fractional Flow Reserve; NSTEMI= Non-ST-segment elevation myocardial infarction; vFFR= vessel 
Fractional Flow Reserve
Figure 4. Scatter Plots showing the relationship between vFFR vs. wire-based FFR 
(A) and inter-observer variability (B) and Bland- Altman plots of differences against the means. The 
mean bias is represented by the solid red line and the 95% confidence interval is represented by the 
dashed lines.
Figure 5. ROC Curves for vFFR and 3D-QCA. Comparison is made with a wire-based FFR at a cut point 
of 0.80
13
Chapter 13 - The FAST-studyPart IV - Innovations in Coronary Physiology
251 || 250
DISCUSSION
The FAST study confirmed the feasibility of a novel 3D-QCA based software tool 
to calculate FFR without the use of a pressure wire or microcatheter. In the pre-
clinical technical validation model, vFFR proved to have a strong correlation with 
CFD and invasively measured flow parameters. In our clinical validation study, we 
confirmed an excellent agreement and high diagnostic value of vFFR compared 
to invasively measured FFR using a dedicated pressure wire under maximum 
hyperemia. Finally, we showed that vFFR had a low inter-observer variability.
Angiography guided coronary revascularization has been the cornerstone of 
routine PCI since its first introduction in September 1977 17. In the past decade a 
wealth of data has become available demonstrating pitfalls of angiographic lesion 
assessment and the superiority of FFR guided PCI as compared to angiography 
guided PCI 4, 18-20.
Based on these compelling data, the use of FFR received strong recommendations 
in current revascularization guidelines 18, 20. Even though the use of FFR proved 
to be contrast saving, cost effective and associated with improved quality of life, 
FFR is still not being performed in the vast majority of cases 5, 19, 21, 22. The latter 
has been hypothesized to be due to the need for (in some countries) expensive 
hyperemic agents with known adverse events as dyspnea and arrhythmias and 
or intolerance due to pulmonary disease and the use of a costly pressure wire 7, 8. 
More recently, the adenosine free index iFR proved to be a valuable alternative to 
FFR in several large scale randomized controlled clinical trials which demonstrated 
the non-inferiority of iFR as compared to FFR 7, 8. However, iFR still requires the 
use of a costly pressure wire. For these reasons, the search for cheaper, faster and 
more patient-friendly methods to assess coronary physiology remains imperative.
Several recent studies assessed the potential value of FFR derived from 3D-QCA 
and blood flow simulation 9, 10. In the VIRTU-1 study 23, Morris et al. developed a 
computer model that accurately predicted virtual FFR from angiographic images 
alone assuming 3D reconstruction, using a Philips workstation. The authors 
showed a good correlation (r =0.84) of virtual FFR values with FFR measured 
invasively. However, in this 3D-QCA-based FFR study, FFR was calculated based on 
lengthy CFD analysis hampering direct clinical applicability 9, 10, 23, 24. In our in-vitro 
models we similated flow by using Navier-Stokes equations (Kratos, Multi-Physics 
5, version 20), on a finite element mesh derived from the 3D surface mesh of the 
phantom. The measured flow was used to generate a parabolic velocity profile 
at the inlet. No-slip boundary conditions were used at the wall, and stress-free 
outflow was prescribed 25. We demonstrated an excellent correlation between 
CFD based experimental pulsatile and constant flow and CAAS Workstation vFFR 
pressure drop results.
More recently published studies validated easier methods using contrast flow 
models to calculate 3D-QCA-based FFR by using frame counting 11, 12. In the FAVOR 
Pilot Study, Tu and coworkers assessed the diagnostic accuracy of quantitative 
flow ratio (QFR) as measured offline in three different ways, based on the different 
mean hyperemic flow velocities 11: 1) fixed empiric hyperemic flow velocity (fQFR) 
2) modeled hyperemic flow velocity derived from angiography without drug-
induced hyperemia (cQFR) and 3) measured hyperemic flow velocity derived from 
angiography during adenosine-induced hyperemia (aQFR). The authors observed 
a good agreement with FFR for all three QFR values with mean differences of 
0.003±0.068; 0.001±0.059 and 0.001±0.065 respectively. The diagnostic 
accuracy for identifying a positive FFR (FFR<0.80) was 80%, 85% and 87% for 
fQFR, cQFR and aQFR respectively. Comparable results were recently presented 
by Xu et al. in the FAVOR II China Study in which the authors demonstrated that 
even when performed online, QFR has high feasibility and accuracy in identifying 
hemodynamically significant coronary artery stenosis 12. In both studies, QFR 
was performed using a prototype software package (QAngio XA 3D prototype, 
Medis Medical Imaging System, Leiden, the Netherlands). However, despite the 
apparently good correlation of QFR to invasively measured FFR, the contrast flow 
models (cQFR and aQFR) have several limitations. Coronary flow velocity is a 
highly sensitive variable. It is well known, that coronary perfusion occurs mainly 
during diastole. This implies that coronary velocity is not constant during the 
entire cardiac cycle and therefore passage of contrast agent might be different in 
systole and diastole.
In addition, there are phasic changes in resistance as well. The perfusion of the 
left coronary artery (LCA) is predominantly diastolic while the perfusion of right 
coronary artery (RCA) is both systolic and diastolic, due to lower pressure in the 
right ventricle as compared with the left ventricle. Therefore, one could assume 
differences while using frame count methods to obtain pressure gradients in the 
left vs. the right coronary artery. Furthermore, administration of contrast for 
performing coronary angiography is usually performed using manually contrast 
injections. The pressure used for contrast injection intrinsically influences 
coronary flow velocity and frame count measurements. In case contrast injection 
was indeed performed manually, larger variations might be expected in inter-
study variability. Unfortunately, no data is available thus far on the reproducibility 
of QFR. In contrast, in the present study, we demonstrated an excellent inter-
observer variability (r=0.95; p<0.001). Assessment of inter-observer variability 
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was based on redo the analysis of one time acquisition. The mean QCA-based 
diameter stenosis in the FAVOR II China Study was 46.5% and about 34% of 
the measured lesions had an FFR ≤0.80. In the present study, we selected the 
intermediate coronary stenosis by visual assessment. The mean QCA-based 
diameter stenosis was 37%. However, despite relatively low diameter stenosis, 
42% of the patients had an FFR ≤0.80.
Furthermore, we used a more simplified method for computation of 3D-QCA-
based FFR by using CAAS Workstation 8.0 (Pie Medical Imaging, Maastricht, 
the Netherlands). Based on well-validated 3D coronary reconstruction 26, 27, 
CAAS Workstation generated a 3D coronary reconstruction using 2 angiographic 
projections with at least 30 degrees apart. vFFR was calculated instantaneously 
by utilizing a proprietary algorithm which incorporates the morphology of the 
3D coronary reconstruction and routinely measured patient specific aortic 
pressure.The CAAS Workstation 8.0 used for the in vitro experimental model was 
adapted to allow importing a 3D geometry of the phantom. In the FAST study, we 
demonstrated a high diagnostic accuracy of vFFR in the identification of patients 
with significant FFR as well, (AUC of 0.93 [95% CI: 0.88 – 0.97]). 
In addition, this is the first validation study of this novel software with a limited 
sample size and offline assessment of vFFR. There is room for improvement in terms 
of diversity in study population and procedural and angiographic characteristics 
like tandem lesions and bifurcations. Clinical outcome studies should be obtained 
to assess the value of vFFR measured by CAAS Workstation for the hemodynamic 
assessment of lesion severity into daily clinical practice. 
Limitations
Our study has several limitations. First, it is a single center experience in which we 
restricted our analyses to those recordings with undamped pressure wave forms. 
Previous work showed the high prevalence of suboptimal FFR curves in clinical 
practice (up to 30%) suggesting an additional benefit when using techniques based 
on angiography and simplified flow models 28. Second, the software’s accuracy in 
complex vessels, e.g. bifurcations and diffusely diseased vessels, remains to be 
determined in larger patient cohorts. Furthermore, as mentioned in the methods 
section, contour detection was performed semi-automatically. 
CONCLUSION
vFFR based on 3D-QCA as determined using novel software has a high linear 
correlation to invasively measured FFR, a high diagnostic accuracy to detect FFR 
≤ 0.80 along with a low inter-observer variability.
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Chapter 14
Validation of novel 3-Dimensional Quantitative 
Coronary Angiography based software to 
calculate Vessel Fractional Flow Reserve 
(vFFR) post stenting: Fast Assessment of 
STenosis severity POST stenting, The FAST 
POST-study
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ABSTRACT
Objectives: To validate novel dedicated 3D-QCA based software to calculate 
post PCI vessel-FFR (vFFR) in a consecutive series of patients and to assess the 
diagnostic accuracy and to assess inter-observer variability.
Background: Low post percutaneous coronary intervention (PCI) Fractional Flow 
Reserve (FFR) predicts future adverse cardiac events. However, FFR assessment 
requires the insertion of a pressure wire in combination with the use of a hyperemic 
agent.
Methods: FAST POST study is an observational, retrospective, single-center 
cohort study. One hundred patients presenting with stable angina or non ST- 
elevation myocardial infarction, who underwent post PCI FFR assessment using a 
dedicated microcatheter were included. Two orthogonal angiographic projections 
were acquired to create a 3D reconstruction of the coronary artery using CAAS 
workstation 8.0. vFFR was subsequently calculated using the aortic root pressure. 
Results: Mean age was 65±12 years and 70% was male. Mean microcatheter 
based FFR and vFFR were 0.91±0.07 and 0.91±0.06 respectively. A good linear 
correlation was found between FFR and vFFR (r = 0.88; p <001). vFFR had a 
higher accuracy in the identification of patients with FFR values <0.90, AUC 0.98 
(95% CI: 0.96-1.00) as compared to 3D-QCA AUC 0.62 (95% CI: 0.94-0.74). 
Assessment of vFFR had a low inter-observer variability (r = 0.95; p <0.001). 
Conclusion: 3D-QCA derived post PCI vFFR correlates well with invasively 
measured microcatheter based FFR and has a high diagnostic accuracy to detect 
FFR <0.90 with low inter-observer variability.
INTRODUCTION
In contrast to fractional flow reserve (FFR), coronary angiography has limited 
ability to accurately assess the hemodynamic significance of coronary stenosis 1-6. 
Furthermore, FFR post PCI is a strong and independent predictor of major adverse 
cardiac events (MACE) up to 2 years 7-9. However, despite unequivocal evidence 
supporting the use of FFR to guide clinical decision-making, adoption into routine 
practice has been limited and in particular FFR assessment after stenting is rarely 
performed. The latter illustrates the need for tools that allow simple and fast post 
PCI physiological assessment without the need for a pressure wire and hyperemic 
agent. 
Vessel FFR (vFFR) as assessed by three-dimensional quantitative coronary 
angiography (3D-QCA) proved to have a high correlation with FFR and a high 
diagnostic accuracy to detect FFR ≤ 0.80 and a low inter-observer variability 10.  
The aim of the present study was to validate 3D-QCA based vFFR with microcatheter 
based FFR post stenting in a consecutive series of patients, assess the diagnostic 
accuracy to detect an FFR <0.90 and determine inter-observer variability. 
MATERIALS AND METHODS
The FAST POST (Fast Assessment of STenosis severity POST PCI) study is an 
observational, single-center cohort study with the aim to assess the diagnostic 
accuracy of offline post PCI vFFR assessment as compared to invasively measured 
FFR using the Acist NavvusTM rapid exchange FFR (ACIST Medical Systems) 
microcatheter.
Based on the findings of the FAST I trial (n=100), a sample of 100 patients was 
selected from the FFR SEARCH registry to validate post PCI vFFR. FFR SEARCH 
registry was a prospective registry in which FFR measurements were routinely 
performed after angiographically successful PCI in 1000 consecutive patients 
between March 2016 and May 2017. Patients referred for coronary angiography 
with at least one hemodynamically significant stenosis who underwent PCI with 
stenting were eligible. Inclusion criteria for the present study were age ≥18 
years and presentation with either stable- or unstable angina or non ST-elevation 
myocardial infarction. Angiographic inclusion criteria study were: at least one 
significant stenosis in one of the epicardial coronary arteries (diameter stenosis 
of >70% on QCA or hemodynamically significant stenosis defined as FFR ≤0.80). 
Exclusion criteria were patients with ST-elevation myocardial infarction (STEMI), 
coronary bypass grafts (CABG), cardiogenic shock or severe hemodynamic 
14
Chapter 14 - The FAST Post StudyPart IV - Innovations in Coronary Physiology
263 || 262
instability and adenosine intolerance. The sample of 100 patients for the present 
study was derived from a consecutive cohort of the 200 most recent patients in the 
FFR SEARCH registry. The majority of the patients were excluded due to STEMI. 
Furthermore, patients with inadequate pressure waveform or lack of two adequate 
orthogonal view to create a 3D reconstruction of the vessel, were excluded. 
Figure 1. Flowchart of all included and excluded patients
The significant percentage of cases that had to be excluded due to a lack of 
qualifying angiograms should be put into perspective to procedures that were 
performed in routine practice with a lack of focus on post PCI vFFR.
All procedures were performed according to standard local routine clinical practice. 
FFR was defined as mean distal coronary artery pressure divided by mean aortic 
pressure during maximum hyperemia achieved by continuous intravenous infusion 
of adenosine at a rate of 140 μg/kg/min through an antecubital vein. Post PCI FFR 
assessment was performed using the Acist Navvus microcatheter, 2 cm distal from 
the most distal stent-edge. Subsequently, two standard monoplane angiographic 
projections (at least 30 degrees apart, preferably orthogonal) were performed 
after a bolus of 200mcg nitroglycine. An additional projection was recorded with 
the Navvus catheter in situ to capture the position of the device. Aortic root 
pressure was constantly recorded, the pressure measurement taken before the 
start of the FFR measurement was used as input in the CAAS/vFFR software. 
Angiograms and pressure waveforms were stored as DICOM image format for 
offline analyses. 
We recently reported the methodology of vFFR calculation 10. vFFR computation 
was performed offline by 2 independent observers, blinded to the invasive post 
PCI FFR measurement, in order to assess inter-observer variability (KM, MB). 
A total of three 2D images, were exported to the CAAS workstation 8.0 (Pie 
Medical Imaging, Maastricht, the Netherlands) that used the same algorithms for 
vFFR computation as previously described 10. Two views with at least 30 degrees 
differences in rotation/angulation to create a 3D reconstruction of the coronary 
arteries and one view to determine the position of the FFR pressure wire. Within 
CAAS Workstation vFFR the pressure drop is calculated instantaneously by applying 
physical laws including viscous resistance and separation loss effects present in 
coronary flow behavior, as described by Gould and Kirkeeide 11, 12. The methods 
however are based on a single angiographic projection. Within CAAS vFFR, the 
geometry of the coronary artery is derived from well-validated 3D reconstructions 
13, 14 which reduces the effects of foreshortening, out of plane magnification and 
non-symmetric coronary lesions.
The two independent observers used the same cine-images for the calculation of 
vFFR. Although temporal alignment of the cardiac cycle between the two angiograms 
was performed automatically by ECG triggering, manual frame selection was 
allowed. Contour detecting was performed semi-automatically, delineating the 
vessel contour from the ostium to the most distal position of the Navvus catheter. 
The percent diameter stenosis, minimal lumen diameter, reference lumen diameter, 
minimal lumen area and lesion length were measured from the same 3D model as 
in which the vFFR was determined. vFFR was calculated automatically integrating 
the invasively measured aortic root pressure and the automatically generated 
3D QCA dimensions. Based on well-validated 3D coronary reconstruction 13, 14, 
CAAS Workstation generated a 3D coronary reconstruction using 2 different 
angiographic projections. vFFR was calculated instantaneously with a proprietary 
algorithm which incorporates the morphology of the 3D coronary reconstruction 
and routinely measured real-time aortic pressure.
Statistical analysis
Continuous variables are presented as mean ± standard deviation. All continuous 
variables were normally distributed. Categorical variables are expressed as counts 
and percentages. All statistical tests are 2-tailed. Pearson’s correlation coefficient 
(r) was used to assess the relationship between FFR and vFFR and to assess 
inter-observer variability. Agreement between the indices and the inter-observer 
variability were assessed by Bland-Altman plots with corresponding 95% limits of 
agreement. Receiver-operating characteristic (ROC) area under the curve (AUC) 
analysis was used to estimate the diagnostic performance of both vFFR and 3D 
QCA-based diameter stenosis as compared to the microcatheter-based FFR with a 
threshold of <0.90 which has been used in previous studies as an arbitrary cut-off 
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value to predict clinical outcome 1, 5, 8. Statistical analysis was carried out using the 
SPSS statistical package version 24 (IBM, Armonk, North Castle, New York, USA).
RESULTS
Baseline and procedural characteristics are summarized in Table 1. Mean age was 
65±12 years and the majority of patients were male (70%). Diabetes was present 
in 21% of the cases. A prior myocardial infarction (MI) or PCI was present in 26% 
and 33% of the patients respectively. In 50 % of the cases, the FFR measurement 
was performed in the left anterior descending artery. Mean 3D QCA-based diameter 
stenosis post PCI was 11±15% with a reference vessel diameter of 3.0±0.6 mm. 
Mean distal coronary artery pressure to mean aortic pressure in the resting state 
during the whole cardiac cycle (Pd/Pa) was 0.96 ±0.04. Mean FFR and vFFR were 
0.91±0.07 and 0.91±0.06 respectively, Table 1. A good linear correlation was 
found between FFR and vFFR (r =0.88; p<001), Figure 2. Assessment of vFFR had 
a low inter-observer variability (r =0.95; p<0.001), Figure 3. vFFR had a higher 
accuracy in the identification of patients with FFR values <0.90, AUC 0.98 (95% 
CI: 0.96-1.00) as compared to 3D-QCA AUC 0.62 (95% CI: 0.94-0.74), Figure 4.
A vFFR threshold of <0.90 was associated with a sensitivity and specificity of 80% 
and 97% respectively to identify FFR <0.90. The positive predictive value (PPV) 
and negative predictive value (NPV) were 94 % and 88% respectively. 
Figure 2. Scatter Plot showing the relationship between vessel-FFR (vFFR) and invasive measured 
FFR using a rapid exchange microcatheter (FFR) (A) and Bland- Altman plots of differences against the 
means (B). 
The mean bias is represented by the solid red line and the 95% confidence interval is represented by 
the dashed lines. FFR = Fractional Flow Reserve; vFFR = Vessel Fractional Flow Reserve.
Table 1. Baseline characteristics
 
 Total, n=100 
Age, y, mean±SD 65±12 
Male sex, n (%) 70 (70) 
Cardiovascular risk factors, n (%)  
Hypertension 59 (59) 
Hyperlipidemia 53 (53) 
Diabetes Mellitus 21 (21) 
Current Smoker 30 (30) 
Medical history and co-morbidity  
Prior ACS, n (%) 26 (26) 
Prior PCI, n (%) 33 (33) 
Peripheral artery disease, n (%) 8 (8) 
Creatinin, µmol/L, µmol/L, Mean±SD 99 (84) 
Hemoglobine, (mmol/L), Mean±SD 8.7 (1.0) 
BMI, Mean±SD 24 ± 4 
Measured vessel, n (%)  
 Left main stem 6 (6) 
 Left anterior descending artery 50 (50) 
 Left circumflex artery 22 (22) 
 Right coronary artery  22 (22) 
3D- Quantitative Coronary Angiography, mean±SD  
Lesion length, mm 10.5±10 
Minimal lumen diameter, mm 2.7±0.7 
Reference vessel diameter, mm 3.0±0.6 
Diameter stenosis, % 11±15 
Indices, mean±SD  
Pd/Pa  0.96 (0.04) 
FFR 0.91 (0.07) 
vFFR  0.91 (0.06) 
 
 
 
  
Values are n, mean±SD of n (%); ACS =Acute coronary syndrome; BMI= Body Mass Index; FFR= 
Fractional Flow Reserve; PCI = Percutaneous coronary intervention; SD = Standard deviation; vFFR= 
vessel Fractional Flow Reserve. 
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Figure 3. Scatter Plot  (A) and Bland- Altman Analysis of inter-observer variability (B). 
The mean bias is represented by the solid red line and the 95% confidence interval is represented by 
the dashed lines.
Figure 4. ROC Curves for vFFR and 3D-QCA. Comparison is made with an FFR at a cut point of 0.89. 
3D-QCA = Three dimensional quantitative coronary angiography; vFFR = Vessel Fractional Flow 
Reserve.
DISCUSSION
The main findings of the FAST POST study can be summarized as follows: 1) vFFR 
allows to identify post PCI FFR <0.90 with a high diagnostics accuracy 2) vFFR, 
showed good correlation and agreement with post PCI FFR as measured using 
a dedicated microcatheter and 3) post PCI vFFR computation has a low inter-
observer variability.
Pre-PCI FFR has become an important tool in detecting hemodynamically 
significant lesions in patients with stable and unstable coronary artery disease 
and FFR-guided PCI proved to significantly improve PCI outcomes as compared to 
angiography guided PCI alone 4, 5, 15-17. 
There has been increasing interest in the assessment of post PCI FFR since several 
studies demonstrated an increased risk of MACE in patient with low pressure 
wire- based post-PCI FFR. In contrast to the generally accepted pre PCI FFR cut 
off of 0.80, there is at present no generally accepted number related to post PCI 
assessment. Previous studies however demonstrated that the optimal threshold 
to predict clinical outcome appeared to be around 0.90 18-26. The clinical relevance 
of the latter was recently strengthened by the results of the FFR-SEARCH registry, 
the largest microcatheter-based post PCI FFR study thus far, demonstrating that 
up to 56% of the patients had at least one lesion with a post PCI FFR ≤0.90 
despite adequate angiographic result 27. Almost 11% of the patients had at 
least one lesion with a post PCI FFR ≤0.80, a number that confirmed previous 
studies showing post PCI FFR rates ≤0.80 in 6 to 9.5% of the cases but was 
significantly higher as compared to findings from the DK-CRUSH VII study (4%) 
18, 22, 28. Differences in these rates have been explained by differences in baseline 
characteristics and linked to more complex lesion phenotypes like bifurcations, 
extensive calcification, CTO, LAD lesions or in-stent restenosis (low post PCI FFR) 
and prior MI, presence of diabetes or presentation with ACS (higher post PCI FFR).
A dedicated IVUS substudy of FFR-SEARCH demonstrated that residual proximal or 
distal lesions, or stent related problems including underexpansion, malapposition 
and edge dissections or hematomas were present in 84% of the patients with a 
post PCI FFR ≤0.85, despite adequate angiographic results 29.
Nevertheless, despite strong recommendations and increasing evidence on the 
cost-effectiveness of FFR in case of pre-treatment lesion assessment, FFR is still 
underused in clinical practice 30, 31. This reality has been linked to reimbursement 
issues, the need for hyperemic agents like adenosine and possible concomitant 
adverse events like dyspnea, chest pain, rhythm disturbances and hypotension 
32, 33. Although, the use of post PCI iFR has emerged as a non-hyperemic faster 
and easier method to evaluate post stenting physiological results, the need for 
a pressure wire remains a fact 34. Moreover, pressure wires that are used pre 
procedurally might get damaged and are often replaced during the course of the 
PCI which mitigates their user-friendliness in a post PCI setting. While the use of 
FFR microcatheters might solve part of this issue, the search towards less invasive 
methods to assess coronary physiology continues and several studies assessed 
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the potential value of FFR derived from three-dimensional quantitative coronary 
angiography (3D-QCA) and computational flow modeling 35, 36. 
In the FAST I study we recently demonstrated a good correlation between vFFR 
using CAAS 8.0 and pre PCI FFR measured using a conventional pressure wire 
along with a low inter-observer variability 10. Similar results were found in the 
FAVOR studies using computational approaches to derive FFR from diagnostic 
coronary angiography (QFR) based on frame counting and contrast flow models 
as well as FFRangio, CathWorks) which allows functional angiographic mapping of 
the entire coronary tree 37-39. The PIONEER QFR substudy assessed the difference 
of QFR immediately post stenting and at nine months follow up between two 
different drug eluting stents and reported that the QFR did not differ between 
the groups 40. The HAWKEYE study investigated the prognostic value of post PCI 
QFR and reported that lower values of post stenting QFR predict clinical outcome 
41. However, in none of both studies pressure wire or microcatheter based FFR 
data were available as a reference. The present study is the first to validate vFFR 
against microcatheter based FFR in a post PCI setting. In the present study we 
were able to show an excellent correlation between vFFR and invasively measured 
FFR using a dedicated microcatheter and a high diagnostic accuracy to detect 
post PCI FFR <0.90. Interestingly, given the fact that the present population 
solely consisted of patients with optimal angiographic results, vFFR proved to be 
<0.90 in 41% of the cases. The present findings are at clear odds with recently 
reported data by Pizzato et al. who reported a weak correlation between vFFR 
and pressure wire based FFR 42. However, several methodological and anatomic 
differences between both studies should be highlighted. At first, vFFR computation 
is based on aortic pressure. No mentioning about this step was made by Pizzato 
et al. It is unlikely the authors were able to retrospectively retrieve accurate 
real-time aortic pressures from >50 centers. If inadequate, a poorer correlation 
could be explained. Second, angiographic lesion severity was clearly different in 
both studies (53% vs. 37% in FAST I). The latter is however less likely to explain 
potential differences in accuracy.
Based on the results of the present study, the calculation of post stenting vFFR 
using the CAAS Workstation could be a useful tool to identify and potentially 
optimize the outcomes of patients at higher risk for future adverse cardiac 
events. Previous studies have shown that post stenting FFR reclassified 20% of 
angiographically satisfactory lesions, which required further intervention thereby 
providing an opportunity for complete functional optimization at the time of the 
index procedure 43. Larger clinical outcome studies are warranted to assess the 
practicalities and value of angiography based post PCI FFR and its potential to 
optimize long-term outcomes.
Limitations
Our study reflects a single-center experience with a relatively small patient 
sample size. The vFFR was compared to FFR using the Acist Navvus microcatheter. 
Microcatheter based FFR correlated well with conventional pressure-wire wire 
based FFR. The latter findings should be interpreted in the light of a known 
overestimation of microcatheter based FFR as compared to routine pressure wire 
based FFR recordings of approximately 0.03 reported in previous studies that was 
mainly linked to larger differences in smaller caliber vessels 44, 45. Furthermore, 
vFFR calculation was performed off-line by two independent observers, there 
was no independent core-lab involved. Both online and independent corelab 
adjudication of vFFR will be performed in the ongoing international multicenter 
FAST II study (ClinicalTrials.gov ID: NCT03791320). Furthermore, the accuracy 
of the technique is strongly dependent on the quality of the angiographic cine-
images. Image acquisition should meet the criteria of non-overlapping images with 
at least 30 degrees differences in angulation. Although these are pre-requisites 
that theoretically should be fulfilled in all pre procedural angiographies, previous 
studies showed that up to 65% of routine angiograms are of insufficient quality 
to be used in angiography-based FFR software due to insufficient luminal contrast 
opacification, overlap or lack of adequate orthogonal views. Also costs of angio 
based FFR are currently a topic of debate between software vendors, hospitals 
and health care reimbursement plans. No definitive universal pricing models have 
been made for the different software packages available. Finally, the average FFR 
in the present cohort was relatively high, directly related to the post PCI nature of 
the patient cohort. Yet, still 41% had a post PCI vFFR of <0.90. 
CONCLUSION 
The 3D-QCA derived vFFR post PCI correlates well with invasively measured 
microcatheter based FFR and has a high diagnostic accuracy to detect FFR <0.90 
with low inter-observer variability.
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A 39-year-old male received a coronary angiography, 14 years after cardiac 
allograft transplantation, indicating a significant lesion in the left coronary artery 
(LAD). Coronary angiography revealed an intermediate lesion in the LAD, for 
which further physiological assessment was considered necessary. (Figure 1). 
Subsequent pressure wire based FFRpw was 0.87, suggesting a non-significant 
lesion, however non-hyperemic 3D based quantitative coronary angiography 
based vessel fractional flow reserve (vFFR) was 0.74 (Figure 1B). Given the 
discrepancies, optical coherence tomography was performed showing a fibrofatty 
plaque with a minimal lumen area (MLA) of 1.70mm2. The LAD was subsequently 
treated with a 3.0x15mm stent. There has been ongoing debate on the validity 
of using FFR in denervated hearts due to high rates of microvascular dysfunction 
and an unreliable hyperemic response 1. Anatomical based assessment might be 
the preferable choice to assess the significance of intermediate coronary lesions 
in denervated hearts 2, 3. 
Figure 1.
A: Coronary angiography of a patients, 14 years after allograft cardiac transplant. The LAD shows a 
angiograpic intermediate stenosis in the mid segment, Pd/Pa values in blue and FFR values in red. 
Optical coherence tomography of the LAD shows a 15 mm lesion with a minimal lumen area (MLA) of 
1.70mm2 and appropriate landing zones. B. Vessel fractional flow reserve (vFFR) of the LAD. The vFFR 
is 0.74, which indicates a significant lesion (threshold ≤0.80). 
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ABSTRACT
Background: Instantaneous wave free ratio (iFR) offers a reliable non-hyperemic 
assessment of coronary physiology but requires dedicated proprietary software 
with a fully automated algorithm. We hypothesized that diastolic pressure ratio 
(dPR), calculated with novel universal software, has a strong correlation with iFR, 
similar diagnostic accuracy relative to resting Pd/Pa and Fractional Flow Reserve 
(FFR).
Methods and results: An observational, prospective, single-center cohort study 
including patients who underwent iFR or FFR. Dedicated software was used to 
calculate the dPR from DICOM pressure waveforms. The “flat” period on the dP/
dt signal was used to detect automatically the period, where the resistance is low 
and constant, and to calculate the dPR, which is an average over five consecutive 
heartbeats. 
The software was validated by correlating iFR results with dPR. Software validation 
was done by comparing 78 iFR measurements in 44 patients who underwent iFR. 
Mean iFR and dPR were 0.91±0.10 and 0.92±0.10 respectively, with a significant 
linear correlation (R=0.997; p<0.001). Diagnostic accuracy was tested in 100 
patients who underwent FFR. Mean FFR, resting Pd/Pa and dPR were 0.85±0.09; 
0.94±0.05; 0.93±0.07 respectively. There was a significant linear correlation 
between dPR and FFR (R =0.77; p<0.001). Both Pd/Pa and dPR had good 
diagnostic accuracy in the identification of lesions with an FFR ≤0.80 (AUC 0.84 
(95% CI: 0.76-0.92) and 0.86 (95% CI: 0.78 to 0.93) respectively). 
Conclusion: dPR, calculated by a novel validated software tool, showed a strong 
linear correlation with iFR. dPR correlated well with FFR with a good diagnostic 
accuracy to identify positive FFR. 
INTRODUCTION
As compared to angiography guided percutaneous coronary intervention (PCI), 
Fractional Flow Reserve (FFR) guided PCI has been shown to significantly improve 
patient outcomes and cost-effectiveness and is currently considered the gold 
standard to identify the hemodynamic severity of coronary artery stenosis 1-6. 
However, the concept of FFR which is based on maximum hyperemic conditions 
requiring intracoronary or intravenous hyperemic agents with potential side effects 
like dyspnea, chest pain and arrhythmias 7.
In recent years, non-hyperemic pressure ratios (NHPR), such as the instantaneous 
wave-free ratio (iFR) and resting distal coronary artery pressure/aortic pressure 
(Pd/Pa), were introduced as alternative invasive indices to assess the severity of 
coronary artery stenosis 8, 9. While Pd/Pa presents the ratio from the mean resting 
distal pressure to aortic coronary pressure during the whole cardiac cycle, iFR 
is based on the same ratio measured during the so-called “wave-free period”, a 
period during diastole in which the microvascular resistance is low, and constant. 
As compared to FFR, the diagnostic accuracy of iFR has been assumed to be slightly 
better than Pd/Pa 10. While Pd/Pa can be calculated from any type of pressure wire 
or microcatheter, the algorithm of iFR belongs to the iFR core laboratory (Imperial 
College, London, United Kingdom) and its use is restricted to the proprietary 
software of a single vendor (Philips Volcano)
The aim of this study was to validate the diastolic pressure ratio (dPR), calculated 
using novel software applicable to any type of pressure wire or microcatheter, to 
assess the correlation of dPR with iFR and to assess the diagnostic accuracy of dPR 
as compared to FFR and resting Pd/Pa. 
METHODS
Study design and patient population
Dedicated software was developed in the Erasmus Medical Center (Erasmus MC) 
(FM, JL, KW). The software was designed to calculate a dPR from DICOM pressure 
tracings generated by any type of pressure wire or catheter using either electrical 
(Piezo-Resistive) or optical sensors and from spreadsheet data (csv file), provided 
by the S5i console (Volcano Corporation, Rancho Cordova, California; FFR software 
version 2.4.1.2723) offline. The dPR study consisted of two parts: 1) validation of 
the dPR software with original iFR results and 2) assessment of the correlation of 
dPR with FFR and its diagnostic accuracy for identification of positive FFR. 
For the purpose of this retrospective study patients were not subjected to study 
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interventions, neither was any mode of behavior imposed, otherwise than as part 
of their regular treatment. Therefore according to Dutch law, no formal approval 
was required. This study was conducted according to the privacy policy of the 
Erasmus MC and to the Erasmus MC regulations for the appropriate use of data 
in patient orientated research, which are based on international regulations, 
including the declaration of Helsinki. All patients consented to the use of their 
data for scientific research.
The data, analytic methods, and study materials will not be made available to other 
researchers for purposes of reproducing the results or replicating the procedure.
Coronary angiography and calculation of dPR
All procedures were performed according to standard local clinical practice. 
Pressure measurements were performed after an intracoronary bolus of nitrates 
(100-200 µg), in case there was doubt regarding the hemodynamic significance 
of intermediate coronary artery lesions. Pd/Pa was defined as the ratio of mean 
distal coronary artery pressure to mean aortic pressure in the resting state during 
the whole cardiac cycle. FFR was defined as lowest ratio of mean distal coronary 
artery pressure divided by mean aortic pressure during maximum hyperemia 
achieved by continuous intravenous infusion of adenosine at a rate of 140 μg/
kg/min through an antecubital vein. The dPR was defined by the ratio between 
the mean diastolic pressure distal to the stenosis and the mean diastolic aortic 
pressure in resting conditions. The diastolic period used to calculate the dPR 
was automatically delineated based on the dP/dt curve of the aortic pressure at 
the point at which the resistance was low, constant and stable. The dP/dt curve 
represents the increase and decrease of the pressure over time during the heart 
cycle. dP is the pressure difference between sample points and dt is the time 
difference between the same sample points. The “flat line” of the dP/dt tracing 
was used as trigger for the software to detect the “wave-free period” within the 
range of 60-80% of the cardiac phase as a first default. Because of this range 
the wave-free period detected by dP/dt tracing can be shorter than the wave-free 
period detected by original iFR. Both original iFR and calculated dPR values were 
stored in a spreadsheet, created by the dPR software and from each measurement 
a graphic representation was provided in PDF format (Figure 1), showing the 
pressure and dP/dt tracings together with the triggered regions and region of 
interest (ROI) to calculate dPR.
Figure 1. Sample tracing of the ECG, Aortic Pressure and dP/dt with the effect of different periods in 
the heart cycle 
Calculation of the index (dPR) during diastole by automatically indicating the “flat” period of the dP/Dt 
signal in 5 consecutive heartbeats.
Validation with iFR
A total of 78 iFR measurements from 44 patients were used for the validation step. 
iFR measurements were performed using the Verrata® pressure wire along with 
the original proprietary software (Philips Volcano). The csv spreadsheet files were 
imported in the software. The spreadsheet values of the reference aortic pressure 
and the wire pressure signals were used by the software to automatically analyze 
the dP/dt tracing and calculate the corresponding dPR based on 5 consecutive 
heart beats. 
Validation with FFR
From April 2017 through September 2017, patients referred for coronary 
angiography for stable or unstable coronary artery disease and an indication to 
perform FFR, were included. A consecutive cohort of 100 patients with adequate 
pressure tracings was enrolled. DICOM recorded tracings derived from either a 
Pressure Wire (Pressure WireTM X, Abbott Vascular, Santa Clara, CA,USA) or micro 
catheter (Navvus, ACIST Medical Systems, Eden Prairie, MN, USA) were eligible. 
Pressure waveforms were automatically exported to Siemens Sensis®, converted 
to DICOM and stored in a local hospital database. 
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Statistical analysis
Continuous variables are presented as mean ±standard deviation. All continuous 
variables were normally distributed. Categorical variables are expressed as 
frequencies (n) and percentages (%). All statistical tests are 2-tailed. Pearson’s 
correlation coefficient (R) was used to assess the relationship between the several 
indices. Agreement between the indices and the inter-observer variability were 
assessed by Bland-Altman plots with corresponding 95% limits of agreement. 
Receiver-operating characteristic (ROC) area under the curve (AUC) analysis 
was used to estimate the diagnostic accuracy of dPR as compared to FFR with a 
threshold of ≤0.80. Statistical analysis was carried out using the SPSS statistical 
package version 21 (IBM, Armonk, North Castle, New York, USA).
RESULTS
Validation with iFR
A total of 44 patients (age 70±10, 70% male) presenting with stable or unstable 
coronary artery disease underwent iFR measurements in 78 vessels (LAD n=38, 
LCX n=22, RCA n=18). Baseline characteristics of the iFR cohort are summarized 
in Table 1. Mean iFR and dPR were 0.91±0.10 and 0.92±0.10 respectively. An 
excellent correlation was found between both indices; (R = 0.997; p<0.001); 
Mean bias -0.0016±0.084), (Figure 2).  
Figure 2. Scatter Plot showing the relationship between the iFR and dPR (left panel) and Bland- Altman 
plots of difference against the mean (right panel)
The mean bias is represented by the solid red line and the 95% confidence interval is represented by 
the dashed lines. Abbreviations as in Table 1. 
Table 1. Baseline characteristics iFR cohort 
 Total (N=48) 
Age, y mean (±SD) 70 (10) 
Male sex, n (%) 31 (70) 
Clinical indication procedure, n (%)  
 Stable angina 32 (67) 
 Unstable angina 2 (4) 
 Non ST segment elevation MI 14 (29) 
Cardiovascular risk factors, n (%)  
Hypertension 23 (52) 
Hyperlipidemia 17 (38) 
Diabetes Mellitus 14 (32) 
Smoker 8 (18) 
Family history of CVD 16 (36) 
Co-morbidity, mean (±SD)  
Creatinine µmol/L 111 (46) 
Hemoglobine (mmol/L) 8.1 (1.2) 
BMI 27 (4) 
Measured vessel Lesions, n (%)  
 Left anterior descending artery 38 (49) 
 Left circumflex artery 22 (28) 
 Right coronary artery 18 (23) 
Indices, mean (±SD)  
iFR 0.91 (0.10) 
dPR 0.92 (0.10) 
 
 
 
  
Values are n, mean±SD of n (%); BMI =Body Mass Index; CVD =cardiovascular disease; dPR =resting 
diastolic pressure ratio; iFR =instantaneous wave-free ratio; MI =myocardial infarction.
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Patient demographics and procedural data of the FFR cohort
Baseline and procedural characteristics of the FFR cohort are summarized in Table 
2. 
Table 2. Baseline characteristics of FFR cohort 
 Total 
cohort 
FFRMC  
(N=50) 
FFRPW 
(N=50) p value 
Age, y mean (±SD) 66 (11) 67 (13) 66 (8) 0.94 
Male sex, n (%) 80 (80) 39 (78) 41 (82) 0.62 
Clinical indication procedure, n 
(%)     
Stable angina 56 (56) 20 (40) 36 (72) 0.001 
Unstable angina 11 (11) 7 (14) 4 (8) 0.34 
Non ST segment elevation MI 33 (33) 23 (46) 10 (20) 0.01 
Cardiovascular risk factors, n 
(%)     
Hypertension 65 (65) 34 (68) 31 (62) 0.53 
Hyperlipidemia 55 (55) 26 (52) 29 (58) 0.55 
Diabetes Mellitus 22 (22) 12 (24) 10 (20) 0.63 
Smoker 18 (18) 11 (22) 7 (14) 0.30 
Family history of CVD 27 (27) 17 (34) 10 (20) 0.12 
Co-morbidity, mean (±SD)     
Creatinine µmol/L 96 (46) 96 (40) 97 (50) 0.94 
Hemoglobine (mmol/L) 8.5 (1.1) 8.6 (1.0) 8.3 (1.1) 0.27 
BMI 28 (4) 28 (5) 27 (4) 0.25 
Measured vessel Lesions, n (%)     
Left anterior descending artery 67 (67) 34 (68) 33 (66) 0.83 
Left circumflex artery 14 (14) 6 (12) 8 (16) 0.57 
Right coronary artery 19 (19) 10 (20) 9 (18) 0.80 
Indices, mean (±SD)     
Resting Pd/Pa 0.94 (0.05) 0.94 (0.05) 0.94 (0.05) 0.73 
FFR 0.85 (0.09) 0.85 (0.08) 0.85 (0.09) 1.00 
dPR 0.93 (0.07) 0.93 (0.06) 0.92 (0.07) 0.87 
 
 
 
  
Values are n, mean ±SD of n (%); BMI= Body Mass Index; CVD =cardiovascular disease; dPR =resting 
diastolic pressure ratio; FFR =Fractional Flow Reserve; FFRPW =FFR measured by pressure wire system; 
FFRMC =FFR measured by the Acist FFR wire system; MI =myocardial infarction; Pd/Pa =resting distal to 
aortic coronary pressure.
Mean age was 66 years and the majority of patients were male (80%). Clinical 
presentation was stable angina (56%), unstable angina (11%) and non ST 
segment elevation myocardial infarction (33%). Diabetes was present in 22% 
of the cases. The majority of the FFR measurements were performed in the left 
anterior descending artery (67%). The left circumflex artery and the right coronary 
artery were measured in 14% and 19% of the cases respectively. 
Relationship between dPR, Pd/Pa and FFR
Mean FFR, resting Pd/Pa and dPR were 0.85±0.09, 0.94±0.05 and 0.93±0.07 
respectively (Table 2). A good linear correlation was found between dPR and FFR 
(R = 0.77; p<0.001) (Figure 3).The linear correlation between FFR and Pd/Pa 
was 0.81 (p<0.001). The correlation between FFR as measured using the Navvus 
system (FFRMC) and dPR was higher as compared to pressure wire based FFR 
(FFRPW) and dPR (R =0.81 vs R =0.76 respectively). dPR showed to have good 
diagnostic accuracy in the identification of patients with FFR values ≤0.80 (AUC of 
0.86 [95% CI: 0.78-0.93]). Comparable results applies to Pd/Pa as well (AUC of 
0.84 [95% CI: 0.76 – 0.92]) (Figure 4). The optimal cutoff value for an FFR ≤0.80 
derived from the ROC analyses was 0.91 for dPR and 0.92 for Pd/Pa.
Figure 3. Scatter Plot showing the relationship between FFR and two different resting indices (Pa/Pa 
and dPR) and Bland- Altman plots of difference against the mean
The mean bias is represented by the solid red line and the 95% confidence interval is represented by 
the dashed lines. Abbreviations as in Table 1 and 2. ∆ represents FFR measurements as measured using 
the Navvus system (FFRMC) and O represents pressure wire based FFR measurements (FFRPW)
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Figure 4. ROC Curves for dPR and Pd/Pa. Comparisons are made with an FFR at a cut point of 0.80. 
Abbreviations as in Table 1. 
DISCUSSION
In the present study, we demonstrated the feasibility of using a non-hyperemic 
pressure ratio, the dPR, calculated using novel software applicable to any type of 
pressure wire or microcatheter. dPR had an excellent linear correlation with iFR 
and a strong diagnostic accuracy in identifying lesions with an FFR ≤0.80. 
FFR has become the gold standard to determine the severity of epicardial coronary 
stenoses and myocardial ischemia based on studies demonstrating significantly 
better outcomes with FFR-guided PCI as compared to angiography guided PCI 5, 
4, 6, 11, 12. Nevertheless, despite strong guideline recommendations and increasing 
evidence on its cost-effectiveness, the adoption of FFR in routine clinical practice 
remains low 13-16. The latter has been linked to reimbursement issues and the 
need for hyperemic agents. Hyperemic agents like intravenous adenosine might 
provoke transient dyspnea, chest pain, vomiting, rhythm disturbances and 
hypotension in up to 37.5% of the cases 8, 9. For these reasons the search for 
cheaper, faster and more patient-friendly methods remains relevant and several 
studies assessed the concept of the adenosine-independent index iFR as an 
alternative method to assess lesion severity. As mentioned, the concept of FFR 
is based on maximum hyperemic conditions necessitating the use of intravenous 
hyperemic agents. Nevertheless, even during hyperemia, intracoronary resistance 
is not static but instead fluctuates in a phasic pattern throughout the cardiac 
cycle with the lowest resistance during diastole due to decompression of the 
microvasculature and due to the lowest difference in pressure between the aorta 
and the coronary artery during diastole 17. The iFR concept relies on the theory that 
intracoronary resistance is naturally low, constant and stable during the “wave-
free” period precluding the need for hyperemic agents 18. iFR had a high diagnostic 
accuracy to predict positive or negative FFR values. More recently, iFR guided PCI 
demonstrated to be non-inferior to FFR in reducing a composite of death from 
any cause, nonfatal myocardial infarction or unplanned revascularization within 
12 months 8, 9. However, in a pooled meta-analysis of this two trials, a numeric 
excess in the incidence of death and myocardial infarction was found in the iFR 
group 19. Although no large scale randomized outcome studies are available on 
the efficacy of Pd/Pa as compared to FFR-guided revascularization, iFR appeared 
more sensitive than Pd/Pa to differentiate stenosis severity and showed a lower 
maximum difference in estimated major adverse cardiac event risk influenced by 
the measurement variability compared with resting Pd/Pa 10. The latter supports 
the concept of applying the diastolic period to calculate pressure gradients 
when refraining from the use of hyperemic agents. At present, the use of iFR is 
restricted to the use of a single device and software (Philips Volcano) whereas a 
large variety of pressure wires and microcatheters are available to measure Pd/
Pa and FFR. In the current study, we demonstrated the feasibility of a fast, simple 
and reproducible method of measuring a dPR based on non-hyperemic DICOM 
pressure waveforms derived from either PW or microcatheter devices which could 
open up the field for a more widespread use of diastolic pressure gradients in real 
world clinical practice. By using a simple software tool to automatically detect 
the flat period in the dP/dt curve that indicates the so called “wave-free” period 
we found that the resultant dPR correlated nearly perfect with the original iFR 
output of Phillips Volcano (r=0.997, p<0.001). Subsequently, our results showed 
a correlation between dPR and FFR (r=0.77) in line with previous results from the 
VERIFY study demonstrating a correlation coefficient r of 0.789 between iFR and 
FFR 20. Additionally, dPR showed a high diagnostic accuracy in the identification 
of patients with FFR values ≤0.80 (AUC of 0.86 (95% CI: 0.78-0.93)) while the 
AUC was 0.84 (95% CI: 0.76 – 0.92) for Pd/Pa. Also these results are in line with 
previous findings as published in the Resolve study in which the AUC was 0.81 and 
0.82 for iFR and Pd/Pa respectively 21. In the present study, we used the flat period 
of the dP/dt signal to identify the “wave free period”. While during this period 
in diastole there is the least amount of pressure variation between aortic and 
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distal pressures, it allowed us to develop software using the same methodology 
in any pressure-wire or microcatheter. It is likely that using either period during 
diastole to compute the dPR would result in equal results. van ‘t Veer et al. looked 
at the correlation between iFR and resting indices during different parts of the 
diastole by using a simple Matlab algorithm and concluded that all diastolic resting 
indices were identical to iFR 22. Therefore, any diastolic resting index can be used 
with the same advantages and disadvantages inherent within iFR. However, in 
our validation cohort of 78 iFR measurements we found two cases with a bias 
beyond the 95% confidence interval. Analysis of these cases (Figure 5) showed 
that the dP/dt triggered a shorter “wave-free” period, resulting in a shorter ROI, 
in one case positioned earlier in the heart sequence, resulting in a lower dPR 
ratio compared to iFR, in the other case positioned later in the heart sequence, 
resulting in a higher dPR as compared to iFR. In conclusion, the length of the 
interval used in the present algorhythm depends on the length of the flat line on 
dP/dt waveform which might slightly differ per cardiac cycle. Conclusions about 
accuracy of iFR versus dPR and correlation to FFR cannot be drawn based on these 
two cases but warrant further research.   
Kobayashi et al. looked at the influence of lesion location on the diagnostic accuracy 
of resting indices contrast FFR (cFFR), iFR and Pd/Pa and found that this three 
resting indices are less accurate in left main and proximal ramus descendens artery 
lesions as compared to other lesion locations 23. The authors in the VERIFY 2 study, 
hypothesized that in comparison with FFR, revascularization decisions based on 
either binary cutoff values for iFR and Pd/Pa or hybrid strategies incorporating 
iFR or Pd/Pa will result in similar levels of disagreement. They found that binary 
cutoff values for iFR and Pd/Pa result in misclassification of 1 in 5 lesions 24. We 
know that perfusion of the left coronary artery is predominantly diastolic while 
the perfusion of right coronary artery is both systolic and diastolic, due to lower 
pressure in the right ventricle as compared to the left ventricle.
While the diagnostic accuracy of NHPR in predicting positive FFR in general might 
differ between left and right sided assessments, we do not see any reason to 
believe that any difference might be expected in the diagnostic accuracy of dPR 
as compared to iFR. 
Thereby, our study population is too small to analyze the differences between 
different lesion locations and between right (19%) vs left coronary artery 
(81%) (Table 2). However, we  think there is no reason to believe that the dPR 
calculated based on dP/dt has superior diagnostic accuracy as any of the other 
resting indices.Finally, small previous studies demonstrated a good correlation 
between FFRMC and FFRPW however also suggested an overestimation of FFR with 
FFRMC compared to FFRPW by approximately 1% 25. While in the present study 
mean FFRMC and FFRPW were similar, the correlation between FFRMC and dPR was 
higher as compared to FFRPW and dPR (R=0.81, p<0.001 and R=0.76, p<0.001 
respectively). We assume that the fact that the microcatheter was used merely for 
post-PCI FFR measurements, with subsequently lower pressure gradient, might 
have impacted our findings. Larger studies are needed to confirm any differences 
in optimal cut-off values for both devices. 
Figure 5. Explanation of discrepancy between iFR and dPR
Two cases with a bias beyond the 95% confidence. Compared to iFR, dPR software triggers a shorter 
region of interest (ROI). Depending on the position of the ROI in the sequence this may result in a 
higher or lower Pd/Pa ratio compared to iFR. Case A: iFR includes a region with a “lump” in the distal 
pressure, dPR detected a “lump” in Dp/Dt and did not include the region beyond this “lump”, positioned 
the ROI earlier in the sequence, resulting in a lower ratio. Case B: dPR ignored a steeper region in 
the Dp/Dt signal, positioned the ROI later in middle of the sequence, resulting in a higher Pd/Pa ratio 
compared to iFR.
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Limitations
The present results are based on a single center experience in which we restricted 
our analyses to those recordings with undamped pressure wave forms. The latter 
could have artificially influenced our results since recent core laboratory study 
data, assessing the prevalence of erroneous or suboptimal FFR measurements 
in clinical practice, demonstrated that in up to 30% of the recordings, pressure 
signals were inadequate 26. In order not to be biased by measurements and results 
based on dampening pressure waveforms which might have biased the final FFR, 
iFR or Pd/Pa we scrutinized the pressure waveforms from tracings in the cases 
selected. In order to be able to mitigate to amount of bias caused by dampened 
pressure waveforms, we only selected cases in which pressure tracings and 
waveforms were adequate. Furthermore, Navvus microcatheter may confound 
the relationship with stenosis severity, which may be relevant when considering 
relationships between Pd/Pa and FFR. However, all included vessels in the present 
study were >2.5mm and that makes the comparison more reliable. 
CONCLUSION
Resting diastolic pressure ratio (dPR), calculated by a novel algorithm, had an 
excellent correlation with iFR, a high linear correlation to both Pd/Pa and FFR and 
a better diagnostic accuracy as compared to Pd/Pa.
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Chapter 18
Intravascular Polarimetry in Patients With 
Coronary Artery Disease
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ABSTRACT
Background: Polarization-sensitive (PS-) optical frequency domain imaging 
(OFDI) measures polarization properties of tissue together with conventional 
cross-sectional OFDI images of subsurface microstructure.
Objectives: This first-in-human pilot study of intravascular polarimetry aimed 
to investigate birefringence and depolarization features of coronary plaques in 
patients and to examine the relationship of these features with established structural 
characteristics available to conventional OFDI and with clinical presentation.
Methods: 30 patients undergoing PS-OFDI (acute coronary syndrome; ACS, 
n=12 and stable angina pectoris; SAP, n=18) participated in this study. 342 
cross-sectional images evenly distributed along all imaged coronary arteries were 
classified into one of seven plaque categories according to conventional OFDI. 
Polarization features averaged over the entire intimal area of each cross-section 
were compared between plaque types and with structural parameters. Further, 
we assessed the polarization properties in the fibrous caps of ACS and SAP culprit 
lesions and compared them with structural features using a generalized linear 
model.
Results: The median birefringence and depolarization showed statistically 
significant differences among plaque types (both p<0.001, one-way ANOVA). 
Depolarization significantly differed between individual plaque types (p<0.05), 
except between fibro-fatty and fibro-calcified plaques. Caps of ACS lesions and 
ruptured caps exhibited lower birefringence than caps of SAP lesions (p<0.01). In 
addition to clinical presentation, cap birefringence also associated with macrophage 
accumulation as assessed by normalized standard deviation.
Conclusion: Intravascular polarimetry provides quantitative metrics that help to 
characterize coronary arterial tissues and may offer refined insight into coronary 
arterial atherosclerotic lesions in patients. 
Central illustration. Polarization properties in plaque progression and destabilization
In a less advanced stage of atherogenesis, birefringence and depolarization increase along with the 
proliferation of thick collagen, smooth muscle cells and lipid content (atherogenesis and progression). 
Birefringence of the plaques declines in hand with the reduction of interstitial collagen, and the 
development of the lipid/necrotic core, which in turn leads to a significant increase in depolarization, 
corresponding to the transition of pathological intimal thickening (FP and FF) to a fibroatheroma 
(progression and destabilization). Abbreviations as in Figure 2 and 4.
INTRODUCTION
Plaque morphology and composition have been implicated in the pathogenesis 
of acute coronary syndromes (ACS) 1-2. The high resolution of optical coherence 
tomography (OCT) and optical frequency domain imaging (OFDI) has enabled 
identification of several structural features of plaque instability 3-6. Despite much 
progress, prospective identification of rupture-prone plaques, which would be 
crucial to stratify risk and improve patient management, remains elusive 7-10. 
Current OCT/OFDI imaging modalities rely on subjective interpretation and fall 
short of providing an objective and quantitative assessment of plaque morphology 
and composition 11-14. 
Recently, we have introduced intravascular polarimetry by using polarization-
sensitive optical frequency domain imaging (PS-OFDI) in combination with standard 
intravascular OFDI catheters 15-17. Intravascular polarimetry complements the 
high-resolution imaging of subsurface microstructures known from OCT and OFDI 
with polarimetric measurements of tissue birefringence and depolarization 15, 16. 
Tissue with fibrillar architecture, such as interstitial collagen or layered arrays of 
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arterial smooth muscle cells, exhibits birefringence, which can serve to assess 
collagen and smooth muscle cell content 16, 18. Depolarization corresponds to the 
randomization of the detected polarization states 19 caused by the propagation 
of light through tissue containing lipid particles, macrophage accumulation, or 
cholesterol crystals 16. In our previous study comparing intravascular polarimetry 
with histopathology, we showed that tissue birefringence and depolarization 
provide useful compositional information and offer advanced tissue characterization 
16. The present study aimed to investigate, for the first time, the polarization 
properties of atherosclerotic plaques in patients with coronary artery disease. 
We explored how the quantitative polarization metrics evaluated in entire cross-
sections vary between different types of plaques, classified by conventional OFDI 
according to established qualitative structural criteria (plaque analysis). Moreover, 
we compared the polarization properties measured locally in the fibrous caps of 
culprit lesions between patients with ACS and SAP (cap analysis).
METHODS
Study population
This first-in-human pilot study of intravascular polarimetry enrolled 30 non-
consecutive patients (ACS, n = 12 and stable angina pectoris; SAP, n = 18) 
undergoing percutaneous coronary intervention at Erasmus University Medical 
Center (Erasmus MC) between December 2014 and July 2015. The ethics 
committee at Erasmus MC approved the protocol and each patient gave 
written informed consent before inclusion into the study, which was conducted 
in compliance with the protocol and the Declaration of Helsinki. PS-OFDI was 
performed using commercial intravascular catheters (FastViewTM, Terumo Corp., 
Tokyo, Japan) with a custom-built PS-OFDI system (Supplementary methods), as 
previously described in detail 15-17. Imaging in the 30 patients yielded a total of 36 
pullbacks, performed either before the procedure (n = 15, whereof culprit/target 
vessel, n = 13, and non-culprit/non-target vessel, n = 2) or after the procedure 
(n = 21). Patient characteristics are summarized in Table 1. 
Study design
The present study comprises a plaque analysis evaluating entire cross-sections 
evenly distributed along all imaged coronary arteries and a cap analysis focusing 
solely on the fibrous cap of culprit lesions (Figure 1A). For the plaque analysis, 
all pullbacks were uniformly divided into segments of 5 mm length, progressing 
distally and proximally from the culprit lesion (Figure 1B). From the resulting 
total of 508 segments, comprising 2540 mm pullback length, 166 segments were 
excluded from the analysis due to the following criteria: 1) containing a stent or 
from within 5 mm proximal or distal to an implanted stent (n = 150); 2) subject 
to pre-dilatation (n = 2); and, 3) poor image quality due to insufficient blood 
clearing (n = 14). In each of the retained 342 segments, the cross section with the 
smallest lumen area was identified for further analysis. Cross-sections containing 
a side branch of diameter > 1.5 mm were replaced with another section from 
the same segment. For fibroatheromas, instead of the smallest lumen area, the 
cross-section with the thinnest fibrous cap thickness (FCT) was used for analysis. 
For the cap analysis, we identified the culprit lesion in patients with ACS (n = 4) 
and SAP (n = 9) who underwent PS-OFDI imaging prior to percutaneous coronary 
intervention (Figure 1A). ACS culprit lesions were identified based on invasive 
coronary angiography, electrocardiographic ST-segment alterations, and/or 
regional wall motion abnormality on echocardiographic assessment. SAP target 
lesions were determined on the basis of left ventricular wall motion abnormalities, 
nuclear scan, stress test, and coronary angiographic findings. For the cap analysis, 
we identified the cross section with the smallest luminal area in the culprit/target 
lesion of each patient (Figure 1B). Every other cross-sectional image up to 5 mm 
both proximally and distally, if featuring a lipid arc exceeding > 90 degree, was 
included into the analysis, resulting in a total of 244 cross-sections.
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Figure 1. Study population, design and lesion selection 
(A) Study population and data analysis. (B) PS-OFDI pullbacks were divided into 5 mm segments, 
centered on the culprit segment for the plaque analysis. Red broken lines indicate the selected cross-
sectional images within each 5 mm segment, corresponding to the cross-section with the smallest 
luminal area. The cap analysis focused on the culprit/target segment centered around the cross 
section with the smallest luminal area in the culprit lesion of each patient. Cross-sectional images were 
analyzed every 2 frames both proximally and distally up to 5 mm, as long as the lipid arc exceeded 
> 90 degrees. Scale bars measure 1 mm for cross-sectional images (white) and 5 mm for the 
longitudinal image (black), respectively. ACS = acute coronary syndrome, PR = plaque rupture, SAP = 
stable angina pectoris, and PS-OFDI = polarization-sensitive optical frequency domain imaging. 
Conventional OFDI analysis
Two independent investigators (A.K. and L.Z.) analyzed the conventional OFDI 
appearance of the selected images using QCU-CMS viewing software (Leiden 
University Medical Center, Leiden, The Netherlands). Conventional OFDI analysis 
was performed blinded to the polarimetric signals. Luminal area was measured in 
all cross-sections. Percent area stenosis was calculated as previously reported 8, 
taking the mean of the largest lumen within 5 mm proximal and distal to the lesion 
containing the current cross-section as the reference. 
Each selected cross-section was then categorized as either of normal artery, 
fibrous plaque (FP), fibro-fatty plaque (FF), fibro-calcified plaque (FC), thick cap 
fibroatheroma (ThCFA), thin cap fibroatheroma (TCFA), or plaque rupture (PR), 
based on the conventional OFDI signal (Figure 2 A1 to G1). Briefly, a vessel with 
a tunica intima thinner or similar in thickness to the tunica media was labelled as 
normal artery (Figure 2 A1). FP was defined as a plaque with high backscattering 
and relatively homogeneous OFDI signal (Figure 2 B1). Plaques with calcium, 
that appears as signal-poor or heterogeneous region with a sharply delineated 
border within fibrous tissue, were classified as FC (Figure 2 D1) 9. A plaque with 
a lipid arc of more than 90 degrees was defined as a fibroatheroma. A lipid-rich 
plaque with a lipid arc extending less than 90 degrees was categorized as FF, 
to appreciate the optical properties of the small lipid-rich area (Figure 2 C1). In 
fibroatheromas, the FCT was measured around its thinnest part 3 times by each 
observer and then the averaged value was calculated. If the FCT was <65 µm 
the plaque was categorized as TCFA and as ThCFA otherwise. PR was defined as 
a plaque featuring intimal disruption and cavity formation (Figure 2 E1 to G1). In 
cases of discordance between the observers, a third investigator (B.B.) acted as 
referee to achieve consensus classification.
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Figure 2. Representative PS-OFDI for all plaque types
(A1 to G1) Typical intensity images, (A2 to G2) birefringence images, and (A3 to G3) depolarization 
images of all plaque types. Rows show representative images of normal artery (A1 to A3), FP (B1 to 
B3), FF (C1 to C3), FC (D1 to D3), ThCFA (E1 to E3), TCFA (F1 to F3), and PR (G1 to G3), respectively. 
(A2 and A3) Normal artery feature very low birefringence and low depolarization in the intima. The 
media features high birefringence, independent of the lesion type, and is clearly visible in normal 
arteries. (B2 and B3) Fibrous tissue in FP exhibits heterogeneous patterns of birefringence and 
relatively homogeneous, low depolarization. (C2 and C3) Fibrous regions covering the lipid-pools of FF 
generally present with high birefringence. The Lipid-rich areas cause pronounced depolarization. (D2 
and D3) Calcifications in FC show rather low birefringence and moderate depolarization. Depolarization 
of calcifications increases with the presence of lipid. (E2 and E3) Fibrous caps of ThCFA exhibit 
heterogeneous birefringence. (F2 and F3) Fibrous caps of TCFA typically reveal low birefringence. 
Depolarization in the diffuse border of the cap promptly transitions from low to high. (G2 and G3) The 
caps of PR have low birefringence. The most intimal layer from 3 to 9 o’clock in the intensity image 
displays relatively high and heterogeneous birefringence compared to the fragments of white thrombus 
at 1 and 11 o’clock. White bar = 1 mm. FC = fibro-calcified plaque, FF = fibro-fatty plaque, FP = fibrous 
plaque, PR = plaque rupture, PS-OFDI = polarization-sensitive optical frequency domain imaging, TCFA 
= thin cap fibroatheroma, and ThCFA = thick cap fibroatheroma.
Quantitative birefringence and depolarization analysis
PS-OFDI analysis was performed at Massachusetts General Hospital blinded to 
the conventional OFDI measurements and clinical information. Co-registration 
between conventional OFDI and polarimetric signals is intrinsic, since they are 
computed from the exact same raw data. For the plaque analysis, we segmented the 
intimal layer of each cross-section using custom-written software in MATLAB (The 
MathWorks, Inc., Natick, Massachusetts). In addition to the lumen, we segmented 
the internal elastic lamina (IEL), whenever visible, using the birefringence map to 
leverage from the improved visibility of the media in the birefringence map 16. In 
areas where the IEL segmentation was unattainable, typically in lipid-rich areas 
of advanced lesions, an automatic outer border corresponding to a tissue depth 
of 1 mm from the lumen surface was used. We also segmented calcifications and 
areas of thrombus. To compute the average birefringence of cross-sections, we 
evaluated the median of the birefringence in the area bounded by the lumen and the 
IEL or outer border segmentation, excluding the guidewire shadow, and featuring 
a depolarization of ≤0.2 as previously reported 17. The median depolarization was 
computed within the entire segmented area after masking the guidewire shadow. 
For the cap analysis, the border between the fibrous caps of the culprit 
fibroatheromas and the underlying lipid/necrotic core was drawn manually, 
together with the lipid arc angle extending from the center of the lumen (total 
cap analysis). Mean and thinnest FCT were automatically calculated from the 
segmented fibrous cap in MATLAB. Furthermore, to investigate the features of 
fibrous caps at their thinnest part (focal cap analysis), we also defined a narrower 
arc angle, centered on the thinnest part of each cap (29˚ on average). In addition, 
we evaluated the normalized standard deviation (NSD) within the fibrous caps, 
which has been shown to correlate with macrophage infiltration 3, 12. NSD was 
computed by first evaluating the standard deviation of the linear-scale backscatter 
intensity data within elliptical regions of interest, extending by 80 µm in depth and 
12˚ in the circumferential direction and moved across the entire cap area. These 
values were then normalized with the difference between the maximum and the 
minimum intensity within each fibrous cap.
Statistical analysis
Continuous outcome measures were reported as mean ± SD. For the plaque 
analysis, the mean polarimetry signals of the different plaque types were compared 
with one-way analysis of variance. Pairwise comparison was performed with a 
generalized linear model using a generalized estimating equation (GEE), since 
cross-sectional images are clustered within each pullback and within each patient. 
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For comparison with clinical presentation in the cap analysis, the one PR lesion 
in the SAP group was classified together with the ACS lesions into an ACS and/or 
PR group. Differences in the means between the two groups were analyzed with 
an unadjusted generalized linear model using a GEE. The relationship between 
polarization properties and clinical and conventional OFDI parameters were 
determined by a univariate generalized linear model using a GEE to take into 
consideration the intra-subject correlations among multiple cross-sectional images 
from individual patients. β and 95% confidence interval (CI) for birefringence 
are given in units of × 10−3 throughout the manuscript. A p-value of <0.05 was 
considered to indicate statistical significance, and all tests were two-sided. SPSS 
22.0 was used for all analyses (IBM Corp., Armonk, NY, USA).
RESULTS
Polarization properties of individual plaque types
Table 1 summarizes patient characteristics and OFDI parameters for the overall 
study population.
The selected 342 cross-sectional images representing all imaged vessels were 
classified into normal artery (n = 31), FP (n = 84), FF (n = 45), FC (n = 81), 
ThCFA (n = 88), TCFA (n = 11), and plaque rupture (n = 2) based on conventional 
OFDI. Intra- and interobserver kappa coefficients for overall plaque classification 
were 0.95 and 0.89, respectively. For the sub-classification of fibroatheromas into 
ThCFA, TCFA and PR, intra- and interobserver were 0.96 and 0.91, respectively. 
Figure 3 shows significant differences in median birefringence and depolarization 
among the 7 plaque types (p < 0.001 for both, One-way ANOVA). Comparing 
individual plaque types, normal arteries were significantly less birefringent than 
all other plaque types (p < 0.01), except for PR (p = 0.408). FPs featured the 
highest birefringence (p < 0.05), followed by FFs, FCs, ThCFAs, TCFAs and PRs 
in decreasing order (Figure 3A), but without statistical significance between most 
categories. Normal arteries also featured the lowest depolarization. Plaque rupture 
showed the highest depolarization among the 7 plaque types. Except FF versus 
FC, all plaque types had statistically significant differences in depolarization when 
compared individually (Figure 3B).
Table 1. Patient and OFDI lesion characteristics
 
 
 
 
 
 
  
 Overall (n = 30) 
Patient characteristics  
Age, years 63 ± 9 
Male 24 (80) 
Hypertension 12 (40) 
Diabetes Mellitus 5 (17) 
Dyslipidemia 13 (43) 
STEMI 1 (3.3) 
NSTEMI 5 (17) 
Unstable angina 6 (20) 
Previous myocardial infarction 8 (27) 
Previous PCI 14 (47) 
Previous CABG 4 (13) 
Imaged vessel (n=36)  
 LAD 18 (50) 
 LCX 6 (17) 
 RCA 12 (33) 
OFDI lesion characteristics   
Analyzed frames 342 
Luminal area, mm2 6.1 ± 3.3 
Percent area stenosis, % 40 ± 20 
Plaque morphology  
 AIT 31 (9.1) 
 FP 84 (25) 
 FF 45 (13) 
 FC 81 (24) 
 ThCFA 88 (26) 
 TCFA 11 (3.2) 
 PR 2 (0.6) 
Lipid arc, degree 57 ± 72 
Calcium arc, degree 73 ± 50 
Minimum fibrous cap thickness, µm 140 ± 81 
Polarization properties  
Birefringence, ×10-3 0.50 ± 0.11 
Depolarization 0.12 ± 0.09 
Variables are expressed as mean ± SD or n, (%). 
ACS = acute coronary syndrome, AIT = adaptive intimal thickening, CABG = coronary artery bypass 
graft, CAD = coronary artery disease, FC = fibro-calcified plaque, FF = fibro-fatty plaque, FP = fibrous 
plaque, PCI = percutaneous coronary intervention, LAD = left anterior descending coronary artery, LCX 
= left circumflex coronary artery, NSTEMI = non-ST-segment elevation myocardial infarction, PCI = 
percutaneous coronary intervention, PR = plaque rupture, RCA = right coronary artery, SAP = stable 
angina pectoris, STEMI = ST-segment elevation myocardial infarction, TCFA = thin cap fibroatheroma, 
ThCFA = thick cap fibroatheroma, and OFDI = optical frequency domain imaging.
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Figure 3. Plaque characterization and polarization properties
(A) The differences between individual groups were significant with the exception of normal artery 
versus PR; FP versus FF; FF versus FC, ThCFA, and TCFA; ThCFA versus TCFA. (B) A significant gradual 
variation in depolarization was observed among plaque types (p < 0.001, p < 0.05 for ThCFA versus 
TCFA and PR, TCFA versus PR) except for FF versus FC. Normal indicates normal artery and other 
abbreviations as in Figure 2. 
Calcifications featured low birefringence and low depolarization 
(Supplementary Figure S1 A and B). Calcifications located in fibrous tissue 
exhibited lower birefringence and depolarization than those in lipid-rich lesions 
(both p < 0.001), as shown in Supplementary Figure S1 C and D. Thrombus (white 
thrombus) presented very low birefringence and depolarization (Supplementary 
Figure S2 A and B). 
Polarization properties of fibrous caps in culprit lesions
The lipid arc and minimum FCT differed with statistical significance between the 
ACS/PR and the SAP group, as shown in Table 2. 
When comparing the polarimetric signals of the fibrous caps in the culprit lesions we 
found a lower birefringence in the ACS/PR group than in SAP patients (p = 0.002), 
but comparable depolarization (p = 0.772) (Figure 4A and B). Table 3 shows GEE 
model parameters for the relationship between polarization properties, clinical 
presentation, and conventional OFDI parameters, when analyzing the entire cap. 
Table 2. OFDI and polarimetry lesion characteristics in culprit/target lesion
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ACS/PR group (n = 5) 
SAP group 
(n = 8) p value 
 Analyzed frames 88 156  
OFDI lesion characteristics    
Luminal area, mm2 3.7 ± 2.1 3.8 ± 2.2 0.871 
Percent area stenosis, % 56 ± 23 55 ± 22 0.934 
Lipid arc, degree 219 ± 88 171 ± 72 0.045 
Calcium arc, degree 95 ± 36 100 ± 62 0.951 
Minimum fibrous cap thickness, µm 219 ± 109 291 ± 146 0.027 
Mean fibrous cap thickness, µm 377 ± 124 406 ± 125 0.506 
NSD in total cap 2.0 ± 1.5 2.2 ± 1.6 0.596 
NSD in focal cap 4.4 ± 3.2 3.9 ± 3.2 0.533 
Polarization properties    
Birefringence (plaque), ×10-3 0.44 ± 0.07 0.52 ± 0.08 0.001 
Birefringence (total cap), ×10-3 0.42 ± 0.10 0.53 ± 0.16 0.002 
Birefringence (focal cap), ×10-3 0.38 ± 0.10 0.49 ± 0.18 <0.001 
Depolarization (plaque) 0.28 ± 0.12 0.21 ± 0.12 0.034 
Depolarization (total cap) 0.10 ± 0.04 0.10 ± 0.03 0.772 
Depolarization (focal cap) 0.11 ± 0.05 0.11 ± 0.04 0.845 
Variables are expressed as ± standard deviation. P-values were obtained by generalized linear models 
using GEE. GEE = generalized estimating equation and NSD = normalized standard deviation. Other 
abbreviations as in Table 1. 
Figure 4. Polarization properties in caps of culprit/target lesions
(A and B) Difference in birefringence (A) and depolarization (B) between patients with ACS/PR and SAP. 
Fibrous caps in ACS/PR patients exhibited significantly lower birefringence compared to SAP patients. 
ACS = acute coronary syndrome, PR = plaque rupture, and SAP = stable angina pectoris. 
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Birefringence of the total cap was negatively correlated with ACS/PR (β = −0.156; 
p = 0.002) and NSD (β = −0.021; p = 0.013). Depolarization of the total cap 
was negatively associated with mean FCT (β = −0.001; p < 0.001) and positively 
with lipid arc (β = 0.001; p = 0.001) and tended to be correlated with NSD 
(β = 0.005; p = 0.062). Further, we analyzed narrow regions of interest centered 
on the thinnest part of each fibrous cap (Table 4). 
The generalized linear model using GEE showed that ACS/PR (β = −0.138; 
p < 0.001), thinnest FCT (β = 0.005; p = 0.001) and NSD (β = −0.012; p = 0.001) 
were associated with birefringence. Factors associated with depolarization were 
thinnest FCT (β = −0.001; p = 0.005) and NSD (β = 0.004; p < 0.001).
DISCUSSION
This first-in-human pilot study of intravascular polarimetry demonstrates 
how it augments conventional OFDI plaque characterization with quantitative 
polarization properties, measured through standard intravascular OFDI catheters 
simultaneously with the conventional OFDI signal. The polarization features offer 
refined insight into tissue composition, consistent with our current understanding 
of the mechanisms involved in plaque progression and destabilization. The major 
finding of this study is that fibrous caps in ACS culprit lesions and ruptured 
plaques exhibit lower birefringence compared to the caps of target lesions in 
SAP patients within our limited study cohort. Compared to the interpretation of 
conventional OFDI, which relies on subjective identification of qualitative features, 
polarimetry offers quantitative metrics, leading a way to objective and automated 
characterization of atherosclerotic plaques. The improved assessment of plaque 
composition afforded by the polarization features may provide novel insight 
into the mechanism of plaque progression and instability in human coronary 
atherosclerosis.
Polarimetric plaque characterization
Smooth muscle cells and collagen are known to influence the polarization of near 
infrared light 18. Our recent study of intravascular PS-OFDI in cadaveric human 
hearts revealed that normal intimal tissue exhibits low birefringence compared 
to intimal tissue in fibrous, early, and advanced atherosclerotic lesions 16. 
In the present study, we observed significant differences in birefringence and 
depolarization among all plaque types, despite analyzing the entire manually 
segmented intimal layer, comprising both the angle subtended by the plaque 
and the remainder of the cross-section. Depolarization featured significant 
differences even between individual plaque types, whereas birefringence was less 
distinguishing. These observations suggest that PS-OFDI provides insight into 
biological aspects of plaque progression and destabilization, complementary to 
the structural information available to conventional OFDI. Combined analysis of 
birefringence and depolarization in more refined automatically segmented regions 
of interest may offer automated tissue characterization. Moreover, accurate 
diagnosis of TCFA by OCT/OFDI remains challenging 13, and future studies are 
warranted to investigate the polarization features of thin and thick fibrous caps 
and early and late necrotic cores in detail. 
Polarization properties in fibrous caps
Within our limited patient cohort, we observed that the fibrous cap of the culprit 
lesion in ACS/PR patients exhibited significantly lower birefringence than in the 
caps of target lesions in SAP patients. Fibrillar collagen is the primary extracellular 
matrix molecule imparting both birefringence and mechanical stability to the 
fibrous cap overlying an atheroma 20. Histopathological studies showed that 
ruptured fibrous caps lack layered smooth muscle cells and feature different 
collagen phenotypes than intact caps 20, which offers an explanation for the low 
birefringence observed in the fibrous caps of ACS/PR patients. In addition to cap 
birefringence, minimum FCT and lipid arc angle also featured statistically significant 
differences between these two patient groups. Yet, FCT alone is insufficient to 
identify caps that are prone to rupture 4, 5, 8, 9. The polarization metrics available to 
intravascular polarimetry complement these structural features and may advance 
our understanding of the pathogenesis of ACS with or without fibrous cap rupture 
10, 21.
Furthermore, birefringence and depolarization of the fibrous cap were associated 
with increased NSD, suggesting macrophage accumulation. Inflammation is a known 
mechanism of plaque destabilization 2, 22, 23. Macrophages release enzymes including 
matrix-metalloproteinases that destroy the extracellular matrix and weaken the 
cap 22. Our observations suggest that the presence of active macrophages may 
increase depolarization, whereas the effect of their presence causes a reduction in 
birefringence. The physical mechanism inducing depolarization in atherosclerosis 
remains to be elucidated. We speculate that lipid droplets exceeding the size of 
the wavelength used for OFDI and small cholesterol crystals, which have been 
postulated to be a crucial factor in the initiation of inflammatory response in 
atherosclerosis 24, are the origin of the observed depolarization. 
The few occurrences of white thrombus in the present study had minimal impact 
on the underlying polarization signatures. However, the stronger attenuation of 
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red thrombus may lead to an apparent increase in depolarization that would impair 
interpretation of the underlying vessel wall, similar to conventional OFDI imaging.
Study limitations
First, our study consists of a small number of patients from a cohort of 
nonconsecutive patients and was cross-sectional in design. Considering potential 
selection bias of patients, our findings should be interpreted with caution, although 
we included all patients imaged with intravascular polarimetry. Furthermore, 
the limited number may lead to a potential over-estimation of the differences 
between polarization features when performing multiple pairwise comparisons 
and prevented multivariate analysis. Owing to its compatibility with clinical 
OFDI imaging catheters, intravascular polarimetry can be readily applied to any 
patient eligible for conventional OFDI imaging, and future well-designed studies 
are needed to ascertain our current findings. Second, our plaque classification 
corresponds well to the current understanding of plaque subtypes in OFDI 6 and 
could be readily performed on the conventional OFDI signal, yet conventional 
OFDI has limited ability to classify lesion types, especially in advanced lesions 11, 14. 
Although lipid-rich plaques offer some prognostic implication 8, clear identification 
of fibroatheromas with OCT/OFDI remains debatable. Combination of intravascular 
ultrasound and OCT/OFDI has been shown to improve diagnostic accuracy of 
identifying fibroatheromas 13. Future histopathological validation studies are 
needed to inspect the ability of polarization properties to distinguish between 
different plaque types and potentially enable automated plaque classification. 
Third, we observed that NSD was associated with depolarization in the focal 
fibrous caps but not in the entire caps. Macrophage infiltration frequently occurs 
very locally and averaging the signals across entire caps carries less meaning 
than across a local region of interest. Moreover, the required normalization of 
the NSD depends delicately on the ROI, and evidence supporting the NSD metric 
remains scant. We suspect that both NSD and depolarization capture aspects 
of macrophage infiltration, but validation studies with histology are needed to 
identify how depolarization relates to macrophage infiltration. Finally, no patient 
in the current study presented plaque erosion, the second most common cause 
of ACS.
CONCLUSION
This study presents polarization properties of coronary atherosclerotic lesions in 
patients with coronary artery disease. The fibrous caps of culprit lesions in ACS/PR 
patients featured lower birefringence than in SAP patients. When averaged across 
entire cross-sections, the polarimetric signals varied among distinct morphological 
plaque subtypes. Quantitative assessment of plaque polarization properties by 
intravascular polarimetry may open new avenues for studying plaque progression 
and detecting high-risk patients. Prospective studies in larger populations are 
needed to evaluate how polarization metrics could translate into improved patient 
outcomes and optimized medical therapy compared to utilizing only the structural 
features available to conventional OFDI.
Clinical Competencies
Modification of the optical frequency domain imaging (OFDI) apparatus along 
with recently developed image reconstruction methods enabled measurements 
of polarization properties of the coronary arterial wall. Intravascular polarimetry 
permits quantitative assessment of polarization properties through standard 
intravascular OFDI catheters simultaneously with intensity image cross-sections. 
This first-in-human pilot study of intravascular polarimetry demonstrated that 
polarization properties differ between culprit lesions of acute coronary syndrome or 
plaque rupture and stable angina pectoris, and also among different morphological 
plaque subtypes. 
Translational Outlook
Quantitative assessment of plaque structure and composition by intravascular 
polarimetry may open new avenues for studying coronary atherosclerosis and 
may contribute to advancing our understanding of plaque progression and 
destabilization in patients. Future well-designed studies are needed to investigate 
how the risk of future acute coronary events may manifest in the polarization 
properties of coronary atherosclerotic lesions at an early timepoint.
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Supplementary Methods
Intravascular PS-OFDI
All procedures were performed according to standard practice in the Erasmus 
MC catheterization laboratory 1. Briefly, the imaging system operated at a 
center wavelength of 1300 nm with a wavelength scanning range of 110 nm, 
corresponding to a radial resolution of 9.4 µm, assuming a refractive index of 
1.34. The intravascular catheter was pulled back at a rate of 20 mm/s with 
continuous injection of non-ionic contrast solution at a rate of 3-4 mL/s, and 
images were acquired at a rate of 100 frames/s, each consisting of 1024 radial 
scans. Intravascular PS-OFDI offers insight into tissue composition by quantifying 
birefringence and depolarization through standard intravascular imaging catheters, 
as described in detail previously 2. In short, the imaging system employed 
a polarization diverse receiver to determine the polarization state of the light 
scattered by the tissue, and an electro-optic polarization modulator to vary the 
polarization state of the light illuminating the vessel wall between consecutive 
radial scans. Polarimetric analysis was performed offline with spectral binning 
to reconstruct maps of tissue birefringence and depolarization 3. Birefringence 
is the unitless ratio of change in retardation (phase delay between two principle 
polarization states) per propagation distance traveled by light. It corresponds 
to the difference of the refractive indices experienced by light polarized parallel 
and orthogonal to the fibrillary components, such as collagen fibers and layered 
smooth muscle cells 4. In the present study, birefringence is displayed in the rage 
of 0-1.8×10−3 . Depolarization corresponds to a randomization of the detected 
polarization states, induced by propagation and scattering of light inside tissue 
2,5. As a measure of tissue depolarization, we computed the complement to 1 of 
the degree of polarization. 3 Depolarization ranges from 0 for completely polarized 
light without any randomness to 1 for completely depolarized, i.e. randomized 
light. Comparison of polarization properties with plaque burden and stenosis 
severity to investigate the association of polarization properties with stenosis 
severity, we examined the correlation of birefringence and depolarization with 
percent area stenosis. Plaque cross-sectional area (CSA) was defined as IEL CSA 
minus lumen CSA and computed only in normal artery and FP. Percent plaque 
CSA (%CSAplaque) was calculated as plaque CSA divided by the IEL CSA. The 
GEE approach was employed to determine the relationship between polarization 
properties, percent area stenosis for all plaque types and %CSAplaque for normal 
artery and FP, respectively. 
Supplementary Figure S1. Polarization properties of calcification
Median birefringence and depolarization were measured in calcifications, manually segmented in the 
intensity images of the 342 cross-sectional images of the plaque analysis. Calcifications were classified 
into 2 groups according to the presence or absence of lipid in the surrounding lesion (calcification 
within fibrous tissue or calcification within lipid). Calcifications exhibit low birefringence (A) and low 
depolarization (B). C and D show comparisons of polarization properties of calcifications with and 
without lipid (fibrous tissue). (C) Calcifications in fibrous tissue exhibit lower birefringence compared to 
those in a lipid-rich lesion (p < 0.001). (D) Higher depolarization was observed in calcifications in lipid-
rich tissue than in those located in fibrous tissue (p < 0.001). Association was tested by unadjusted 
generalized linear model using GEE. GEE = generalized estimating equation.
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Supplementary Figure S2. Polarization properties of white thrombus
The plaque and cap analysis combined contained a total of 10 cross-sectional images with white 
thrombus. Based on intensity signal in conventional optical frequency domain imaging (OFDI), all the 
thrombus was classified as white thrombus. Manual segmentation, performed by tracing the boundary 
of the thrombus, revealed very low birefringence (A) and depolarization (B) in white thrombus.
Supplementary Figure S3. Associations between polarization properties and percent plaque
Cross-sectional area 
(A and B) Association between percent area stenosis and polarization properties for all crosssections.  
(C and D) Association between percent plaque area and polarization properties in normal artery and FP. 
Association was tested by unadjusted generalized linear model using GEE. The percent area stenosis in 
all plaque types combined was significantly associated with depolarization (β = 0.023; p < 0.001), but 
not with birefringence (β = 0.004; p = 0.273) (Supplementary Figure 3A and 3B). Since %CSAplaque 
can only be accurately calculated in normal artery and FP where the IEL is reliably identified in OFDI 
imaging, we also compared the polarization properties and %CSAplaque in normal artery and FP. 
Birefringence (β = 0.055; p < 0.001) and depolarization (β = 0.007; p < 0.001) correlated positively 
with %CSAplaque (Supplementary Figure S3-C and -D). CSA = cross-sectional area, FP = fibrous 
plaque, and GEE = generalized estimating equation.
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Case presentation
A 69 year old female patient was admitted to our institution for potential treatment 
of a non-ST segment elevation myocardial infarction after 8 days of intermittent 
pain. Angiography showed an unusual filling defect in the mid right coronary 
artery with TIMI III flow and moderate stable disease in the left coronary system. 
Optical frequency domain imaging (OFDI) revealed a honeycomb-like structure 
with multiple intraluminal microchannels confirming the presence of recanalized 
thrombus (Figure 1). Fresh thrombus (<1 day) comprises platelet aggregates, 
erythrocytes, and fibrin. Lytic thrombus (1 to 5 days), containing areas of necrosis 
and granulocytes, transforms into organized thrombus (>5 days) characterized by 
the presence of smooth muscle cells (SMCs), homogeneous or hyalin fibrin, and 
depositions of connective tissue and capillary ingrowth 1. The patient was included 
in the POLARIS-I registry, designed to assess the added value of measuring 
birefringence with polarization sensitive OFDI in ACS patients. Collagen and SMCs 
have been shown to display higher birefringence than other tissue components in 
the vessel wall 2. In the present case (Figure 1, right panel), high birefringence 
signals can be appreciated in connective tissue between the microchannels 
suggesting the presence of collagen and SMCs.
To date, the progression and consistency of thrombus can only be reliably assessed 
using histopathological examination, which has no place in an acute setting. PS-
OFDI may be of value to study age, stability and morphometric characteristics of 
coronary thrombus.
 
Figure 1. Conventional intensity and polarimetric properties of organized thrombus with microchannels
Upper panel: longitudinal view of the right coronary artery. The dashed white lines denote the cross-
sectional locations for A, B and C. (A,B,C) Three locations with clear recanalization in organized 
thrombus; from left to right: Conventional OFDI intensity, birefringence, magnified birefringence (* 
denotes zones of high birefringence surrounding microchannels). 
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Summary and conclusion
Both physiological assessment and intravascular imaging have emerged as excellent 
tools to improve angiographic lesion classification and their implementation proved 
to significantly improve short- and long-term outcomes of PCI. Nevertheless, 
despite significant improvements in plaque modification technologies and stent 
design over the past 3 decades, the risk of future adverse cardiac event rates 
remains substantial. The aim of the present thesis was to address the specific 
benefits of intravascular imaging and physiology when used in a post PCI setting 
to provide more insights into the details of target vessel failure and subsequent 
patient outcome. 
In part one, this thesis starts with a review of the current literature supporting the 
clinical application of intravascular imaging and physiology in a post procedural 
setting. In chapter 3-5 we specifically evaluated the use of post PCI FFR and 
looked into the distribution, predictors and long-term clinical outcome related to 
post procedural FFR in a real-world patient population (FFR-SEARCH).
In part two, chapter 6-9, we addressed the specific benefit of (post) PCI 
intravascular imaging in procedural planning and evaluation. As such we proposed 
a more detailed approach to assess OCT detected stent edge dissections in the 
largest clinical outcome study on the topic to date and provided further details 
on the normal dimension of left main coronary arteries in order to better guide 
physicians confronted with left main stenting. Secondly, we illustrated the 
importance of post PCI intravascular imaging in two clinical studies assessing the 
performance of novel bioresorbable scaffolds. 
In part three, chapter 10-12, we assessed the potential of a synergistic use of 
post procedural physiology (as a simple gatekeeper) and intravascular imaging 
(IVUS) to provide further mechanistic insights into the rationale of the low post 
PCI FFR. In the FFR SEARCH IVUS study we demonstrated for the first time that 
focal residual disease can be frequently found in patients with a low post PCI FFR 
providing a rationale for post PCI optimization in a specific group of patients that 
proved to be at higher risk of future adverse events. The latter formed the basis 
for the design of the FFR REACT trial.  
In part four, chapter 13-17, we introduced several simplified and faster methods 
to assess post PCI physiology (3D-QCA based FFR and dPR). 
Finally, in part five (chapter 18-20), we collaborated with the Massachusetts 
General Hospital and Wellman Center for Photomedicine to develop and validate 
a novel imaging modality (PS-OFDI) to increase our understanding of plaque 
morphology in both stable and unstable coronary artery disease. 
PART I 
VALUE OF POST PCI PHYSIOLOGY
In chapter 2, we present a general overview of the current literature with 
regard to post procedural treatment evaluation. Although clinical outcomes after 
PCI are gradually improving, several subpopulations still perform worse. Recent 
studies demonstrated that with the use of conventional intravascular imaging 
and physiology, clinical outcomes can be improved, while also newer modalities 
like angiography based fractional flow reserve and hybrid imaging catheters are 
entering the stage. Nevertheless, merely using these modalities is not enough 
and in order to truly improve patient outcome, optimal intravascular dimensions 
with minimal vascular injury should be targeted. When assessing post PCI results 
using either type of physiological or imaging technology, a broad spectrum of 
stent and vessel related anomalies can be expected, such as malapposition, 
underexpansion, stent edge dissections, side branch jailing and residual disease. 
Since not all of these issues warrant treatment, and can or should be improved, 
a profound knowledge of what to expect, how to recognize and when to treat 
these intraluminal problems is needed. The present review provides a detailed 
assessment of the incidences and impact of anatomic predictors of PCI failure 
reflected against the use of conventional and novel diagnostic tools with a specific 
focus on improving post PCI outcome. 
The FFR SEARCH registry is the largest prospective study investigating the 
prognostic value and determinants of post PCI FFR. A total of 1000 patients were 
included in this single centre registry in Rotterdam in whom the FFR was measured 
after a successful PCI in 959 patients. While the primary endpoint consisted of 
clinical outcomes after two years, the initial study report in chapter 3 provides 
readers with the post PCI FFR distribution and 30 day outcome figures. The FFR 
SEARCH registry illustrated that post PCI FFR assessment using a dedicated 
microcatheter is a safe and feasible method to measure the physiological status of 
a coronary artery after stent placement. The average additional time to measure 
the FFR was 5 minutes and no complications related to the microcatheter occurred. 
The FFR was measured at the ostium of the artery, at the proximal stent edge, 
distal stent edge and ±20 mm distal of the most distal stent edge. The mean 
Pd/Pa in resting condition was 0.96±0.04, while the mean post PCI FFR under 
maximal hyperemia was 0.90±0.07. Although a satisfactory angiographic result 
was achieved, post PCI FFR remained ≤0.80 in 78 lesions (9.8%). Conversely, 
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post PCI FFR was >0.90 in 396 lesions (50%). Several factors were associated 
with a low post-PCI FFR, including bifurcations or calcified lesions. Furthermore, 
patients with diabetes mellitus or peripheral arterial disease were more likely to 
have ≥1 lesion with a post PCI FFR ≤0.90. Finally, post-PCI FFR did not correlate 
with clinical events at 30 days.
In order to provide a decisive answer as to what are the predictors of post 
procedural fractional flow reserve values, chapter 4, was designed. We identified 
several independent patient and vessel related variables which predicted the post 
PCI FFR. In a LME-model, adjusting for independent predictors of post PCI FFR, 
females had a significantly higher mean post PCI FFR as compared to men (adjusted 
β=0.013, CI [0.005 to 0.02], p=0.001, R2 for the complete model=0.54). The 
vessel in which the physiological measurements were taken was the strongest 
predictor, resulting in an average of 0.06 lower post PCI FFR value in LAD vessels. 
Additionally, type A lesions, in-stent restenosis, CTO’s, post PCI MLD and pre – 
and post dilatation were significant predictors for post PCI FFR.
In the main paper of the FFR SEARCH register, chapter 5, the two year clinical 
results are discussed. On a patient level, post PCI FFR < 0.90 was not associated 
with MACE (HR 1.08, [95% CI, 0.73-1.60] p=0.707). On a vessel level however, 
FFR < 0.90 post PCI resulted into a higher rate of target vessel revascularizations 
(HR 0.52 [95% CI, 0.27-1.00] p=0.049) and a trend towards higher rate of stent 
thrombosis (HR 0.35 [95% CI, 0.11-1.13] P=0.079).
PART II 
UTILITY OF (POST PCI) INTRAVASCULAR IMAGING
Chapter 6 assessed the impact of untreated stent edge dissections (SEDs) as 
detected by OCT and potential predictors for device orientated clinical events 
(DOCE) at one year. The main findings of this study, representing the largest cohort 
of patients with SEDs as assessed by OCT, could be summarized as follows: 1) 
one-year cardiac event rates potentially attributable to the presence of untreated 
SEDs were 6.7%; 2) in patients with untreated SEDs, dissection length was the 
only independent predictor for DOCE at 1 year while cavity depth and reference 
lumen area where the only predictors for distal and proximal SEDs respectively; 
3) follow-up OCT indicated (early) spontaneous healing in the majority of SEDs.
In Chapter 7 we aimed to investigate the luminal integrity 6 to 9 months 
after implantation of the Fantom bioresorbable scaffold (BRS) with the use of 
IVUS. In this sub-study of the FANTOM II study we confirmed the efficacy of 
the Fantom BRS in patients with stable coronary artery disease by successfully 
inhibiting neointimal hyperplasia at 6 and 9 months as assessed by IVUS. With a 
backbone that is designed to be absorbed within 4 to 5 years, our results show 
minimal obstruction volumes both at 6 and 9 months respectively, strengthening 
the recently published clinical and angiographic finding. Although the Fantom II 
study only represents the performance of the scaffold in highly selected cases, 
the obstruction volumes found are comparable to contemporary metallic DES like 
Resolute Onyx. 
The results from chapter 8 suggest that the latest magnesium BRS iteration, 
the Magmaris, suffers from premature dismantling with subsequent loss of 
vessel support. Together with incomplete distal device expansion, this could have 
contributed to a higher than expected lumen loss. Our results revealed a significant 
decrease in patent struts with a heterogeneous resorption pattern as soon as 
4–5 months post implantation. The latest was demonstrated by an important 
reduction of attenuation and backscattering indices. Offline OCT at follow-
up demonstrated a decrease in minimal lumen area (MLA) by 43.44 ± 28.62% 
(p = 0.042), along with a significant decrease in scaffold area at the site of the 
MLA by 38.20 ± 25.74% (p = 0.043). While our findings need to be confirmed in 
a randomized fashion, it seems imperative to follow the European working group 
recommendations on BRS and limiting their use to clinical trials or registries with 
adequate follow-up. Finally, our results suggest that clinical and angiographic 
follow-up alone might not be sufficient to establish the safety and long-term 
efficacy of new BRS, and warrants the use of serial intravascular coronary imaging 
at baseline and follow-up.
In chapter 9 we assessed the luminal dimensions of non-obstructive left main 
coronary arteries (LMCA) with the use of IVUS in a large real world cohort. We 
demonstrated for the first time how non-diseased LMCA dimensions and length 
vary within the population and how women display smaller luminal dimensions 
compared to men. No clinically relevant predictors were found for both LMCA 
mean lumen area and length as correlation coefficients were low. These findings 
might guide physicians in deciding on stent- and post dilatation balloon sizing, and 
support the use of intravascular imaging in LMCA stenting. Given the structural 
undersizing based on QCA, IVUS helps in correctly identifying the exact LMCA 
length and area and thereby improves outcomes of complex LMCA PCI. More 
specifically, we demonstrated that 19% of the patients presented with IVUS derived 
mean luminal dimensions of >5 mm, requiring post dilatation with balloons up to 
5 mm along with the use of stents with sufficient post dilatation margins.
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PART III 
SYNERGISTIC USE OF INTRACORONARY IMAGING 
AND PHYSIOLOGY
Several recent studies demonstrated the value of low post PCI FFR in predicting 
late adverse cardiac events. Unfortunately, details on the actual rationale for these 
low PCI FFR values often remain elusive since no data on residual angiographically 
apparent disease were reported, nor were details presented on intravascular 
imaging findings. In the IVUS sub-study of the FFR SEARCH registry (Chapter 10) 
we demonstrated, for the first time, that clear signs of residual luminal narrowing, 
including focal lesions, underexpansion and malapposition, were present in a 
significant amount of vessels with an impaired post PCI FFR. Findings that were not 
readily apparent on QCA or post PCI angiography. The study included 95 patients 
(100 vessels) with an FFR value ≤0.85 and 20 with an FFR value above 0.85. In 
the low FFR cohort, residual focal lesions, underexpansion or malapposition was 
present in up to 87% of the vessel. Additionally, in the present study FFR pressure 
drops were more pronounced in vessels with residual proximal focal lesions but 
not with distal lesions. 
In the succeeding follow-up study, chapter 11, of the IVUS cohort we assessed 
two year clinical events. We demonstrated a clear trend towards worse clinical 
outcomes at two years when IVUS derived residual lesions and underexpansion are 
present in patients with a post PCI FFR ≤0.85. In order to answer the subsequent 
question, as to why then post procedural FFR remain low with good clinical 
outcome, we identified several independent patient and vessel related variables 
which predicted the post PCI FFR. In a GLME-model, adjusting for independent 
predictors of post PCI FFR, females had a significantly higher mean post PCI FFR 
as compared to men (adjusted β=0.013, CI [0.005 to 0.02], p=0.001, R2 for the 
complete model=0.54). The vessel in which the physiological measurements were 
taken was the strongest predictor, resulting in an average of 0.06 lower post PCI 
FFR value in LAD vessels. Additionally, a history of smoking, type A lesions, in-
stent restenosis, CTO’s, pre procedural lesion length and pre – and post dilatation 
were significant predictors for post PCI FFR.
In chapter 12 we elaborated on the FFR REACT study design. The FFR REACT 
study is an investigator initiated prospective, single-center randomized controlled 
trial conducted at the Erasmus Medical Center designed to assess if FFR guided 
PCI optimization directed by IVUS in patients with an increased risk for MACE 
(post PCI FFR below 0.90) will decrease target vessel failure at 1 year. Up to 290 
patients with a post PCI FFR <0.90 will be randomized (1:1) to either standard 
of care (no additional intervention) or IVUS-directed optimization of the FFR 
(treatment arm). Inclusion started in October 2017 and enrolment is expected to 
be complete in Q1 2020. All patients will be followed for 3 years. 
PART IV 
INNOVATIONS IN CORONARY PHYSIOLOGY 
Based on previously performed research, the use of FFR received strong 
recommendations in current revascularization guidelines. Even though the use 
of FFR proved to be contrast saving, cost effective and associated with improved 
quality of life, FFR is still not being performed in the vast majority of cases. 
The latter has been hypothesized to be due to the need for (in some countries) 
expensive hyperemic agents with known adverse events as dyspnea and 
arrhythmias and or intolerance due to pulmonary disease and the use of a costly 
pressure wire. The FAST study (chapter 13) confirmed the feasibility of a novel 
3D-QCA based software tool to calculate FFR without the use of a pressure wire 
or microcatheter (vessel FFR, vFFR). In the pre-clinical technical validation model, 
vFFR proved to have a strong correlation with computation fluid dynamics and 
invasively measured flow parameters. In our clinical validation study we confirmed 
an excellent agreement and high diagnostic value of vFFR compared to invasively 
measured FFR using a dedicated pressure wire under maximum hyperemia. 
Finally, we showed that vFFR had a low inter-observer variability.
In the subsequent study on vFFR, we utilized the FFR SEARCH database in order 
to assess the feasibility of vFFR in a post procedural setting (Chapter 14). The 
main findings of the study could be summarized as follows: vFFR allows to identify 
post PCI FFR <0.90 with a high sensitivity and specificity; vFFR showed good 
correlation and agreement with post PCI FFR as measured using the dedicated 
Navvus microcatheter and post PCI vFFR computation remained to have a low 
inter-observer variability. Based on the results of this study, calculation of post 
stenting vFFR using CAAS workstation, could be a useful and easy to use tool to 
identify and potentially optimize the outcomes of patients at higher risk for future 
adverse cardiac events. Larger clinical outcome studies should be obtained to 
assess the value of post stenting vFFR to optimize PCI outcomes. 
In chapter 15 we proposed another potential group of patients whom might 
benefit from 3D-QCA based vFFR: patients with possible epicardial disease 
after a cardiac transplant. In the early years after cardiac transplantation, 
both negative remodeling of the epicardial arteries as well as a decrease in 
microvascular resistance (IMR) are common findings. At the longer term however, 
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IMR substantially increases, decreasing the maximum achievable flow down the 
epicardial vessels. FFR has proven to be a useful tool to identify the hemodynamic 
severity of intermediate coronary artery lesions. However, there has been ongoing 
debate on its validity in denervated hearts. Recent studies therefore suggested to 
measure IMR in order to appreciate the status of the allograft in order to be able 
to better interpret the FFR. 
The recently validated software that calculates vFFR might offer a solution to the 
problem. In order to illustrate the latter we presented a case of a 39 year old 
male patient, 14 years after allograft cardiac transplantation with a suspected 
significant lesion. Invasive assessment using conventional intracoronary 
physiology assessment using FFR showed a significant discrepancy with findings 
on OCT and the vFFR. Illustrated by the present case, we believe that a strong 
argument can be made towards to use of these novel technologies that might 
potential be superior to conventional assessment in the routine follow-up of these 
high risk patients.
Another method to assess the hemodynamic severity of a coronary lesion without 
the need for a hypereamic agent lies in the instantaneous wave free ratio (iFR). 
iFR offers a reliable assessment of coronary physiology but requires dedicated 
proprietary software with a fully automated algorithm. Chapter 16 comprises of 
the pivotal study investigating the feasibility of a non-hyperemic pressure ratio, 
the dPR, calculated using a novel software applicable to any type of pressure wire 
or microcatheter. dPR had an excellent linear correlation with iFR and a strong 
diagnostic accuracy in identifying lesions with an FFR ≤0.80. The dPR assessment 
proved to be a fast, simple and reproducible non-hyperemic ratio based on 
DICOM pressure waveforms which could open up the field for a more widespread 
use of diastolic pressure gradients in real world clinical practice. By using a 
simple software tool to automatically detect the flat period in the dP/dt curve 
that indicates the so called “wave-free” period we found that the resultant dPR 
correlated nearly perfect with the original iFR output of Phillips Volcano (r=0.997, 
p<0.001). Subsequently, our results showed a correlation between dPR and FFR 
(r=0.77) in line with previous results from the VERIFY study demonstrating a 
correlation coefficient r of 0.789 between iFR and FFR.
Despite the unequivocal evidence supporting the use of pre PCI physiological lesion 
assessment, the use of the technology in a post PCI setting is still rare. Instead, 
post PCI results are routinely assessed by visual angiographic assessment, a 
technique that showed to correlate poorly with functional assessment in the vast 
majority of cases. The importance of the latter was illustrated by a growing body 
of evidence showing the strong predictive value of post PCI FFR for future adverse 
events. However, at present little is known about the use of post PCI dPR and its 
independent predictors. 
Chapter 17 discusses the results of the post hoc analysis of the FFR SEARCH 
registry with the applied dPR algorithm. The study showed that despite optimal 
angiographic PCI results 15% of the patients and 13% of the vessels end with a 
post PCI dPR of ≤0.89. Second, LAD lesions, diabetes, stent diameter, in-stent 
restenosis, pre and post reference diameter proved to be independent predictors 
of post PCI dPR and finally, there was a strong trend towards higher rates future 
adverse events in case post PCI dPR was ≤0.89.
PART V 
INNOVATIONS IN INTRAVASCULAR POLARIMETRY 
ASSESSEMENT
At this stage, intravascular polarimetry had been investigated as a basis for 
assessing coronary atherosclerosis in both cadaveric human coronary arteries and 
patients with mainly stable coronary disease, yet it is currently unknown what 
added value the polarimetric measurements might have in patients with unstable 
coronary artery disease. In order to investigate the latter, the POLARIS-I study 
was initiated with the aim to include up to 35 patients with unstable coronary 
artery disease (unstable angina or non ST elevated myocardial infarction) and a 
clinical indication for plaque characterization with OCT/OFDI. 
The first-in-human pilot study of intravascular polarimetry in chapter 18 
demonstrated how the technology could strengthen conventional OFDI plaque 
characterization with quantitative polarization properties, measured through 
standard intravascular OFDI catheters simultaneously with the conventional OFDI 
signal. The polarization features offer refined insight into tissue composition, 
consistent with our current understanding of the mechanisms involved in plaque 
progression and destabilization. The major finding of this study is that fibrous caps 
in culprit lesions and ruptured plaques of patients presenting with an acute coronary 
syndrome exhibit lower birefringence as compared to the caps of target lesions in 
patients with stable disease. Compared to the interpretation of conventional OFDI, 
which relies on subjective identification of qualitative features, polarimetry offers 
quantitative metrics, leading a way to objective and automated characterization of 
atherosclerotic plaques. The improved assessment of plaque composition offered 
by the polarization features may provide novel insight into the mechanism of 
plaque progression and instability in human coronary atherosclerosis.
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In chapter 19 we elaborate on the potential added value of PS-OFDI to study 
thrombus. A 69 year old female patient was admitted to our institution for potential 
treatment of a non-ST segment elevation myocardial infarction after 8 days of 
intermittent pain. Angiography showed an unusual filling defect in the mid right 
coronary artery with TIMI III flow and moderate stable disease in the left coronary 
system. PS-OFDI revealed a honeycomb-like structure with multiple intraluminal 
microchannels confirming the presence of recanalized thrombus. Collagen and 
smooth muscle cells have been shown to display higher birefringence, evidently 
PS-OFDI may be of value to study age, stability and morphometric characteristics 
of coronary thrombus
The final chapter of this dissertation, chapter 20, discusses the POLARIS-I registry 
to focus on the polarization properties of intracoronary thrombus in patients 
presenting with ACS as assessed with PS-OFDI. We were able to demonstrate, for 
the first time, a significantly higher birefringence in healing coronary thrombus as 
compared to fresh thrombus. Additionally, we found that birefringence is dependent 
on the age of the thrombus when using the time until intravascular imaging as 
approach of measuring. Finally, no difference in birefringence was found between 
the fibrous caps of ruptured plaques and remote fibroatheromas. To date, the 
composition and progression of thrombus can only be reliably assessed using 
histopathological examination, which has no place in an acute setting. PS-OFDI 
might be a valuable new imaging modality to help further study age, stability and 
morphometric characteristics of coronary thrombus. 
Future perspectives
The future of interventional cardiology would most probable coincide with several 
transitions with regard to intravascular imaging and physiology. Contemporary 
academic research already illustrates a glimpse of these transitions which might 
happen simultaneously. Although the three transitions that I envision might be 
developed separately in different institutions or medical companies, at some point 
they all need to be brought together in the catheterization laboratory to help the 
clinician in improving patient outcome. 
First, intravascular imaging, primarily IVUS and OCT, should be used in a higher 
proportion of cases. Large clinical trials have already shown that target vessel 
failure can be reduced using IVUS when optimal luminal dimension are reached. 
Clinical interventional cardiologists need a better understanding on when to use 
intravascular imaging and how to interpret it. Post PCI evaluation using imaging is 
a critical step in the treatment of a patient presenting with coronary artery disease 
and any interventional cardiologist should at least consider this option. At present 
intravascular imaging catheters are expensive and not reimbursed in all countries. 
The latter will also need to change in order to increase the adoption rates. 
Second, a more simplistic interpretation with the use of (intravascular) physiology 
should be developed to assess the hemodynamic significance of a coronary 
segment. Important steps have already been made using both hyperemic and 
non-hyperemic indexes. Even more simplified models are studied at the moment, 
precluding the need for a pressure wire, where coronary physiology is assessed 
using angiography and assumptions based on simplified computational fluid 
dynamics. Future studies should test these novel physiological modalities in 
randomized controlled trials, while also including post procedural assessment, 
tandem lesions and patients with impaired microvascular resistance. 
Finally, novel imaging modalities should not merely provide the operators with 
more information and additional intergrated images, but support neural networks, 
with the aim to automatically assess clinical relevant segments that warrant 
additional treatment. Contemporary acoustic – and photo medicine evolves at 
such a rapid pace that topical familiarity on the most recent body of research 
and well-advised implementation is hard. At the moment, cumulative evidence is 
being presented on the novel applicability of hybrid imaging and their ability to 
provide a unique insight in plaque vulnerability in unstented segments to identify 
lesions that are prone to rupture. Although basic interpretation of conventional 
imaging modalities such as IVUS and OCT is key, state of the art hybrid imaging 
catheters should provide the operator with treatment recommendations, rather 
than images that require extensive knowledge and training to fully appreciate 
their underlying information. 
Conclusion
Clinical outcomes after PCI are gradually improving, although several 
subpopulations still perform worse. Recent research demonstrated that with the 
use of conventional intravascular imaging and physiology, clinical outcomes can 
be enhanced and also newer modalities, for instance angiography based FFR and 
hybrid imaging catheters are entering the stage. Nevertheless, merely using these 
modalities is not enough and in order to truly improve patient outcome, optimal 
intravascular dimensions with minimal vascular injury is warranted. Procedural 
success can be suboptimal due to several factors, including stent related 
anomalies like malapposition, stent underexpansion, stent edge dissections, jailed 
side branches, or residual focal disease, missed on angiography. Although some 
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of latter might truly increase target vessel failure on the long run, some on the 
other hand have proven to be self-resolving and a well-balanced decision needs 
to be made concerning potential treatment. Each intravascular modality, able to 
assess procedural success, has its own perks and drawbacks, warranting academic 
research and clinical experience to rightfully select the appropriate modality. 
With this dissertation, we aimed to contribute to the body of evidence supporting 
the clinical application of intravascular imaging and physiology. We were able 
to assess the feasibility of conventional intravascular imaging and physiology 
strategies in a post procedural setting. We identified post procedural anomalies 
with the use of OCT, IVUS and FFR and assessed their impact on clinical outcome. 
Finally, we implemented novel imaging and physiology modalities to gain further 
insight in plaque morphology and simplify hemodynamic coronary assessment. We 
hope this dissertation contributes towards the next step in clinical PCI evaluation 
and therefore improve patient outcome. 
Samenvatting en conclusie
Zowel fysiologische metingen als intravasculaire beeldvorming blijken een 
excellente manier om angiografische laesies te classificeren en het gebruik 
van deze modaliteiten verbetert significant korte en lange resultaten na een 
dotterbehandeling. Desalniettemin is er ondanks aanzienlijke verbetering in 
plaque modificerende technologie en stentontwerp in de laatste 3 decennia nog 
steeds een aanzienlijk risico op cardiale problemen en stent falen. Het doel van 
dit proefschrift was om de specifieke voordelen van intravasculaire beeldvorming 
en fysiologie na een dotterprocedure te onderzoeken en meer inzicht te krijgen in 
de details voor het falen van een kransslagader en de daarbij behorende slechte 
uitkomst voor een patiënt
In deel één begint dit proefschrift met een overzicht van de huidige literatuur ter 
ondersteuning van de klinische toepassing van intravasculaire beeldvorming en 
fysiologie in een post procedurele setting. In hoofdstuk 3-5 hebben we specifiek het 
gebruik van post-PCI FFR geëvalueerd en gekeken naar de distributie, voorspellers 
en klinische uitkomsten op lange termijn gerelateerd aan post-procedurele FFR in 
patiëntenpopulatie die lijkt op de klinische praktijk (FFR-SEARCH).
In deel twee, hoofdstuk 6-9, hebben we de specifieke voordelen van intravasculaire 
beeldvorming (na een dotterbehandeling) onderzocht. Zodanig hebben we een 
meer gedetailleerde benadering voorgesteld om OCT-gedetecteerde dissecties op 
een stent rand te beoordelen in de grootste klinische studie over dit onderwerp 
tot nu toe. Daarnaast hebben we onderzoek gedaan naar de afmetingen van 
hoofdstam kransslagaders om interventiecardiologen beter te kunnen begeleiden. 
Verder hebben we het belang van intravasculaire beeldvorming na een procedure 
geïllustreerd in twee klinische onderzoeken die nieuwe biologisch afbreekbare 
stent evalueerden.
In deel drie, hoofdstuk 10-12, hebben we het potentieel van synergetisch 
gebruik van fysiologie na een behandeling (als een eenvoudige poortwachter) 
en intravasculaire beeldvorming (IVUS) onderzocht om verdere inzichten te 
verschaffen over de oorzaken van een lage FFR na een behandeling. In de FFR 
SEARCH IVUS-studie hebben we voor het eerst aangetoond dat focale residuele 
ziekte vaak kan worden aangetroffen bij patiënten met een lage post-PCI FFR, wat 
het opstapje vormt voor optimalisatie middels IVUS na een procedure met een 
lage post procedurele FFR. Dit laatste vormde de basis voor het ontwerp van de 
FFR REACT-studie.
In deel vier, hoofdstuk 13-17, hebben we verschillende vereenvoudigde en snellere 
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methoden geïntroduceerd om post-PCI-fysiologie te beoordelen (FFR gebaseerd 
op 3D-QCA en dPR).
Ten slotte werkten we in deel vijf (hoofdstuk 18-20) samen met het Massachusetts 
General Hospital en het Wellman Center for Photomedicine om een nieuwe 
beeldvormingsmodaliteit (PS-OFDI) te ontwikkelen en te valideren om ons begrip 
van plaquemorfologie in zowel stabiele als onstabiele kransslagaders te vergroten.
DEEL I 
FYSIOLOGIE NA EEN DOTTERBEHANDELING
In hoofdstuk 2 presenteren we een overzicht van de huidige literatuur met 
betrekking tot post procedurele behandeling evaluatie. Hoewel klinische 
resultaten na een dotterbehandeling geleidelijk verbeteren, presteren 
verschillende subpopulaties nog steeds suboptimaal. Recente studies laten 
zien dat met het gebruik van conventionele intravasculaire beeldvorming en 
fysiologie, klinische resultaten kunnen worden verbeterd. Daarnaast beginnen 
ook nieuwere modaliteiten zoals op angiografie gebaseerde FFR en hybride 
beeldvormende katheters aan een opmars. Desondanks is alleen het gebruik 
van deze modaliteiten niet voldoende om klinische resultaten te verbeteren en 
zal men moeten streven naar optimale intravasculaire dimensies met minimaal 
vaatletsel. Bij het beoordelen van het resultaat na een dotterbehandeling met 
behulp van fysiologie en beeldvorming, kan een breed spectrum aan stent- en 
vaatgerelateerde afwijkingen worden verwacht, zoals stents die niet tegen de 
vaatwand liggen (malappositie), onvolledig geëxpandeerde stents, scheurtjes 
aan de stentrand, zijtak vernauwing en residuele ziekte. Aangezien niet al deze 
kwesties kunnen of dienen behandeld te worden, is grondige kennis nodig over 
wat men kan verwachten, hoe men dit kan herkennen en wanneer het behandeld 
dient te worden. Dit hoofdstuk biedt een gedetailleerd overzicht van de incidentie 
en impact van vaatgerelateerde afwijkingen met het gebruik van conventionele 
en nieuwe diagnostische hulpmiddelen. We richten ons hierbij specifiek op het 
verbeteren van de resultaten na een dotterbehandeling. 
Het FFR SEARCH register is het grootste prospectieve onderzoek naar de 
prognostische waarde en determinanten van FFR na een dotterbehandeling. 
In totaal zijn 1000 patiënten geïncludeerd in dit register uit Rotterdam, bij wie 
in 959 gevallen de FFR werd gemeten na een succesvolle dotterbehandeling. 
Hoewel het primaire eindpunt bestond uit de klinische resultaten na twee jaar, 
omvat het eerste onderzoeksrapport in hoofdstuk 3 de distributie van de FFR 
waardes na een dotterbehandeling en de 30 dagen klinische uitkomsten. Het FFR 
SEARCH register illustreerde dat FFR na een dotterbehandeling een veilige en 
reële methode is om de fysiologische status van kransslagaders na stentplaatsing 
te meten met behulp van de Navvus rapid exchange monorail microcatheter. De 
gemiddelde tijd om de FFR te meten was 5 minuten boven de normale procedure 
tijd en daarnaast zijn er geen complicaties opgetreden dankzij de microkatheter. 
De FFR werd gemeten aan de opening van de kransslagader, aan de proximale 
stentrand, distale stentrand en ± 20 mm distaal van de meest distale stentrand. 
De gemiddelde Pd / Pa in rusttoestand was 0.96±0.04, terwijl de gemiddelde FFR 
na de dotterbehandeling onder maximale hyperemie 0.90±0.07 was. Hoewel in 
alle gevallen een acceptabel angiografisch resultaat werd bereikt, bleef de FFR 
na de dotterbehandeling ≤0.80 in 78 laesies (9.8%). Omgekeerd zijn de FFR 
na de behandeling >0.90 in 396 laesies (50%). Verschillende factoren waren 
geassocieerd met een lage post procedurele FFR, waaronder bifurcaties en 
verkalkte laesies. Bovendien hadden patiënten met diabetes mellitus of perifere 
arteriële ziekte meer kans op het hebben van ≥1 laesie met een FFR ≤0.90. Tot 
slot correleerde FFR na een dotterbehandeling niet met klinische uitkomsten op 
30 dagen.
Om een definitief antwoord te geven op de vraag, wat de voorspellers zijn 
van post procedurele FFR waardes, hebben we hoofdstuk 4, ontworpen. We 
hebben verschillende onafhankelijke patiënt en vaat gerelateerde variabelen 
geïdentificeerd die de post PCI FFR voorspelden. In een LME-model, gecorrigeerd 
voor onafhankelijke voorspellers van post PCI FFR, hadden vrouwen een 
significant hogere post PCI FFR vergeleken met mannen (gecorrigeerde β = 
0.013, CI [0.005 tot 0.02], p = 0.001, R2 voor het volledige model = 0.54). Het 
vat waarin de fysiologische metingen werden verricht, was de sterkste voorspeller, 
wat resulteerde in een post procedurele FFR van 0.06 lager in LAD vaten. Andere 
voorspellers voor een lagere post procedurele FFR waren, type A laesies, in-stent 
restenose, CTO’s, post procedurele MLD en en pre- en postdilatatie.
In het concluderende artikel van het FFR SEARCH register, hoofdstuk 5, worden 
de klinische resultaten na twee jaar besproken. Op patiëntniveau was de post 
procedurele FFR <0.90 niet geassocieerd met meer cardiale complicaties (HR 
1.08, [95% CI, 0.73-1.60] p = 0.707). Op vatniveau resulteerde een FFR <0.90 
na een dotterbehandeling echter in een hoger percentage revascularisaties van 
het gemeten vat (HR 0.52 [95% CI, 0.27-1.00] p = 0.049). Tot slot werd er een 
trend gezien met een hoger percentage stenttrombose (HR 0.35 [95 % CI, 0.11-
1.13] P = 0.079).
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DEEL II 
GEBRUIK VAN INTRAVASCULAIRE BEELDVORMING 
(NA EEN DOTTERBEHANDELING)
In hoofdstuk 6 is onderzocht wat de invloed van onbehandelde stentrand 
dissecties (SEDs), geïdentificeerd met OCT en potentiële voorspellers voor klinische 
gebeurtenissen gerelateerd aan deze dissecties (DOCE) na één jaar zijn. De 
belangrijkste bevindingen van deze studie, die het grootste cohort van patiënten 
met OCT gedetecteerde SEDs bevat, kunnen als volgt worden samengevat: 
1) cardiale incidenten die mogelijk te wijten zijn aan de aanwezigheid van 
onbehandelde SEDs traden op 6.7%; 2) bij patiënten met onbehandelde SEDs was 
de dissectielengte de enige onafhankelijke voorspeller voor DOCE na 1 jaar, terwijl 
de diepte van de SED en de referentie lumen oppervlakte de enige voorspellers 
waren voor respectievelijk distale en proximale SEDs; 3) een herhaling van de 
OCT tijdens een vervolg katheterisatie toonden (vroege) spontane genezing in 
een grote meerderheid van de SEDs.
In hoofdstuk 7 hebben we getracht de vaatwand integriteit te onderzoeken, 6 en 
9 maanden na het plaatsen van een Fantom oplosbare stent met behulp van IVUS. 
In deze sub studie van de FANTOM II-studie bevestigden we de werkzaamheid van 
de Fantom oplosbare stent bij patiënten met een stabiel kransslagader lijden. We 
toonden dit aan door succesvolle inhibitie van nieuwe vaatwand vernauwing op 6 
en 9 maanden na het plaatsen van de stent. De Fantom oplosbare stent heeft een 
geraamte dat ontworpen is om binnen 4-5 jaar op te lossen en met de huidige 
studie hebben we aangetoond dat er na zowel 6 als 9 maanden minimale obstructie 
volumes te zien zijn. Dit laatste onderstreept de goede klinische resultaten in 
de recent gepubliceerde studie. Ondanks dat de FANTOM II- studie alleen zeer 
geselecteerde patiënten bevat, zijn de obstructie volumes vergelijkbaar met de 
hedendaagse metalen stents zoals de Resolute Onyx. 
De resultaten van hoofdstuk 8 suggereren dat de nieuwste oplosbare magnesium 
stent iteratie, de Magmaris, lijdt aan voortijdige ontmanteling met daaropvolgend 
verminderde vat ondersteuning. Samen met een suboptimale distale stent expansie, 
heeft dit bijgedragen aan een hoog verlies van lumenoppervlakte. Onze resultaten 
lieten een significante afname van intacte stent struts zien met een heterogeen 
resorptiepatroon, 4-5 maanden na de implantatie. Dit laatste werd onderstreept 
door een opmerkelijke reductie van helderheid en achterwaartse lichtverstrooiing 
van de struts. Een herhaling van de OCT tijdens een vervolg katheterisatie 
toont een afname van de minimale lumenoppervlakte aan van 43.44 ± 28.62% 
(p = .042), samen met een significante afname van het stentoppervlakte van 
38.20 ± 25.74% (p = 0.043) op de locatie van de minimale lumenoppervlakte. 
Hoewel onze bevindingen op gerandomiseerde wijze moeten worden bevestigd, 
lijkt het absoluut noodzakelijk om de aanbevelingen van de Europese werkgroep 
voor oplosbare stents op te volgen en het gebruik ervan te beperken tot enkel 
klinische proeven en registers met adequate vervolging. Tot slot suggereren onze 
resultaten dat vervolging door middel van intravasculaire beeldvorming van de 
kransslagader tijdens de initiële plaatsing en tijdens een herhaal katheterisatie 
aan te raden is en dat enkel klinische en angiografische vervolging niet voldoende 
zou zijn om de veiligheid en de lange termijn werkzaamheid van deze nieuwe 
oplosbare stents vast te stellen.
In hoofdstuk 9 hebben we de kransslagader afmeting en volumes van niet-
obstructieve hoofdstamkransslagaders (LMCA) onderzocht met behulp van IVUS 
in een groot “real world” cohort. We hebben voor de eerste keer aangetoond 
dat niet-zieke LMCA dimensies en lengtes binnen een populatie variëren en hoe 
vrouwen kleinere vaat dimensies hebben in vergelijking met mannen. Er werden 
geen klinisch relevante voorspellers gevonden, omdat de correlatiecoëfficiënten 
laag waren. Desondanks kunnen deze bevindingen artsen helpen bij het bepalen 
van de grootte van de stents en de grootte van post dilatatie ballonen. Verder geeft 
dit nogmaals aan hoe belangrijk intravasculaire IVUS is bij de behandeling van 
LMCA vernauwingen. Gezien de structurele onderschatting van LMCA dimensies 
op basis van kwantitatieve angiografie helpt IVUS bij het correct identificeren 
van de exacte LMCA-lengte en oppervlakte en verbetert daardoor de uitkomsten 
van complexe percutane LMCA behandelingen. Tot slot toonden we aan dat 19% 
van de patiënten, op basis van IVUS, een gemiddelde vat diameter hadden van 
>5 mm, wat aangeeft dat dilatatie na het plaatsen van een stent met een 5 mm 
ballon nodig zou zijn in combinatie met een stent die deze marge aankan.
DEEL III 
SYNERGETISCH GEBRUIK VAN INTRACORONAIRE 
BEELDVORMING EN FYSIOLOGIE 
Recente studies tonen aan dat een lage FFR na een procedure een goede 
voorspeller is voor toekomstige kransslagader problemen en heropnames. 
Wanneer men alleen kijkt naar de angiografische resultaten, dan blijkt het vaak 
onduidelijk waarom patiënten met een lage FFR deze problemen ontwikkelen, 
mede omdat eerdere studies geen IVUS resultaten presenteerden bij patiënten 
met een lage FFR na de behandeling. In de IVUS sub-studie van het FFR SEARCH 
register (hoofdstuk 10) hebben we voor de eerste keer aan kunnen tonen dat 
patiënten met een lage FFR na een procedure veelal tekenen vertoonden van focale 
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vatvernauwing, malapposition en stents die niet volledig geëxpandeerd waren. 
Deze resultaten waren met kwantitatieve angiografie niet detecteerbaar. In de 
studie waren 100 patiënten met een FFR na de procedure van ≤0.85 geïncludeerd 
en 20 met een FFR >0.85. In de lage FFR groep zagen we in 87% van de vaten 
focale vernauwingen, onvolledige stent expansie of malappositie. Verder zagen 
we in de huidige studie dat een FFR verval over een proximaal segment vaker 
voorkwam bij vaten met een focale proximale vernauwing, dit was niet het geval 
voor distale vernauwingen. 
In het vervolg op de bovenstaande studie, hoofdstuk 11, beoordeelden we de 
klinische resultaten, na twee jaar van het IVUS cohort. We zagen een duidelijke 
trend van afnemende klinische resultaten na twee jaar wanneer residuele laesies 
en onderexpansie van stents op IVUS aanwezig waren bij patiënten met een post-
PCI FFR ≤ 0.85.
In hoofdstuk 12 zetten we het studieontwerp van de FFR REACT uiteen. De 
FFR REACT studie is een door de wetenschap geïnitieerde prospectieve, single-
center gerandomiseerd gecontroleerde studie uitgevoerd in het Erasmus Medisch 
Centrum. De studie is ontworpen om te onderzoeken of een dotterbehandeling 
verbeterd kan worden door te kijken naar de FFR en IVUS in patiënten die 
een verhoogd risico hebben op additionele kransslagader problematiek (FFR 
na dotterbehandeling <0.90) en of dit een kransslagader probleem na 1 jaar 
verminderd. In totaal zullen 290 patiënten met een FFR na de dotterbehandeling 
<0.90 worden gerandomiseerd (1:1) in ofwel de standaardbehandeling (geen 
extra interventie) of optimalisatie van de FFR met IVUS (behandelarm). De studie 
is gestart in oktober 2017 en de inclusie zal naar verwachting in Q1 2020 voltooid 
zijn. Alle patiënten zullen gedurende 3 jaar worden vervolgd.
DEEL IV 
INNOVATIES IN KRANSSLAGADER FYSIOLOGIE
Op basis van eerder onderzoek krijgt het gebruik van FFR een duidelijke aanbeveling 
in de huidige richtlijnen voor kransslagader dotterbehandelingen. Hoewel het 
gebruik van FFR kosteneffectief is en zorgt voor minder contrast gebruik en de 
levenskwaliteit na een behandeling verbetert, wordt het in meerderheid van de 
gevallen nog steeds niet gebruikt. Dit is waarschijnlijk te wijten aan de hoge 
kosten van hyperemische middelen in sommige landen, nadelige bijwerkingen 
zoals kortademigheid en hartritmestoornissen, intolerantie vanwege longziekten 
en het gebruik van een kostbare druk draad. De FAST studie (hoofdstuk 13) 
illustreert de toepasbaarheid van een nieuwe programma, gebaseerd op 3D-QCA, 
om de FFR te berekenen zonder het gebruik van een drukdraad of microkatheter 
(vat FFR, vFFR). In het preklinische technische validatiemodel bleek vFFR een 
sterke correlatie te hebben met toegepaste vloeistofdynamica en invasief gemeten 
stromingsparameters. In onze klinische validatiestudie bevestigden we een 
uitstekende overeenkomst en een goede diagnostische nauwkeurigheid tussen 
vFFR en de FFR, die invasief was gemeten onder maximale hyperemie met behulp 
van een drukdraad. Tot slot toonden we aan dat vFFR een lage variabiliteit heeft 
tussen verschillende onderzoekers.
In de vervolg studie over vFFR hebben we de FFR SEARCH database gebruikt om 
de toepasbaarheid van vFFR na een dotterbehandeling te beoordelen (hoofdstuk 
14). De belangrijkste bevindingen van het onderzoek kunnen als volgt worden 
samengevat: vFFR maakt het mogelijk om een post procedurele FFR <0.90 
te identificeren met een hoge sensitiviteit en specificiteit; vFFR liet een goede 
correlatie met invasief gemeten post procedurele FFR zien, zoals gemeten met de 
Navvus microkatheter en tot slot had de berekening van de post procedurele FFR 
wederom een lage inter-observer variabiliteit. Op basis van de huidige resultaten 
zou de berekening van vFFR na het plaatsen van een stent een nuttig en 
gemakkelijk te gebruiken hulpmiddel kunnen zijn om de uitkomsten van patiënten 
met een hoog cardiaal risicoprofiel te identificeren en mogelijk te optimaliseren. 
Grotere klinische onderzoeken zullen de waarde van vFFR na het plaatsen van een 
stent verder moeten beoordelen en evalueren of klinische resultaten verbeterd 
kunnen worden door eventuele vFFR optimalisatie. 
In hoofdstuk 15 hebben we een nieuwe potentiële groep patiënten 
geïdentificeerd die mogelijk baat zou kunnen hebben bij de op 3D-QCA 
gebaseerde vFFR: patiënten met potentieel epicardiaal kransslagaderlijden na een 
harttransplantatie. In de eerste jaren na een harttransplantatie wordt het lumen 
van de epicardiale slagaders kleiner en is er een afname van de weerstand in 
de capillairvaten (IMR). Op de langere termijn neemt de IMR echter aanzienlijk 
toe, waardoor de maximaal haalbare doorstroming door de epicardiale bloedvaten 
afneemt. FFR is nuttig gebleken om de ernst van vernauwingen in de epicardiale 
kransslagaderen te bepalen. Er is echter nog steeds discussie over de validiteit 
ervan in getransplanteerde harten. Recente studies suggereerden daarom de IMR 
te meten en zo de gezondheid van het getransplanteerde hart te bepalen om de 
FFR beter te kunnen interpreteren.
De recentelijk gevalideerde vFFR biedt mogelijk een oplossing voor dit probleem. 
Om dit laatste te illustreren presenteerden we de casus van een 39-jarige 
mannelijke patiënt, 14 jaar na allograft-harttransplantatie met een vermoedelijke 
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significante vernauwing. De conventionele invasief gemeten FFR verschilde 
aanzienlijk met de resultaten van de OCT en de vFFR. Geïllustreerd door middel van 
deze casus, zijn wij van mening dat deze nieuwe technologie mogelijk superieur 
is aan de conventionele methodes bij het routinematige opvolgen van deze hoog 
risicopatiënten. 
De directe golfvrije ratio (Instantaneous wave free ratio; iFR) is een andere 
methode om de hemodynamische ernst van een kransslagader vernauwing te 
bepalen zonder een hyperemisch middel toe te dienen. iFR geeft een betrouwbare 
meting van de kransslagader fysiologie, maar is enkel te berekenen met een 
gepatenteerde software. Hoofdstuk 16 beschrijft een studie die de uitvoerbaarheid 
en nauwkeurigheid van een niet-hyperemische ratio, de dPR, heeft onderzocht 
door middel van een nieuwe software die te gebruiken is met zowel drukdraden 
als kleine drukkatheters. dPR liet een excellente correlatie met iFR zien en een 
hoge diagnostische nauwkeurigheid voor het identificeren van een FFR ≤0.80. 
dPR is een snelle, simpele en reproduceerbare niet-hyperemische ratio gebaseerd 
op DICOM drukgolven, die de mogelijkheid biedt voor een hoger gebruik van 
diastolische drukgradiënten in de klinische praktijk. Door een eenvoudige software 
programma te gebruiken dat automatisch de vlakke periode in de dP/dt-curve 
detecteert, de zogenaamde “golfvrije” periode, vonden we dat de dPR bijna perfect 
correleerde met de oorspronkelijke iFR resultaten van Phillips Volcano (r = 0.997), 
p <0.001). Verder toonden onze resultaten een correlatie tussen dPR en FFR die in 
lijn is met de resultaten van de VERIFY studie (r=0.77 voor dPR vs. FFR en r=0.79 
voor iFR vs. FFR respectievelijk).
Ondanks concreet bewijs dat het gebruik van een fysiologische meting voor het 
plaatsen van een stent aanraadt, worden deze metingen na de behandeling niet 
vaak gedaan. Evaluatie van de behandeling wordt vaak verricht op basis van 
angiografie, een methode die een bewezen slechte correlatie heeft met fysiologie. 
Dit laatste is benadrukt door verschillende studies die illustreerden hoe belangrijk 
FFR na behandeling is als indicator voor succes van de behandeling. Op dit 
moment is er echter weinig bekend over de waarde en voorspellers van de dPR na 
een dotterbehandeling. 
In hoofdstuk 17 worden de resultaten besproken van de post hoc analyse van 
het FFR SEARCH register waar het dPR algoritme op toegepast is. De studie laat 
zien dat ondanks goed angiografisch resultaat, 15% van de patiënten en 13% van 
vaten na een behandeling nog steeds een dPR ≤0.89 hebben. Ten tweede bleken 
metingen in de LAD, patiënten met diabetes, stent diameter, in-stent restenose 
en referentie diameters voor en na de behandeling onafhankelijke voorspellers te 
zijn voor de dPR na een behandeling. Tot slot is er een trend gezien waarbij een 
dPR ≤0.89 zorgde voor meer heropnames na de behandeling. 
DEEL V 
INNOVATIES IN INTRAVASCULAIRE POLARISATIE 
METINGEN
De eerste op mensen geteste studie (hoofdstuk 18) die polariteit meet in de 
kransslagaderen liet zien hoe dit de conventionele OFDI plaque karakterisatie 
versterkt door het kwantitatief meten van polarisatie. Dit werd gemeten met 
een standaard OFDI katheter die gelijktijdig het conventionele OFDI-signaal 
toonde. De polarisatiemetingen bieden een verfijnd inzicht in de samenstelling 
en consistentie van het weefsel in de kransslagaderen en is in lijn met ons 
huidige begrip van de mechanismen die betrokken zijn bij plaque progressie en 
destabilisatie. De belangrijkste bevinding van deze studie is dat de fibreuze kap 
van patiënten die zich presenteren met een acuut coronair syndroom een lagere 
birefringence toonde in vergelijking met fibreuze plaque kappen in patiënten 
met stabiel kransslagader lijden. Terwijl de interpretatie van conventionele OFDI 
berust op subjectieve identificatie van kwalitatieve kenmerken, biedt polarisatie 
kwantitatieve metingen die kunnen leiden naar een objectieve en automatische 
karakterisering van atherosclerotische plaques. De verbeterde beoordeling van 
de plaque samenstelling dankzij de polarisatiemetingen kunnen nieuw inzicht 
verschaffen in de mechanisme van plaque progressie en destabilisatie van 
menselijk kransslagaderlijden.
Op dit moment is intravasculaire polariteit gebruikt in zowel humane kadavers als 
in patiënten om voornamelijk stabiele atherosclerose te bestuderen, maar het is 
tot op heden onbekend of polariteit van toegevoegde waarde kan zijn in patiënten 
met onstabiel kransslagaderlijden. Om dit te onderzoeken is de POLARIS-I studie 
opgezet met als doel om maximaal 35 patiënten te includeren met instabiel 
kransslagaderlijden (onstabiele angina of een hartinfarct zonder ST elevatie) en 
een klinische indicatie voor kransslagader onderzoek met OCT/OFDI.
Tijdens de inclusie periode van de POLARIS-I studie presenteerde er zich een 
unieke patiënt in ons ziekenhuis. Geïllustreerd met de casus beschrijving van deze 
patiënt trachten we in hoofdstuk 19 de waarde van de PS-OFDI te illustreren om 
trombus te bestuderen. Een 69 jaar oude, vrouwelijke, patiënt was verwezen naar 
ons ziekenhuis voor mogelijke behandeling van een hartinfarct zonder ST elevatie 
na 8 dagen van variërende pijn. De angiografie toonde een abnormale vulling 
in het midden van de rechter kransslagader met TIMI III vulling en een matig 
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stabiele ziekte in de linker kransslagaders. De PS-OFDI toonde een beeld dat 
gelijkenis toonde met een honinggraat met meerdere intraluminale microkanalen, 
dit bevestigde dat er een gekanaliseerde trombus aanwezig was. Eerder onderzoek 
liet zien dat collageen en gladde spiercellen een hoge birefringence hebben en 
mogelijk kunnen we de PS-OFDI daarom gebruiken om de leeftijd, stabiliteit en 
andere karakteristieken van kransslagader trombus te bestuderen. 
In het laatste hoofdstuk van dit proefschrift, hoofdstuk 20, hebben we gebruik 
gemaakt van het POLARIS-I register om de polarisatie eigenschappen van 
kransslagadertrombus bij patiënten die zich presenteren met een acuut hart 
infarct te beoordelen met PS-OFDI. In deze studie hebben we voor het eerst aan 
kunnen tonen dat de birefringence in genezende kransslagadertrombus significant 
hoger is wanneer dit vergeleken wordt met verse trombus. Bovendien hebben 
we geconstateerd dat birefringence afhankelijk is van de leeftijd van de trombus 
wanneer de tijd tot intravasculaire beeldvorming als parameter wordt gebruikt. 
Tenslotte werd geen verschil in birefringence gevonden tussen in de kappen van 
gescheurde plaques en afgelegen vetrijke kransslagader plaques. Tot op heden 
kon de samenstelling en progressie van trombus alleen betrouwbaar worden 
beoordeeld met behulp van histopathologisch onderzoek. Histopathologisch 
onderzoek kan echter niet gebruikt worden in acute situaties. PS-OFDI kan een 
waardevolle nieuwe beeldvormingsmodaliteit zijn om de leeftijd, stabiliteit en 
structurele kenmerken van coronaire trombus verder te bestuderen.
Toekomstperspectief
De toekomst van de interventie cardiologie zal waarschijnlijk samen gaan met een 
aantal veranderingen met betrekking tot intravasculaire beeldvorming en fysiologie. 
Recente onderzoeken tonen ons mogelijk al aan hoe deze verandering er uit gaat 
zien. Hoewel de drie overgangen die ik voor ogen heb, afzonderlijk kunnen worden 
ontwikkeld, in verschillende instellingen of medische bedrijven, uiteindelijk zullen 
ze bijeen gebracht dienen te worden in het katheterisatielaboratorium om de arts 
en patiënt te helpen. 
Ten eerste moet intravasculaire beeldvorming, voornamelijk IVUS en OCT, vaker 
gebruikt worden. Grote klinische studies hebben al aangetoond dat nieuwe 
dotterbehandeling in hetzelfde vat minder vaak nodig zijn wanneer optimale 
vat dimensies worden bereikt met behulp van IVUS. Verder is het belangrijk dat 
interventie cardiologen een beter begrip ontwikkelen over wanneer ze intravasculaire 
beeldvorming moeten gebruiken en hoe ze dit kunnen interpreteren. Evaluatie na 
een dotterbehandeling met behulp van beeldvorming is hierbij een cruciale stap 
en dient zeker overwogen te worden bij patiënten met kransslagaderlijden. Op 
dit moment zijn intravasculaire beeldvormende katheters duur en worden ze niet 
in alle landen vergoed. Dit laatste zal ook moeten veranderen als we het gebruik 
willen verhogen.
Ten tweede zal een meer simplistische interpretatie van (intravasculaire) fysiologie 
nodig zijn om de hemodynamische significantie van een kransslagadersegment 
te beoordelen. Er zijn al belangrijke stappen gezet met behulp van zowel 
hyperemische als niet-hyperemische indexen. Op dit moment worden zelfs 
vereenvoudigde fysiologische modellen bestudeerd zonder het gebruik van een 
drukdraad, puur door het gebruik van angiografie en versimpelde vloeistofdynamica 
aannames. Toekomstige studies zouden deze nieuwe fysiologische modellen in 
grote gerandomiseerde studies moeten testen, waarbij ook post procedurele 
beoordeling, bifurcatie vernauwingen en patiënten met verminderde micro 
vasculaire weerstand bestudeerd dienen te worden.
Ten slotte zullen nieuwe beeldvormingsmodaliteiten de cardiologen niet alleen 
meer informatie geven met extra geïntegreerde beelden, maar ook complexe 
computer modellen ondersteunen, met als doel automatisch klinisch relevante 
segmenten te identificeren die een aanvullende behandeling vereisen. 
Hedendaagse intravasculaire beeldvorming ontwikkelt zich in een hoog tempo, 
zodat actuele en klinische kennis over de nieuwste onderzoeken en goed 
geadviseerde implementatie lastig is. Op dit moment wordt er cumulatief bewijs 
verzameld over de nieuwe toepasbaarheid van hybride beeldvorming technieken 
en het vermogen van deze modaliteiten om inzicht te geven in de kwetsbaarheid 
van onbehandelde kransslagadersegmenten. Hoewel de basisinterpretatie 
van conventionele beeldvormingsmodaliteiten, zoals IVUS en OCT vooral van 
belang is, moeten geavanceerde hybride beeldvormingskatheters de cardioloog 
behandelingsaanbevelingen bieden in plaats van beelden die veel kennis, training 
en expertise nodig hebben om ze te begrijpen.
Conclusie
De klinische resultaten na een dotterbehandeling verbeteren geleidelijk, 
hoewel verschillende subpopulaties nog steeds ondermaats presteren. Recent 
onderzoek toonde aan dat met het gebruik van conventionele intravasculaire 
beeldvorming en fysiologie, klinische resultaten verbeterd kunnen worden. Ook 
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nieuwe modaliteiten, bijvoorbeeld op angiografie gebaseerde FFR en hybride 
beeldvormingskatheters doen een intreden. Desalniettemin is alleen het gebruik 
van deze modaliteiten niet voldoende om de klinische resultaten voor een patiënt 
te verbeteren en is het nodig om optimale intravasculaire dimensies met minimaal 
vaatletsel na te streven. Een behandeling kan suboptimaal zijn als gevolg 
van verschillende factoren, waaronder stent gerelateerde afwijkingen, zoals 
malappositie, stent onderexpansie, stentrand scheurtjes, afgesloten zijtakken of 
resterende geïsoleerde kransslagadervernauwingen. Hoewel sommige afwijkingen 
negatieve gevolgen kunnen hebben met als resultaat een herkatheterisatie of 
een hartinfarct, herstellen sommige afwijkingen vanzelf en zal er dus een goed 
overwogen beslissing moeten worden genomen met betrekking tot mogelijke 
behandeling. Elke intravasculaire modaliteit, die in staat om het succes van 
een behandeling te beoordelen, heeft zijn eigen voordelen en nadelen, waarbij 
academisch onderzoek en klinische ervaring er voor zal zorgen dat de juiste wordt 
gekozen op het juiste moment. 
Dit proefschrift draagt  bij aan de onderbouwing voor het klinische gebruik van 
intravasculaire beeldvorming en fysiologie. We zijn in staat geweest om de 
haalbaarheid te onderzoeken voor het post procedureel gebruik van conventionele 
intravasculaire beeldvormings- en fysiologiestrategieën. We identificeerden post 
procedurele afwijkingen met het gebruik van OCT, IVUS en FFR en beoordeelden 
hun impact op de klinische uitkomst. Tot slot hebben we nieuwe beeldvormings- 
en fysiologiemodaliteiten geïmplementeerd om verder inzicht te krijgen in de 
samenstelling van plaques en hemodynamische kransslagaderbeoordeling te 
vereenvoudigen. We hopen dat dit proefschrift bijdraagt  aan de volgende stap in 
de evaluatie van kransslagaderbehandelingen en daarmee de kwaliteit van leven 
voor de patiënt verbetert.
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Dankwoord
Promotor Prof. dr. Felix Zijlstra, beste professor Zijlstra, allereerst zou ik u 
willen bedanken voor alle begeleiding die u me heeft gegeven in de afgelopen 
jaren. Tijdens de coronaire interventies, maar ook de gesprekken die wij 
voerden naderhand, bewonderde ik altijd hoe u met een algehele kalmte en 
vanzelfsprekendheid te werk gaat. Deze uitzonderlijke werkwijze zorgde ervoor 
dat ik me als jonge student niet overweldigd hoefde te voelen. Uw kennis op het 
gebied van de cardiologie en de interne geneeskunde heeft mij geleerd dat we de 
patiënt als geheel moeten zien. Uw deur stond altijd open. Door uw uitnodigende 
houding heb ik nooit geschroomd om langs te komen. Graag wil ik u bedanken 
voor het vertrouwen dat u mij al in deze vroege fase van mijn studie hebt gegeven.
Copromotor dr. Joost Daemen, beste Joost, bedankt! Bedankt voor je toewijding, 
je expertise en de steun die je me hebt gegeven tijdens het promotieonderzoek 
dat wij samen neer hebben gezet. Het was in mijn tweede jaar van geneeskunde 
dat ik het geluk heb gehad dat Ron mij bij jou plaatste. Eigenlijk besef ik me nu 
pas, vele jaren later, hoe onze samenwerking daarin verliep. De eerste versie 
van ons manuscript leverde ik aan 2 kolommen per pagina, want zo deden ze 
dat ook in de tijdschriften. Al vanaf ons eerste project stak je enorm veel tijd in 
mijn leerproces en daar ben ik je ontzettend dankbaar voor. De passie die jij hebt 
voor je beroep als arts reflecteerde zich in de manier waarop je me begeleidde. 
Je wist abstracte principes op een elegante en begrijpbare manier uit te leggen. 
De vele uren die we samen hebben doorgebracht, sparrend, reviserend, zullen me 
altijd inspireren. Je leerde me conceptueel denken over wat ik wil onderzoeken 
en het vervolgens bondig en zorgvuldig formuleren in een manuscript. Naast de 
academische vaardigheden die je me hebt bijgebracht ben ik je ook dankbaar 
voor alle levenslessen die je met me hebt gedeeld. Ik heb het volste vertrouwen 
dat je nog vele promovendi zult opleiden. Afgezien van de grote stappen die ik 
heb gemaakt in het academische veld, heb ik nog een lange weg te gaan. Jouw 
expertise in het cathlab en professionaliteit met patiënten zullen hopelijk altijd 
een drijfveer voor me blijven. Bedankt voor alles! 
Secretaris Prof. Eric Boersma, beste professor Boersma, graag zou ik u willen 
bedanken voor de lessen tijdens mijn research master en uw expertise op het 
gebied van de biostatistiek. Verder stel ik het op prijs dat u bereid was om de rol 
van secretaris op u te nemen. 
Beste Prof. dr. Nicolas van Mieghem, allereerst mijn welgemeende dank voor de 
ervaringen die ik de afgelopen jaren in en rondom het EMC met u heb mogen 
opdoen. De gedachten aan het charisma waarmee je klinisch patiënten helpt, het 
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cathlab leidt en onderzoekers vormt, zal mijn ambitie altijd blijven aanwakkeren. 
Verder zou ik u willen bedanken voor het vertrouwen dat u mij, de Roemeen, al 
vroeg gaf om de interventiecardiologen te assisteren met de interpretatie van 
IVUS en OCT.  
Dear Prof. Brett Bouma, thank you for the trust in me to start the Polaris-I in 
Rotterdam. I am truly grateful for the opportunity you gave me to work on this 
project with your team at the Massachusetts General Hospital. It has been an 
amazing experience as a researcher and needless to say, as a person.  
Verder zou ik de interventie cardiologen van het EMC, Prof. dr. Peter de Jaegere, dr. 
Roberto Diletti, dr. Jeroen Wilschut, dr. Miguel Lemmert, dr. Wijnand den Dekker 
willen bedanken. Beste professor de Jaegere, uw immer goede humeur, doch 
realistische blik in zowel het cathlab als daarbuiten zijn zeer waardevol gebleken. 
Roberto, Mr. 92%*, bedankt voor je expertise en de samenwerking in een aantal 
belangrijke projecten. Jeroen, graag wil ik je bedanken voor het aanstekelijke 
enthousiasme dat jij uit het vak haalt. Iedere keer als je na een procedure nog 
eens de angio’s door zat te nemen en tegen mij zei: ‘‘Kom hier eens kijken, 
dit is uniek!’’ Miguel, bedankt voor je professionele doch vriendschappelijke 
houding, jouw zelfverzekerdheid in het cathlab en je parate kennis over de 
nieuwste literatuur zorgde er altijd voor dat ik het volste vertrouwen had in de 
procedures. Beste Wijnand, dank voor je hulp bij verscheidene projecten en de 
hardloopwedstrijd langs de Parijse Seine.
*CTO succes percentages ondervinden mogelijk fluctuatie
Dr. Peter van Hal, uw inspirerende houding om door middel van onderzoek 
ziekteprocessen te doorgronden en patiënten beter te maken, zijn de start 
geweest van mijn academische vorming tijdens Junior Med School, dit zal ik nooit 
vergeten!
Dr. Klootwijk, dankzij uw colleges in mijn eerste jaar van geneeskunde is mijn 
passie voor het hart ontstaan. 
Jurgen en Karen, jullie hebben me bij het begin van dit traject bij de hand 
genomen, ik kon zo vaak langskomen als nodig was. Die aandacht die jullie me 
gegeven hebben, heeft ervoor gezorgd dat ik met vertrouwen en zelfverzekerdheid 
het cathlab in durfde te gaan. Jullie kennis en bereidheid alles te delen t.a.v. 
intravasculaire beeldvorming en de gang van zaken in dit ziekenhuis, heeft mij 
enorm geholpen als onderzoeker, maar ook zeker als toekomstig arts. 
Dr. Jouke Dijkstra, bedankt voor uw bijdrage aan verschillende projecten en alle 
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ondersteuning die u geboden heeft.
Dr. Kaneshka Masdjedi, beste Ken, graag zou ik je willen bedanken voor de tweede 
helft van dit proefschrift, zonder jou was dit boek zeker 50% dunner geweest. Ik 
ben je enorm dankbaar voor je complementaire karakter, we vormden een perfect 
duo waarin we fysiologie en beeldvorming konden combineren. Jouw klinische blik 
bleek een essentieel onderdeel in mijn ontwikkeling en die van dit proefschrift, de 
chapli kebab niet. Verder zul je altijd een voorbeeld voor me blijven als dokter. 
De elegantie waarmee jij je vorming tot interventiecardioloog combineert met de 
fulltime baan als familieman blijft me verbazen, je elfje kan trots zijn. Ik zal altijd 
met veel plezier terugkijken op onze volledig herschreven epistels, de congressen 
en onze vriendschap. 
Dr. Maria Natalia Tovar Forero, dear Natalia, when you say something too often, 
it may lose its value, therefore I would like to put it into writing. You are the 
best! Your Spanish-Colombian temperament and your fear of bicycles gave you an 
unique personality. You are the one I could always go to, for either clinical, research 
or personal advice. The limitless motivation and your passionate character will 
undoubtedly make you one of the best interventional cardiologists. Thank you for 
everything!      
Beste Tara, graag zou ik je willen bedanken voor al je hulp vanuit Rotterdam toen 
ik aan de andere kant van de wereld was. De hele afdeling, maar voornamelijk 
Joost, mag van geluk spreken dat je nu onderdeel uitmaakt van het team.  
Daarnaast zou ik graag mijn collega onderzoekers van de interventie cardiologie 
willen bedanken. Lida, wat heb ik een bewondering voor je! Er is niemand die 
zo consciëntieus en met zoveel toewijding aan een promotie bezig was als jij. 
Voor niemand is jouw doorzettingsvermogen onopgemerkt gebleven gezien jouw 
immens lange dagen, zelfs na een paar tegenslagen. Het is echter vooral je 
liefdevolle karakter dat mij altijd zal bijblijven. Mannen, beste Herbert, Maarten 
en Joris, bedankt voor de mooie tijd op de afdeling. Vooral bedankt voor de 
gezelligheid, jullie goede humeur, de borrels en congressen.
Dear Francesca, Paula, Mariusz and Marcello, I am very grateful for the time 
we spent together in Rotterdam. Thank you for the continuous amusement at 
lunchtime and the congresses we visited together. Your unique personalities and 
cultural backgrounds made me realize even more that the world is bigger than 
just Holland. It is not always easy to work in a foreign country for such a long 
time, but I truly admire your passion and perseverance. 
Francesca, thank you for your never ending smile and your Italian temper. Paula, 
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you went back to Italy just to take over a few nightshifts at your local hospital. 
Thank you for showing me what true passion for your work and colleagues is. 
Mariusz, thank you for the honor to work with you on several projects, we made 
a great team! Marcello, thank you for your inspiring and hardworking ambition.
Verder zou ik graag de klinische fellows van de interventie-cardiologie willen 
bedanken: Dr. Koen Ameloot, Dr. Matthew Mercieca Balbi, Dr. Pieter Vriesendorp 
en Dr. Rutger-Jan Nuijs. Dankzij jullie passie voor het vak heb ik me geweldig op 
mijn plek gevoeld tijdens mijn periode op de afdeling. Beste Koen, ik bewonder 
enorm hoe jij je gezinsleven, je baan in Genk en je klinische fellowship hebt weten 
te combineren. Beste Pieter en Rutger-Jan, bedankt voor jullie enthousiasme en 
inzet om me onderdeel te laten voelen van het team. Matthew, thank you for your 
kindness, your knowledge and the ability to combine the latter two to answer all 
my basal questions that seem so obvious now. 
Daarnaast zou ik graag alle technici en verpleegkundige  van de interventie 
cardiologie willen bedanken. Beste John, Angelique, Elco, Alise, Quinten, Thom, 
Martin en Anne-Marie, graag zou ik jullie willen bedanken voor jullie vermogen om 
iedere nieuwe onderzoeker de kneepjes van het vak uit te leggen. Hopelijk mag 
de eierwekker jullie nog jaren wakker houden. 
Beste Marianne, Houda, Peggy, Danielle, Shurenska, Alexander en Stefan, 
allereerst mijn welgemeende excuses voor alle herrie die het PS-OFDI apparaat 
maakte. Daarnaast zou ik jullie willen bedanken voor al jullie hulp toen ik me als 
student de interventiecardiologie eigen moest maken. Tot slot waardeer ik jullie 
adaptieve vermogen om constant interesse te tonen in de nieuwste onderzoeken. 
Verder zou ik graag het trialbureau van de cardiologie willen bedanken. Arno 
en Nico, jullie kennis over de gang van zaken in dit ziekenhuis heeft me enorm 
geholpen tijdens mijn onderzoeksperiode. Mattie, dank voor al je kennis, expertise 
en journal clubs. Reon en Dirk, bedankt voor jullie inzet voor de FFR REACT studie. 
Ik heb het volste vertrouwen dat jullie geweldige academische clinici worden. 
Beste Anja, ik ben je enorm dankbaar voor je flexibiliteit, ondanks onze vele 
verzoeken. De cardiologen mogen in hun handen knijpen dat jij er bent! 
My warmest gratitude goes out to the team from MGH who so kindly hosted 
me during my stay in Boston, Massachusetts. Jian, Taylor, Norman, Szu-yu, 
Martin, Kenichiro, Nestor, Natalie, Pelham and Boy, thank you for your hospitality. 
Dear Kenichiro and Martin, the two of you in particular made my stay in Boston 
productive and enjoyable and I would like to thank you for the opportunity to gain 
more insight in the technical aspects of optical imaging.  
E
413 || 412
Mannen van het goede leven, Jaap, Flores, Andries, Luca, Kristian, Joshua, George 
en Steven. Het begon allemaal tijdens de Eureka-week, de daarop volgende 
periode bij Skadi en natuurlijk onze studie geneeskunde. Met enige weemoed 
denk ik af en toe terug aan de tijd dat SBL volhing met foto’s van onze epische 
avon(d/t)uren. Wat hebben we een mooie dingen beleefd en wat ben ik blij dat ik 
jullie mijn vrienden kan noemen.
Gedurende onze studie geneeskunde en mijn promotietraject heb ik getracht te 
leven met het motto: doe iets waar je je passie in kwijt kunt, want dat werkt 
aanstekelijk. Op dit moment zouden we allemaal al in opleiding kunnen zijn tot 
specialist of zelfs volleerd advocaat kunnen zijn, maar toch heeft iedereen zijn 
eigen passie gevolgd en dat waardeer ik enorm aan jullie. Of het nu ging om een 
bestuursjaar, de wereld rondreizen, intensief sporten of jezelf te verbreden in de 
ruimste zin van het woord, jullie deden het stuk voor stuk en dat maakt jullie 
uniek. 
Liefste huisgenoten, Olivier, Koen, Lennart, Ton, Nadia, Caroline en Tessa, graag 
zou ik jullie bedanken als huisgenoten tijdens de beste jaren van mijn studietijd. 
We zijn een prachtig dynamische groep die verbazingwekkend goed bij elkaar 
past. 
Heerendispuut De NUL, het is mij een ware eer jullie als eerste te mogen bedanken 
in een proefschrift. Jullie hebben me geleerd het leven niet voor lief te nemen, 
het niet te onderschatten. Het principe, waarmee deze groep heren bij elkaar 
is gekomen, vind ik nog steeds een prachtig initiatief en ik stel het enorm op 
prijs hoe we als diverse heren een gedeelde passie kunnen hebben voor het vak 
geneeskunde. 
Beste Hugo, Felix, Michiel en Nino, ik wil jullie bedanken voor jullie verbredende 
en provocerende karakters. De uitdagende discussies die we altijd voeren, iets 
wat we op Beekvliet hebben geleerd, zijn een essentieel onderdeel gebleken van 
dit proefschrift en daar ben ik jullie zeer erkentelijk voor. Al jaren lang zorgen 
jullie ervoor dat ik niet opgesloten blijf in een geneeskunde bubbel. Ik hoop onze 
vriendschap nog jaren te kunnen koesteren. 
Nog verder terug naar de basis zou ik graag Thijs, Kees, Elske, Floor, Pim, Jannes 
en Ton willen bedanken. Als jullie dit boek in handen krijgen, zal het waarschijnlijk 
de eerste keer zijn dat jullie erachter komen waar ik me de afgelopen jaren mee 
bezig heb gehouden. Dit maakt jullie echter niet minder waardevol in mijn leven. 
De vriendschap die wij al ruim 20 jaar delen is er eentje die terug gaat naar 
de essentie, een vriendschap zonder het oordeel van volwassen mensen. Jullie 
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plezier in het leven maakt mij een beter mens. 
Lieve multipotentialist, architect, bachelor, botonist, boulderaar, brouwer, 
ceremoniemeester, chef, dichter, grafisch ontwerper, kalf, pedaleur, schilder, sous-
chef, stoker, thigmofiel, zus, 旅行者, bedankt voor al je hulp en vriendschap!
Liefste Sjoukje, ik heb je leren kennen toen ik aan de voet van de Rinjani dit boek 
reviseerde. Sinds die tijd help je me met kritische vragen en oprechte interesse. 
Je onuitputtelijke motivatie en geduld de laatste maanden bleken onmisbaar om 
het uiteindelijk te finaliseren. Ik ben gefascineerd door je vermogen om me vol 
vertrouwen door het leven te laten gaan en de rust en balans te vinden die soms 
essentieel is. Ons samenzijn maakt alle facetten van het leven wonderlijk. 
Tot slot zou ik graag mijn ouders willen bedanken, Pap, Mam, een kind kan geen 
beter paar ouders wensen. Zoals het goede ouders betaamd hebben jullie je 
minstens zoveel zorgen gemaakt over dit proefschrift en de daarbij behorende 
sores als ikzelf. Al van jongs af aan hebben jullie geprobeerd me de normen en 
waarden bij te brengen die voor jullie belangrijk zijn. Ik bewonder enorm hoe 
jullie je eigen belang volledig weg kunnen cijferen voor anderen en hoe jullie 
problemen met elegantie tegemoet treden. Eigenschappen die ik ook heb moeten 
tonen om dit proefschrift tot een goed einde te kunnen brengen. Bedankt voor de 
onvoorwaardelijke liefde, overgave en steun, jullie favoriete zoon. 
E
415 || 414
Epilogue - About the author
About the author
Laurens Joannes Cornelis van Zandvoort was born 14th of 
January 1995 in ’s-Hertogenbosch. He underwent his 
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before that. Finishing Junior Med School in 2013 during high 
school and successfully finalizing his first research project 
about renal disfunction after a lung-transplantation gave 
him the opportunity to be admitted to Erasmus MC and it convinced him of his 
career choice. During the first year of medical school he became a junior research 
assistant at Erasmus MC dept. of Intervention Cardiology and was involved in 
several research projects, focusing on renal artery denervation and coronary 
stents. With the motivation to combine clinical medicine with academic research 
he applied for the research master in Health Science at the Netherlands Institute 
for Health Sciences (NIHES) after finishing the bachelor in medicine in 2016. The 
master program prepared him for an epidemiologic approach to clinical problem 
within his field of interest – Interventional Cardiology. 
The last three years he thrived in several key projects within the interventional 
cardiology department, all focusing on intracoronary imaging and physiology. 
In this period he combined the fundamental courses of the research master 
simultaneously with the research for his dissertation. In 2018 he was granted with 
the Erasmus Trustfonds and the Gerrit Jan Mulder Prize which allowed him perform 
additional in-depth research on the polarization sensitive optical frequency domain 
imaging system, at the Massachusetts General Hospital in Boston, USA. The latter 
opportunity allowed him to incorporate a technical facet to his biostatistical and 
clinical research devotion.
Although, research has been a constant factor throughout his medical education, 
he was able to pursue other interests on relevant topics as well. Already from on 
his first year in medicine and throughout his masters, he worked as a student 
assistant, doing weekly shifts at Sophia Children’s Hospital, dept. of pediatric 
oncology. Furthermore, he developed organizing skills through board membership 
with ‘’De Geneeskundestudent’’, where he was able to organize multiple national 
events for future doctors, such as the personal leadership meeting in Utrecht, the 
Burnout convention in Rotterdam and finally ‘’Talking Medicine’’ in January 2019, 
a large scale congress in the Jaarbeurs in Utrecht on the future of medicine.
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